

Draft Comparative Effectiveness Review

Number XX

Discontinuation of Disease-Modifying Treatment for Multiple Sclerosis

Prepared for:

Agency for Healthcare Research and Quality
U.S. Department of Health and Human Services
540 Gaither Road
Rockville, MD 20850
www.ahrq.gov

This information is distributed solely for the purposes of predissemination peer review. It has not been formally disseminated by the Agency for Healthcare Research and Quality. It does not represent and should not be construed to represent an Agency for Healthcare Research and Quality or Department of Health and Human Services (AHRQ) determination or policy.

Contract No.

Prepared by:

Investigators:

**AHRQ Publication No. xx-EHCxxx
<Month Year>**

This report is based on research conducted by an Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. xxx-xxxx-xxxxxx). The findings and conclusions in this document are those of the authors, who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information, i.e., in the context of available resources and circumstances presented by individual patients.

This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.

This report may periodically be assessed for the urgency to update. If an assessment is done, the resulting surveillance report describing the methodology and findings will be found on the Effective Health Care Program Web site at: www.effectivehealthcare.ahrq.gov. Search on the title of the report.

This document is in the public domain and may be used and reprinted without permission except those copyrighted materials that are clearly noted in the document. Further reproduction of those copyrighted materials is prohibited without the specific permission of copyright holders.

Persons using assistive technology may not be able to fully access information in this report. For assistance contact info@ahrq.gov.

None of the investigators has any affiliations or financial involvement that conflicts with the material presented in this report.

Suggested citation:

Preface

The Agency for Healthcare Research and Quality (AHRQ), through its Evidence-based Practice Centers (EPCs), sponsors the development of systematic reviews to assist public- and private-sector organizations in their efforts to improve the quality of health care in the United States. These reviews provide comprehensive, science-based information on common, costly medical conditions, and new health care technologies and strategies.

Systematic reviews are the building blocks underlying evidence-based practice; they focus attention on the strength and limits of evidence from research studies about the effectiveness and safety of a clinical intervention. In the context of developing recommendations for practice, systematic reviews can help clarify whether assertions about the value of the intervention are based on strong evidence from clinical studies. For more information about AHRQ EPC systematic reviews, see www.effectivehealthcare.ahrq.gov/reference/purpose.cfm.

AHRQ expects that these systematic reviews will be helpful to health plans, providers, purchasers, government programs, and the health care system as a whole. Transparency and stakeholder input are essential to the Effective Health Care Program. Please visit the Web site (www.effectivehealthcare.ahrq.gov) to see draft research questions and reports or to join an e-mail list to learn about new program products and opportunities for input.

We welcome comments on this systematic review. They may be sent by mail to the Task Order Officer named below at: Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, MD 20850, or by email to epc@ahrq.hhs.gov.

Robert Kronick, Ph.D.
Director
Agency for Healthcare Research and Quality

Yen-pin Chiang Ph.D.
Acting Deputy Director
Center for Evidence and Practice Improvement
Agency for Healthcare Research and Quality

Stephanie Chang, M.D., M.P.H.
Director, EPC Program
Center for Evidence and Practice Improvement
Agency for Healthcare Research and Quality

Suchitra Iyer, Ph.D.
Task Order Officer
Center for Evidence and Practice Improvement
Agency for Healthcare Research and Quality

Acknowledgments

[names removed for draft]

Key Informants

In designing the study questions, the EPC consulted several Key Informants who represent the end-users of research. The EPC sought the Key Informant input on the priority areas for research and synthesis. Key Informants are not involved in the analysis of the evidence or the writing of the report. Therefore, in the end, study questions, design, methodological approaches, and/or conclusions do not necessarily represent the views of individual Key Informants.

Key Informants must disclose any financial conflicts of interest greater than \$10,000 and any other relevant business or professional conflicts of interest. Because of their role as end-users, individuals with potential conflicts may be retained. The TOO and the EPC work to balance, manage, or mitigate any conflicts of interest.

The list of Key Informants who participated in developing this report follows:

[names removed for draft]

Technical Expert Panel

In designing the study questions and methodology at the outset of this report, the EPC consulted several technical and content experts. Broad expertise and perspectives were sought. Divergent and conflicted opinions are common and perceived as healthy scientific discourse that results in a thoughtful, relevant systematic review. Therefore, in the end, study questions, design, methodologic approaches, and/or conclusions do not necessarily represent the views of individual technical and content experts.

Technical Experts must disclose any financial conflicts of interest greater than \$10,000 and any other relevant business or professional conflicts of interest. Because of their unique clinical or content expertise, individuals with potential conflicts may be retained. The TOO and the EPC work to balance, manage, or mitigate any potential conflicts of interest identified.

The list of Technical Experts who participated in developing this report follows:

[names removed for draft]

Discontinuation of Disease-Modifying Treatment for Multiple Sclerosis

Structured Abstract

Objective. Examine the long-term consequences of discontinuing disease modifying treatment (DMT) for Multiple Sclerosis (MS) by examining the long-term benefits and harms, reasons for discontinuing treatment, and the evidence for people's values, beliefs, and preferences regarding discontinuing DMT.

Data sources. Medline, PsychInfo, Scopus, and the Cochrane Clinical Trials Registry through August 2014 plus reference lists of included studies and recent systematic reviews.

Methods. Two investigators screened abstracts and full texts of identified references for eligibility. Eligible studies included studies of over 3 years that examined FDA-approved DMT compared to placebo, other active DMT, or no DMT, for adults with clinically isolated syndrome or MS in outpatient settings for patient-centered outcomes. We excluded studies of mitoxantrone (since it has a maximum life-time dosage). Timing was relaxed for women considering pregnancy or are pregnant or patients discontinuing natalizumab due to risk factor changes. We extracted data, assessed risk of bias on individual studies, and evaluated strength of the body of evidence for each comparison and outcome. We also evaluated using Technical Brief methods studies of any design that examined individuals' attitudes, values, preferences for discontinuing treatments and health states, or factors and processes patients with MS and clinicians use in shared decisionmaking.

Results. We identified 27 unique studies with discontinuation information, of which 16 studies contained complete information to allow full analysis of long-term benefits and harms. There was insufficient evidence for long-term benefits for DMT for secondary progressive MS patients, and most outcomes for relapse-remitting MS (RRMS) patients. Low-strength evidence suggests long-term all-cause survival is higher for treatment naïve RRMS patients who did not delay starting interferon beta 1b by 2 years and used DMTs for a longer duration than those who started later. Low-strength evidence suggests that interferon use did not change RRMS patients' disability progression. Limited low-strength evidence suggests long-term harms do not differ from short-term harms. The majority of discontinuation tends to occur in the short-term (2 to 3 years). Another 27 unique studies provided intrapersonal, interpersonal, and shared decisionmaking information. No study directly asked why people are not willing to discontinue when treatment is no longer effective; taken as a whole the literature set provides some insight.

Conclusions. MS patients and providers have little information to guide decisions to discontinue DMT. Well-designed long-term observational studies that address benefits and harms are needed. The preferences literature underscores the complexity of the topic and the processes underlying decisionmaking.

Contents

Executive Summary	ES-1
Introduction	1
Background.....	1
Condition.....	1
Treatment Strategies – and Their Discontinuation	2
Scope and Key Questions	3
Scope of the Review	3
Key Questions.....	4
Organization of This Report	5
Methods	6
Topic Refinement and Review Protocol.....	6
Role of the AHRQ Task Order Officer.....	6
Analytic Framework	6
Literature Search Strategy.....	7
Search Strategy	7
Inclusion and Exclusion Criteria.....	8
Study Selection	9
Data Extraction	9
Risk of Bias Assessment of Individual Studies	9
Data Synthesis.....	10
Strength of the Body of Evidence.....	10
Applicability	11
Results	12
Results of Literature Searches	12
Key Question 1. What is the effectiveness of discontinuing disease modifying treatments?.....	13
Description of Included Studies.....	13
KQ1a. What is the evidence for benefits for continuing treatment versus discontinuing in patients with MS?.....	16
Key Points.....	16
Detailed Synthesis.....	19
KQ 1b. What is the evidence for long-term harms?	20
Key Points.....	20
Detailed Synthesis.....	22
Natalizumab Discontinuation or Drug Holiday	22
Key Points.....	23
Detailed Synthesis.....	24
Pregnancy Drug Holiday.....	25
Key Points.....	26
Detailed Synthesis.....	26
KQ 1c. What reasons for discontinuation of disease modifying treatments have been reported in long-term observational cohort studies?.....	28
Key Points.....	28
Detailed Synthesis.....	28

Key Question 2. What are individuals’ values, beliefs, and preferences regarding discontinuing disease modifying treatments?	29
Description of Included Studies.....	29
Overarching Key Point	29
KQ 2a. What are patients’ and providers’ preferences for discontinuation of disease modifying treatments in patients?.....	29
Intrapersonal Literature.....	30
Key Points	30
Detailed Discussion	35
Interpersonal Literature.....	38
Key Points	38
Detailed Discussion	40
KQ 2b. What are patients and providers preferences for participation in shared decisionmaking to discontinue disease modifying treatments?.....	41
Key Points.....	41
Detailed Discussion	45
Discussion	47
Overview.....	47
Issues.....	49
Future Research	50
Limitations	51
References	52
Abbreviations	60

Tables

Table A. Outcomes reported from unique studies included in the analytic set for long-term DMT use [Executive Summary].....	ES-8
Table B. Harms reported from unique studies included in the analytic set [Executive Summary].....	ES-9
Table C. Studies reporting reasons for discontinuing medication [Executive Summary]....	ES-11
Table D. Summary of KQ1 findings for which evidence was found [Executive Summary].....	ES-13
Table 1. FDA approved disease modifying treatments for MS	2
Table 2. Review PICOTS.....	8
Table 3. Study inclusion criteria	9
Table 4. MS study followup and treatment duration	14
Table 5. Outcomes reported from unique studies included in the analytic set for long-term DMT use.....	17
Table 6. Harms reported from unique studies included in the analytic set.....	21
Table 7. Natalizumab rebound definitions.....	23
Table 8. Studies reporting pregnancy outcomes by drug.....	26
Table 9. Studies reporting reasons for discontinuing medications	28
Table 10. Included studies for intrapersonal literature	31
Table 11. Included studies for interpersonal literature	39
Table 12. Helpful and unhelpful communications in MS.....	40
Table 13. Included studies for shared decisionmaking literature.....	42
Table 14. Summary of KQ1 Findings for which evidence was found.....	47

Figures

Figure A. Conceptual framework for Key Questions [Executive Summary].....ES-4
Figure B. Analytic framework for discontinuing disease-modifying treatments for
Multiple Sclerosis [Executive Summary].....ES-5
Figure 1. Conceptual framework for Key Questions5
Figure 2. Analytic framework for discontinuing disease-modifying treatments for
Multiple Sclerosis.....7
Figure 3. Disposition of studies identified for this review12
Figure 4. Intrapersonal factors30
Figure 5. Interpersonal factors38
Figure 6. Shared decisionmaking factors.....41

Appendixes

Appendix A. Search Algorithms
Appendix B. Excluded Studies
Appendix C. Evidence Tables
Appendix D. Risk of Bias for Included KQ1 Studies

Executive Summary

Background

Multiple sclerosis (MS) is a potentially debilitating disease characterized by demyelination (deterioration of the protective myelin sheaths covering nerves in the brain and spinal cord) and axon loss within the central nervous system. The lesions created by the myelin destruction and resulting scar tissue interfere with normal transmission along nerve fibers within the brain and to and from the brain. This results in classic symptoms associated with MS. The condition affects 2.5 million individuals worldwide and approximately 400,000 in the United States.¹ Twice as many women as men are affected, and diagnosis usually occurs between the ages of 20 and 50.¹ Both symptoms and disease course are highly individualized, depending on where the lesions occur within the central nervous system and the type of MS. Clinically definite MS types include:

- Relapse-remitting MS (RRMS) is the most common form, affecting approximately 85 percent of patients. Patients typically are diagnosed in their 20s or 30s. Neurologic symptoms often present over a course of days, stabilize, and spontaneously resolve; however, over time permanent disability often develops and progresses with further relapses. Median times to disability progression (secondary progressive MS) range from 15 to 29 years.²
- Secondary progressive MS (SPMS) is characterized by worsening disability with or without relapses. Patients may have exacerbations, but the trend over time is a relatively steady progression of disease and disability.¹
- Primary progressive MS (PPMS) represents about 15 percent of patients and affects women and men about equally. This form has the worst prognosis and is characterized by gradual and progressive worsening without distinct relapses.¹
- Primary relapsing MS (PRMS) affects about 5 percent of patients. This form is usually initially diagnosed as PPMS due to a steady worsening of functioning and changed to PRMS when the patient experiences a relapse.

People with clinically isolated syndrome (CIS), a first neurological episode, may or may not go on to develop MS. CIS involves neurological symptoms such as optic neuritis and unilateral body weakness that last at least 24 hours and are caused by inflammation or demyelination in one (monofocal) or more (multifocal) sites in the central nervous system. In a cohort of 107 CIS patients followed for 20 years, 60 patients with three or more lesions (seen via magnetic resonance imaging [MRI]) converted to MS, while only 7 with normal baseline MRI converted.³

MS cannot be cured with current therapies. Current disease-modifying treatments (DMTs) comprise immunomodulating and immunosuppressant medications, which aim to slow the progression of MS and relieve symptoms to improve quality of life. The working hypothesis is that reducing or preventing new lesions and their sequelae slows disease progression. Currently FDA-approved DMT for RRMS include interferon beta-1a and 1b (some formulations also approved for CIS), glatiramer acetate, mitoxantrone (also approved for SPMS and PRMS), natalizumab, fingolimod, and dimethyl fumarate.

A 2013 Cochrane overview review and network analysis of 44 2- to 3-year trials of DMT for MS found moderate to high quality evidence that DMTs are effective against recurrence of relapses in RRMS during the first 24 months of treatment compared with placebo.⁴ The network analysis ranked natalizumab as the most effective drug, followed in order by IFNbeta-1a,

mitoxantrone, glatiramer acetate, and IFNbeta-1b. Confidence in the evidence dropped to moderate for direct comparisons of mitoxantrone or IFNbeta-1b versus placebo and very low for glatiramer acetate versus placebo. Further, natalizumab and IFNbeta-1b were more effective than IFNbeta-1a in reducing the number of RRMS participants with disease progression as measured with surrogate markers. In patients with progressive MS, both pairwise and network analysis found no DMT analyzed prevented disability progression over 2 or 3 years. The overview and network analysis were too recent to include the newest approved drugs such as fingolimod or dimethylfumerate.

Unfortunately, the efficacy level of MS treatments appears to correlate with the frequency and severity of side effects.⁵ The first-line treatments, the interferon drugs and glatiramer acetate, were modestly efficacious and side-effects were tolerable by many patients.⁴ Mitoxantrone, an escalation medication, has a lifetime maximum dosage due to severe cardiotoxicity.⁵ Natalizumab, the first monoclonal antibody, can induce a fatal progressive multifocal leukoencephalopathy (PML). Risk for PML increases with natalizumab use longer than 2 years, anti-JC virus antibody status, and prior use of immunosuppressive agents.⁶ People taking natalizumab may take a drug holiday or discontinue use completely if their risk factor increases assessed by a positive test for the anti-JCV antibody status.

Women considering pregnancy face special considerations for drug holidays. Women must weigh the possible risks of DMT exposure to the unborn fetus against the maternal risk of disease progression if she discontinues DMT. Neurologists commonly counsel a woman to discontinue her medications 3 months prior to trying to conceive, although rates of fetal exposure to DMT vary greatly by country. Unfortunately, conception isn't always easily planned and the drug holiday may continue for much longer than anticipated, possibly years.

DMTs for MS are not intended for life-long use. However, with few exceptions (such as natalizumab use or intended pregnancy), patients who opt for DMTs for MS may end up using it for several years to decades, as long as they tolerate the treatment and the DMT seems effective. Patients may switch between different DMTs in order to find one that is more effective or more tolerable, and studies have found high rates of switching between drugs.⁷ Some patients cannot tolerate any of the DMTs, but if a tolerable drug regime is determined, treatment generally continues until the individual reaches a disease course stage where DMTs no longer help. Such a point may be reached when a person is determined to be nonresponsive to the medication due to disease progression. The determination of when DMT is no longer helpful is challenging. Thus, major questions of interest are whether or not DMTs for MS alter the natural history of the disease in the long-run and when to discontinue DMTs. The related question addresses the influence of patient values, beliefs, and preferences regarding discontinuing DMTs. Such information should support clinicians, patients, consumer advocates, and other decisionmakers on decisions to discontinue treatment.

Scope and Key Questions

This review examines the long-term (more than 3 years) consequences of discontinuing DMT. We looked for evidence that directly assessed discontinuing versus continuing DMT, and also evidence for long-term (more than 3 years) benefits and harms for either continuing or discontinuing, since the decision to continue or discontinue can be informed by the benefits or harms directly linked to either course of action. This information would extend understanding beyond the short-term trials examined in the 2013 Cochrane review. We were also interested in the reasons for discontinuing treatment that were reported in the long-term studies.

We concentrated on outcomes relevant to the patient for decisionmaking, such as relapse rates and changes in disability level, rather than intermediate outcomes such as lab tests for neutralizing antibodies. MRI to identify multiple sclerosis-related lesions has been shown to correlate with short-term relapse rates, 6 months to 2 years.⁵ However, long-term MRI followup as surrogate marker for relapse rates or, more importantly, disease progression, currently lacks evidence.⁸ Thus, we did not use MRI as a long-term outcome in this review. However, we included MRI as a short-term outcome in the subset of patients discontinuing natalizumab due to risk of PML.

People with MS commonly switch between the available DMTs depending on tolerance, presence of adverse effects, and perceived helpfulness of the treatment. The pertinent clinical question for switching medications is how to define the threshold of disease activity for changing medications. This important question is qualitatively different than that of when to stop DMT completely. To adequately address the question of when to switch medication will likely require a review of both short- and long-term research. Therefore, questions related to switching between DMTs are outside the scope of this review.

We synthesized the evidence in the published literature to address the following two key questions (KQ):

KQ1: What are the consequences of discontinuing disease-modifying treatments in adult patients?

- a. What is the evidence for benefits for continuing versus discontinuing treatment?
- b. What is the evidence for long-term harms?
- c. What reasons for discontinuation of disease-modifying treatments have been reported in long-term observational cohort studies?

KQ2: What are individual values, beliefs, and preferences regarding discontinuing disease-modifying treatments?

- a. What are patient and provider preferences for discontinuation of disease-modifying treatments?
- b. What are patient and provider preferences for participation in shared decisionmaking to discontinue disease-modifying treatments?

Figure A provides a conceptual framework that links the KQs. At the top it depicts the logic path both physicians and patients must travel when considering disease-modifying treatments:

- Does it work?
- What drug should I start with?
- When should I switch a patient to a new drug and what should that drug be?
- When should a patient discontinue disease-modifying treatment?

This logic path describes the context within which patients and clinicians make decisions about DMT or, in the case of this review, discontinuation (KQ1). The lower part of the figure, the conceptual basis for KQ2, depicts the progression from an individual's internal decision context and process (such as preferences, values, knowledge, beliefs, and cognitive behaviors and habits) to an interpersonal decision context and processes between the physician and patient. The overlapping ovals representing the clinician and the patient indicate information shared between the two parties versus information and other cognitive processes specific to one individual. Any overlap depends in part on the level of sophistication a patient brings to the

decisionmaking process and in part on how well a physician understands a patient’s beliefs, values, goals, and preferences. For example, a patient newly diagnosed with MS in the novice phase of learning about MS would likely have a smaller overlap.⁹ The interaction between the physician and patient results in decisions that can vary in their level of concordance.

Figure A. Conceptual framework for Key Questions






Figure B provides an analytic framework describing the treatment path and long-term benefits and harms of continuing versus discontinuing disease-modifying treatment for KQ1.

Figure B. Analytic framework for discontinuing disease-modifying treatments for Multiple Sclerosis



DMT=disease modifying treatment; KQ=key question; MS=multiple sclerosis

Methods

The methods for this review follow the methods suggested in the ARHQ Methods Guide for Effectiveness and Comparative Effectiveness Reviews (available at <http://www.effectivehealthcare.ahrq.gov/methodsguide.cfm>). We used Technical Brief methods for KQ2. A complete description of the methods can be found in the full report. All methods and analyses were determined *a priori*.

Literature Search Strategy

We used bibliographic databases to identify randomized controlled trials, systematic reviews, and observational studies with control groups published from 1990 to August 2014 for studies enrolling adults with CIS or MS. Relevant bibliographic databases for this topic include MEDLINE, the Cochrane Central Register of Controlled Trials (CENTRAL), PsychInfo, and Scopus. We supplemented bibliographic database searches with backward citation searches of highly relevant systematic reviews.

Eligibility

For KQ1, we included studies from 1990 to the present that examined patients using FDA-approved DMT compared to placebo, other active DMT, or no DMT, for people with CIS or MS in outpatient settings for patient-centered outcomes. We excluded studies of: pediatric MS patients, mitoxantrone (since it has a maximum life-time dosage); and studies with 3 year or less followup. However timing was relaxed for women considering pregnancy or are pregnant or patients discontinuing natalizumab due to changes in risk of PML.

For KQ2, we included studies of any design that examined individuals' attitudes, values, preferences for discontinuing treatments and health states, perceptions of risk and seriousness of

health states, or factors and processes patients with MS and clinicians use in shared decisionmaking.

Two independent investigators independently determined study eligibility, resolved disagreements through discussions (possibly with a third adjudicator) until consensus was achieved. Study selection involved an extensive full text review process to identify adult subgroups, since subgroup reporting was commonly not evident in titles and abstracts.

Data Extraction

We extracted data from included studies into standardized evidence tables. Extracted data included relevant population, intervention, baseline, and outcomes data on the adult subgroups of interest. Initial data abstraction was quality checked by a second investigator.

Risk of Bias Assessment of Individual Studies

The risk of bias of eligible studies was assessed by two independent investigators using instruments specific to each study design for KQ1. The two investigators consulted to reconcile any discrepancies in overall risk of bias assessments and, when needed, a third investigator was consulted to reconcile the summary judgment. We developed an instrument to assess risk of bias for observational studies using the RTI Observational Studies Risk of Bias and Precision Item Bank for KQ1.¹⁰ We selected items most relevant in assessing risk of bias for this topic, including participant selection, ascertainment, attrition, performance, and appropriateness of analytic methods. Following Technical Brief methods, risk of bias was not assessed for KQ2.

Data Synthesis

For KQ1, we summarized the results into evidence tables and qualitatively synthesized evidence for specific disease-modifying medications and unique population, duration of DMT, length of study followup, and outcomes combinations. We used the best of the available evidence provided by the identified observational literature.¹¹ So while all identified articles underwent abstraction, only the best evidence, based on those studies closest to an “ideal” study design¹² (those studies with the lowest risk of bias) are included in the evidence synthesis.

For KQ2, we summarized the results into evidence tables and conducted a qualitative synthesis. We grouped the literature by mapping the included studies to the conceptual framework (Figure A) and analyzed the study findings for emergent patterns for patient perspectives, clinician perspectives, and clinician/patient interpersonal interactions.

Strength of the Body of Evidence

The overall strength of evidence for select outcomes for KQ1 (relapse rate, change in disability, progression of disease, time to sustained disease progression) within each comparison were evaluated based on four required domains: (1) study limitations (internal validity); (2) directness (single, direct link between intervention and outcome); (3) consistency (similarity of effect direction and size); and (4) precision (degree of certainty around an estimate).¹³ A fifth domain, reporting bias, was assessed when SOE based upon the first four domains was moderate or high.¹³ Based on study design and conduct, risk of bias was rated as low, medium, or high. Consistency was rated as consistent, inconsistent, or unknown/not applicable (e.g., single study). Directness was rated as either direct or indirect. Precision was rated as precise or imprecise. Other factors that may be considered in assessing strength of evidence include dose-response

relationship, the presence of confounders, and strength of association. Based on these factors, the overall evidence for each outcome was rated as:¹³

- **High:** Very confident that estimate of effect lies close to true effect. Few or no deficiencies in body of evidence, findings believed to be stable.
- **Moderate:** Moderately confident that estimate of effect lies close to true effect. Some deficiencies in body of evidence; findings likely to be stable, but some doubt.
- **Low:** Limited confidence that estimate of effect lies close to true effect; major or numerous deficiencies in body of evidence. Additional evidence necessary before concluding that findings are stable or that estimate of effect is close to true effect.
- **Insufficient:** No evidence, unable to estimate an effect, or no confidence in estimate of effect. No evidence is available or the body of evidence precludes judgment.

Following Technical Brief methods, strength of evidence was not assessed for KQ2. This KQ was approached in a hypothesis-generating manner.

Applicability

Applicability of studies was determined according to the PICOTS framework. Study characteristics that may affect applicability include, but are not limited to, type of MS or CIS, unobserved differences in patient preferences, or country within which treatment is provided, given differences in international regulations and treatment preferences.¹⁴

Results

We identified 4359 unique citations searching from 1990 to August 2014. After excluding articles at title and abstract, full texts of 198 articles were reviewed to determine final inclusion. Seven articles were added through hand search. Of the 61 articles retained for KQ1, 11 were specific to discontinuing natalizumab due to increased risk and 12 were specific to discontinuing due to pregnancy. Of the remaining 38 articles comprising 27 unique studies, only 16 studies contained complete information to allow for full analysis. All 38 articles were reviewed for information on reported reasons for discontinuation. For KQ2, 30 articles comprising 27 unique studies were included. Detailed tables and synthesis can be found in the full report.

Key Question 1a. Benefits of continuing versus discontinuing DMT

Key Points

- No studies directly assessed the consequences of continuing versus discontinuing DMT in comparable populations.
- Low strength evidence from one moderate risk of bias study suggests long-term all-cause survival is higher for treatment naïve relapse-remitting MS (RRMS) patients who did not delay starting interferon beta 1b by 2 years and used DMTs for a longer duration than those who started later.
- Low strength evidence from one moderate risk of bias study suggests that interferon use did not change disability progression for RRMS patients.
- Insufficient evidence was available for long-term benefits for DMT for secondary progressive MS (SPMS) patients, and most outcomes for RRMS patients. Except for

those noted above, studies were high risk of bias, had small sample sizes, and reported effects were small in magnitude.

Table A. Outcomes reported from unique studies included in the analytic set for long-term DMT use

Author	Type of MS at Baseline	Median or Mean Years to Final Assessment	All-cause Mortality	Convert to SPMS	Strength of Evidence
INFB1b					
Goodin, 2012 ^{15,16}	RRMS	21y	All-cause mortality: 250 mg arm vs. placebo – HR 0.532 (98% CI, 0.31-0.90) 50 mg arm vs placebo – HR 0.54 (95% CI, 0.32-0.92) favors treatment		Low
INFB mixed					
Shirani, 2012 ¹⁷	RRMS	4.5-10.5y		Time to sustained EDSS ≥6, No difference from contemporary control (HR 1.30; 95% CI: 0.92–1.83) or historical control (HR 0.77; 95% CI: 0.58–1.02)	Low

EDSS=extended disability scale score; HR=hazard ration; mg=milligram; MS=multiple sclerosis; RRMS=relapse remitting multiple sclerosis; SPMS=secondary-progressive multiple sclerosis; y=year

No studies directly assessed continuing versus discontinuing DMT in comparable populations. We therefore turned to literature examining benefits for continuing DMT long-term. Variation among the included studies on long-term benefits for DMT on patient populations, interventions, outcome measurements, and time frames, precluded meaningful pooling. Only two studies provide a low strength of evidence for two benefit outcomes measured long-term for interferons (Table A).

One moderate risk of bias study examined all-cause mortality over a 21 year period for 366 patients who had enrolled in a randomized controlled trial (RCT) (98.4 percent of the original RCT participants) testing interferon beta-1b for treatment naïve RRMS patients in 11 clinics in North America.¹⁵ The study’s strength lies in the nearly complete followup of patients and the objective outcome measure. Participants in the treatment arms showed lower all-cause mortality compared to the placebo arm. The survival rate for the placebo arm was consistent with survival rates reported in MS natural history studies. Median treatment duration for the three groups ranged between 7 years for the placebo group, 14 years for the 50 mg arm, and 12 years for the 250 mg arm. Patients assigned to placebo had both later starts and shorter exposure to DMTs. Thus, the study cannot distinguish between the effects of early use and the effects of long-term use.

One moderate risk of bias study examined the association between interferon beta use and progression to sustained Expanded Disability Status Scale (EDSS) of 6 for 2656 RRMS patients in Canada.¹⁷ Three arms were used: a treatment cohort followed for 5.1 years, a contemporary cohort followed 4 years, and a historical cohort (drawn from pre-interferon period) followed 10.8 years. The strength of this study lies in the almost complete capture of MS patients since patients were unable to obtain DMTs other than from the participating clinic, and the multiple statistical approaches used to test for association, including use of comorbidities (Charlson score) and

socioeconomic status along with age, sex, disease duration, and EDSS. Propensity score adjustments did not substantially change the results. The study did not find statistically significant differences in hazard rates for reaching EDSS 6 for either contemporary or historical cohort comparisons.

Insufficient evidence exists to address long-term benefits for glatiramer acetate, teriflunomide, and natalizumab for either RRMS or SPMS, as well as other important MS outcomes for interferon beta for RRMS beyond all-cause mortality or 5-year disability progression for interferon beta.

Key Question 1b. Evidence for harms

Key Points

- Limited low strength evidence suggests harms over the long term (up to 16 years for interferon, 22 years for glatiramer acetate, and 8.5 years for teriflunomide) do not differ from short-term harms.
- The majority of discontinuation tends to occur in the short-term (2 to 3 years from start).
- Broad variation in harms reporting precludes informative aggregation and summary.
- Evidence is insufficient for whether rebound after discontinuing natalizumab exists due to the high risk of bias and small study sample sizes.
- Evidence is insufficient to address the risks of fetal exposure to DMT during pregnancy in women with MS or the risks to the mother from the drug holiday due to high risk of bias and small sample sizes.

Table B. Harms reported from unique studies included in the analytic set

DMT	Number of Studies Total N Followup	Any Adverse Event	At Least One Serious Adverse Event	Treatment Discontinuation for Adverse Event	Comparator Groups	Reported Results
IFN β -1a ¹⁸	1 N=429 4 y-	Most common AEs: Injection site reactions, headache, flu-like symptoms	NR	NR	No	No difference from short-term events
IFN β -1b ^{16,19}	2 N=746 5 – 16 y	Most common AEs: Injection site reactions, depression, flu-like symptoms, headache	21% to 24%	Discontinuation rates “high” but numbers not reported	No	No difference from short-term events Frequency declined over 16 y time in continuers
IFN β mixed ^{7,20,21}	3 N=587 4 - 8 y	Most common AEs: Injection site reactions, depression, flu-like symptoms, headache.	NR	3% during LT FU. Discontinue for serious AE more likely to happen early in treatment course (1 y)	No	Headache more likely for β -1a, injection site reactions for β -1b, no other differences between type of IFN β Majority of discontinuation occur early/short term.

DMT	Number of Studies Total N Followup	Any Adverse Event	At Least One Serious Adverse Event	Treatment Discontinuation for Adverse Event	Comparator Groups	Reported Results
INFβ mixed ²² SPMS	1 N=146 5 y	NR	NR	3.4%, although timing isn't clear	No	Majority of discontinuation occur early/short term.
Glatiramer Acetate ²³⁻²⁵	3 N=483 4y – 22 y	Only one reported overall rates: 87.3% Most common AE: injection site reactions	NR	Only one reported overall rates: 4.9% in long-term extension	No	Majority of discontinuation occur early/short term No difference from short-term events
Teriflunomide ²⁶	1 N=147 8.5 y followup	98% of 7 mg dose and 100% of 14 mg dose experienced treatment emergent AE	36% of 7 mg dose and 29% of 14 mg dose	13.6% of 7 mg dose and 13.6% of 14 mg dose for AE	One comparison to general population rates for cancer	No difference from short-term events

AEs=adverse events; DMT=disease modifying treatment; FU=followup; IFNβ=interferon beta; GA=glatiramer acetate; im=intramuscular; LTFU=long-term followup; med=median; mg=milligram; MS=multiple sclerosis; NR=not reported; RRMS=relapse remitting multiple sclerosis; sc=subcutaneous remitting multiple sclerosis; SD=standard deviation; SPMS=secondary-progressive multiple sclerosis; y=year

Eleven of the 16 unique studies reported harms in sufficient detail for abstraction (Table B).^{7,15,16,18-33} Only one of the studies was moderate risk of bias;¹⁵ all others were rated as high risk of bias.

The included studies used a wide range of reporting methods and adverse event categories that precluded simple aggregation over the studies. The most commonly reported adverse events were injection site reactions, flu-like symptoms, depression, and headache. Serious adverse events were generally not reported, although two studies gave rates of about 25 percent to 30 percent of participants. Discontinuations tended to occur during the first or second year of the study. When reported, discontinuation rates during long-term followup were low, about 3 percent to 4 percent, but rates due to adverse events were not separate from total discontinuation rates, which would also include perceived lack of efficacy and other reasons not necessarily related to adverse events or side effects. Further, all studies lost participants to attrition. Dropouts from observational studies are more likely to bias reporting towards lack of adverse events. Patients on long-term treatment are self-selected for positive outcomes, even though this may be due to any combination of treatment effects and benign disease course. The studies also did not use large enough patient populations to adequately detect rare events.

Eight observational studies (all high risk of bias) addressed the risks of rebound disease activity with natalizumab treatment interruption. Determining whether rebound exists requires comparing disease activity prior to receiving natalizumab and disease activity after interrupting treatment. None of the studies used appropriate comparison groups. All but one study used a subjective definition for rebound.

Twelve observational studies (all high risk of bias) addressed the benefits and risks to mothers and fetuses of interferon, glatiramer acetate, or natalizumab treatment discontinuation due to pregnancy or intended pregnancy. Women who discontinue DMT with the intention of becoming pregnant risk increased relapses between discontinuation and pregnancy, as well as

post-partum. Given that the studied populations are those who became pregnant, none of the studies capture what happens to women who discontinue DMT but do not become pregnant. Therefore, no research has observed whether such women are at increased risk of relapse.

Key Question 1c. Reasons for discontinuing DMT

Key Points

- The broad variation in discontinuation reporting prevented useful aggregation of studies.
- All studies reported one or more adverse events and inefficacy or progression of disability as reasons to discontinue.
- Patient reasons for discontinuing DMT were not explored.

Table C. Studies reporting reasons for discontinuing medication

DMT	Total Number of Studies	Adverse Event	Inefficacy or Progression of Disability*	Intended Pregnancy	Long-term Stable MS	Death	Protocol Violation	Patient Decision
Glatiramer acetate	3	3	3	2	1	1	2	3
Teriflunomide	1	1	1	0	0	1	1	1
Interferon beta-1a	1	1	1	1	0	1	0	1
Interferon beta-1b	4	4	4	3	0	3	2	3
Interferon beta mixed	7	7	7	5	1	1	0	5
DMT mixed	3	3	3	3	0	1	0	3

*Category includes counts of both discontinuation based on clinician evaluation of disease progression and patient evaluation of lack of efficacy.

Twenty articles of the full reporting set reported reasons for discontinuing treatment (Table C). The wide range of reporting methods and discontinuation categories prohibited detailed quantitative aggregation over the studies. Most articles reported numerous reasons for discontinuations. Unfortunately, the patient’s decision to discontinue category remained largely unexplored. Minimal text generally used phrases like “by own will,”^{22,34} “withdrew consent,”^{19,25} or “voluntary withdrawal.”^{31,35,36}

Key Question 2. Preferences for discontinuing DMT

The 27 included unique studies (30 total articles) represented a wide range of study aims. Designs ranged from factor analysis of questionnaires to experimental psychology lab tests to trials of shared decisionmaking interventions. Study locations were international, including the United States,³⁷⁻⁴⁴ Netherlands,⁴⁵⁻⁴⁷ Germany,⁴⁸⁻⁵⁸ Norway,⁵⁹ a consortium of European countries,⁶⁰ Canada,^{61,62} Italy,⁶³ and Ireland.⁶⁴

Given the complexity of understanding preferences and behaviors, and the wide range of study designs used over a small literature set, all KQ2 key points should be viewed as preliminary.

Key Points for KQ2a. Patient and Provider Preferences for Discontinuing DMT (Intrapersonal)

- Patients overestimated risk of wheelchair use in the intermediate term but underestimated it for life-time risk. This underestimation may indicate the uncertainty felt by MS patients when contemplating their personal trajectories rather than lack of knowledge (two studies).
- Patients are likely to use heuristics in risk assessments (one study).
- With training, patients can improve risk understanding and sense of informed choice (one study).
- Quantified preference studies suggest patients are willing to make risk trade-offs for benefits only to the point where the discomfort from side effects and treatment are equal to or worse than the disease symptoms (two studies).
- Increasing out-of-pocket cost reduces DMT purchases (two studies).
- Common reasons for discontinuing include side-effects, perceived lack of efficacy against disease progression or uncertainty regarding efficacy, administration method and frequency, and cost (five studies).
- MS patients tended to take responsibility for the decision to discontinue (three studies), while viewing their neurologist as the driver for decisions regarding choice of DMT (one study).
- Psychological models of behavior support the presence of rational processes contributing to patient decisionmaking (two studies).

We found 14 studies to populate the intrapersonal portion of Figure A addressing intrapersonal factors in the values and preferences literature. The literature tended to examine attitudes and cognition rather than patient knowledge and how that knowledge impacted decisions. Studies examined risk expectation, preferences for DMT treatment and treatment trade-offs, knowledge of cost factors, reasons for using or discontinuing DMTs, and theoretical approaches to understanding decisionmaking and behavior processes.

Key Points for KQ2a. (Interpersonal)

- MS patients and their physicians can differ significantly in their perceptions of the relative importance of health states and risks (two studies).
- Physicians and patients must communicate in order to clarify differences in perceptions and preferences (one study).

We found much less literature to populate the interpersonal portion of Figure A. Three studies Interpersonal concerns including the knowledge, values, beliefs, and preferences that both the patient and physician bring to a decisionmaking encounter, and also the extent to which this information is shared between the two. Communication issues also are important at the interpersonal level.

Key Points for KQ2b. Patient and Provider Preferences for Participation in Shared Decisionmaking

- MS patients may bring different information-seeking orientations to shared decisionmaking processes (one study).

- Mildly cognitively impaired MS patients show a significantly reduced capacity to understand treatment disclosures, but understanding may be brought back to the level of healthy controls through repetition and recognition cuing (one study).
- The large majority of people with MS prefer a collaborative or active participation role in treatment decisions (three non-U.S. studies).
- Physicians cannot reliably predict patient preferences for an active participation role and may inadvertently pull patients away from their preferred treatment (two studies).
- Both patient and third party observers rated physicians as showing limited skill at involving patients in shared decisionmaking (one study).
- Providing balanced, evidence-based information alone is not sufficient to alter decisionmaking processes to help patients achieve their preferred participation role (one study).

Literature for this KQ sub-question relates to shared decisionmaking for patients and providers. All but one of the identified studies populated the center box in the shared decisionmaking portion of Figure A. Five studies addressed shared decisionmaking from the patient side, four addressed the physician side, and one tested a decision aid to improve shared decisionmaking.

Discussion

MS patients and providers have little information to guide decisions to discontinue DMT. There was no literature that directly compared continuing versus discontinuing DMT in comparable populations. There was sparse information available to address one part of the decisionmaking picture faced by providers and patients, which is long-term benefits and harms. As summarized in Table D, low-strength evidence was found for increased all-cause mortality for patients who started interferon beta 1b 2 years earlier than the comparators, but no differences between treated and comparator groups in time to progression to SPMS (as measured by EDSS greater than 6). Similarly, overall long-term harms were found to be no different than short-term harms. Low-strength evidence implies low confidence in the findings and the expectation that future research could change the findings. Evidence is insufficient to assess long-term benefits and harms for all other patient populations, type of DMT, or outcome.

Table D. Summary of KQ1 findings for which sufficient evidence was found

DMTs Used in Long-term Studies Assessing Discontinuing or Continuing DMTs	Number of Studies Number of Participants	Findings	Strength of Evidence
All cause survival			
Interferon beta 1b	1 study n=366 RRMS	All-cause mortality: 250 mg arm vs. placebo – HR 0.532 (98% CI, 0.31 to 0.90) 50 mg arm vs. placebo – HR 0.54 (95% CI, 0.32 to 0.92) favors treatment	Low (moderate risk of bias, unknown consistency)
Time to progression to SPMS			
Mixed Interferon	1 study n=2656 RRMS	No difference from contemporary or historical control	Low (moderate risk of bias, unknown consistency)
Overall Harms			
Interferon, glatiramer acetate,	3 studies	Long-term harms not	Low (high risk of bias,

DMTs Used in Long-term Studies Assessing Discontinuing or Continuing DMTs	Number of Studies Number of Participants	Findings	Strength of Evidence
teriflunomide	n=746 RRMS interferon beta 1b, 16y; 46 RRMS glatiramer acetate, 22 y; 131 RRMS, 16 SPMS, teriflunomide, 8.5y	different than short term (qualitative finding)	consistent, indeterminate precision)

DMT=disease modifying treatment; HR=hazard ratio; RRMS=relapse remitting multiple sclerosis; SPMS=secondary-progressive multiple sclerosis; y=year

The current literature did not examine whether long-term benefits for DMTs remain after a patient converts to SPMS. For the special cases of natalizumab and planned pregnancy discontinuations, evidence was insufficient to answer whether discontinuation is problem-free.

In the absence of evidence, providers and patients are left with little to inform their preferences and guide their decisions regarding when to discontinue treatments. The majority of included studies reported reasons for patients discontinuing treatments, but the information provided was without detail. Adverse events and inefficacy or progression of disability were two expected categories. Other possible reasons for discontinuation, such as a patient’s desire to try alternative medicine approaches, perceived risk of long-term use, or financial concerns such as out of pocket costs or loss of insurance, are not noted. The “patient decision” category for discontinuing was consistently unexplored.

Key Question 2 aimed to delve into what is known about patient and provider preferences. While the literature was sparse, with only 28 studies available to populate the conceptual map provided in Figure A, each of the three major conceptual areas was at least partially represented. No study directly asked why people are not willing to discontinue when treatment is no longer effective, but taken as a whole the literature set provides some insight.

Overall, one can weave together the general themes found in the KQ2 literature. Even though physicians cannot reliably predict patient preferences for shared decisionmaking, and often have different perceptions of the relative importance of health status or acceptable risks, when it comes to the decision to discontinue DMT treatment, the patient is the driving voice in the decision, and this preference and role are generally unchallenged by the physician. In some DMT discontinuations, the balance of shared decisionmaking may shift to discordance between the physician and patient, with the physician deferring to patient preferences for continuing or discontinuing treatment. The quantified preferences work by Prosser and colleagues⁴⁴ illustrates a paradox, where patients are less likely to prefer DMT during the early course of the disease, when disease symptoms are lower than the side effects of the DMT, and more likely to use it at later stages of the disease when the side effects are less than disease symptoms. This behavior is counter to the hypothesis under which DMTs are assumed to work – reducing relapses early in the disease course to prevent or delay disease progression. Without more solid evidence for the long-term net benefits, or the thresholds at which treatment is no longer effective in preventing disease progression, the decision to discontinue treatment remains preference sensitive.

The preferences literature underscores the complexity of the topic and the processes underlying decisionmaking. Both rational and nonrational processes were found to be at play, and neither had primacy over the other. Cost was a factor in both self-report and through observation of purchasing behavior. Cognitive deficits impairing decisional capacity may be overcome with adequate cuing. Information is a necessary component of decisionmaking, yet nonrational factors can influence what information is sought at what time.

Preferences, values, and beliefs are highly variable, may change over time, and are linked to the nature of the patients' relationships with their doctors. There may well be differences based on age, sex, race, class, and other factors. A patient's preference position between "treat my MS at any cost/comfort from knowledge of receiving treatment" and "need strong evidence that the medication will help and be worth the cost/side effects" may change over time and as the disease changes.

Changing perceptions regarding health states was common across different parts of the intrapersonal literature. Risk perceptions and quantified preferences (which are risk-based as well) both suggested that people with longer MS experience assigned higher values to, or viewed as less serious, disabled states. This is a finding consistent with other research into how people value different health states. Many people overestimate their aversion to hypothetical states of disability and hence eliminate treatment options that might lead to such disability, especially if it could be long-term.⁶⁵⁻⁶⁸ The hypothetical disutilities for these states are consistently higher than those for persons actually experiencing the state.

Issues

Several challenges impede the ability to gather evidence to inform decisions to discontinue DMTs. First, the potential differential effectiveness of DMTs for different patient subpopulations is unclear, due both to lack of studies examining the questions as well as the use of study designs that are unsatisfactory. Whether DMTs for CIS patients is effective remains an open question. DMTs may offer little benefit in exchange for side effects and potential harms for patients with a benign MS course. Conversely, who is at risk of worsened disease activity (such as a rebound effect or overshoot) when DMTs are discontinued, possibly prematurely? We cannot currently predict early or benign disease courses.

Second, the transition from RRMS to SPMS is difficult to ascertain and therefore poses challenges in the decision to discontinue treatment. There are no clear biomarkers and no distinct boundaries for the transition. Further, how does one differentiate between a "stable" RRMS, one which may be induced by DMTs preventing relapses, and SPMS? Currently, EDSS changes, or a score of 6 or 7, and clinical judgment are generally used. However, patients who may be "close" to SPMS but "stable" may look similar, and without clear clinical markers to differentiate, both provider and patient are left with uncertainty.

This observation leads to the third major challenge: measuring disability. The EDSS is the most commonly used scale in research, in part because it is the longest standing. Because the EDSS is largely driven by mobility assessment, available research is generally silent on potential benefits of DMT other than ambulation, such as upper limb function and cognitive impairments. Other validated measures of health status in MS which incorporate more function domains include the MSQOL-54, the Functional Assessment of Multiple Sclerosis (FAMS), and the Multiple sclerosis Quality-of-Life Inventory (MSQLI).⁶⁹⁻⁷¹ As seen in KQ2, given that people with MS can value health domains differently than physicians (or perhaps researchers),⁶¹ the broader range of disability assessment should be pursued regardless of any potential limitations comparing results with studies that used the EDSS exclusively.

Without adequate measures of quality of life, balancing the benefits of treatments against harms becomes challenging, especially across different drug regimens. DMTs are not benign with regard to side effects and risk profiles. Quality of life benefits of treatment are offset by quality of life decreases due to side effects and risk profiles are important.

Much remains to be done to understand patient preferences. Emerging but useful information was available to explore KQ2, but no study directly asked the question about preference for discontinuing treatment or explored why patients are unwilling to discontinue when treatment is no longer effective. Lonergan and colleagues approached the question tangentially, asking physicians about how they counsel patients when considering discontinuation.⁶⁴ Providers who are involved with such counseling sessions would also benefit from research that separates understanding of preferences, which may be clear to the patient, and the mixed feelings such preferences may generate, ranging from fear or grief related to “giving up” on the disease to relief for no longer carrying the burden of DMTs.

Newly approved drugs, such as fingolimod, and drugs in the development pipeline are emphasizing oral administration to improve medication uptake and adherence to treatment programs. Self-injection can be a deterrent to patients with MS starting first-line DMTs and “shot-fatigue” is a significant factor for adherence. Oral medications will certainly have implications for preferences for continuing and discontinuing DMTs.

Future Research

Since only three areas of evidence for KQ1 were sufficient to provide answers with low strength of evidence, essentially all questions related to KQ1 would benefit from further study. The utility of studies for estimating long-term treatment effectiveness in MS can be improved by using prospective, population-based designs with appropriate comparators and standardized data collection methods. Study cohorts must be better characterized with respect to demographic and clinical characteristics, as well as other potential factors that may influence outcome such as socioeconomic status, access to care, health behaviors, and comorbidities. Near-complete patient retention with regularly scheduled patient visits is also necessary. Accounting for treatment effects would improve with better models to predict disability outcomes in MS., including disentangling the young versus old from the new versus long-term disease presence, since the two overlap. Techniques to adjust for selection bias, such as regression analysis or propensity scores, are more easily accomplished with rich datasets. With regard to the question of discontinuing for pregnancy, appropriate comparison groups need to include women who discontinued DMT to attempt pregnancy but didn't conceive.

A prospective 10-year observational study based on the United Kingdom's MS risk sharing scheme is underway to evaluate the effectiveness of the first DMTs, interferon and glatiramer acetate. After NICE recommended against DMTs in 2002,⁷² a pricing scheme was negotiated with participating pharmaceutical companies whereby the drug prices would be reduced if patient outcomes were lower than expected,⁷³ thus the United Kingdom National Health Service and the pharmaceutical companies shared the financial risk for cost-effective treatment. The initial 2-year results published in 2009 found patient outcomes were worse than predicted;⁷⁴ 4-, 6-, and 8-year data have been collected and are being analyzed using an updated modelling methodology. This research initiative should help inform the long-term benefits of these first-line treatments and may suggest improvements to current MS registries or methods that may make analysis of such registries more fruitful.

KQ2 covered a broad array of relevant topics, and investigator-driven research remains a likely source for innovative and interesting approaches to continued exploration. The AutoMS project, an international consortium of six European locations and Australia, formed in 2010 to explore MS patient preferences for shared decisionmaking. Confirming the generalizability of their findings to the United States would be beneficial. Well-designed qualitative and survey

research, perhaps as a mixed-methods study, aimed at directly asking the question why people are not willing to discontinue when treatment is no longer effective would be also useful.

Limitations

Literature on preferences is not indexed to permit easy identification of relevant articles. Search strategies to capture the diffuse literature used natural language as keywords. While we tested multiple terms before settling on the final algorithm, it is likely that relevant articles were missed, and thus the included literature set must be viewed as comprehensive but not exhaustive. Likewise, setting the review scope to exclude adherence literature – as adherence by definition connotes a decision to continue DMT use – may have precluded some relevant literature that looked at lack of adherence as a de facto decision to discontinue use.

References

1. Hilas O, Patel P, Lam S. Disease modifying agents for multiple sclerosis. *Open Neurol J* 2010; May;4:15-24. PMID.
2. Hurwitz B. Analysis of current multiple sclerosis registries. *Neurology* 2011; Jan 4;76(1 Suppl 1):S7-13. PMID: 21205683.
3. Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. *Brain* 2008; Mar;131(Pt 3):808-17. PMID: 18234696.
4. Filippini G, Del Giovane C, Vacchi L, et al. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. *Cochrane Database Syst Rev* 2013; 6:CD008933. PMID: 23744561.
5. Weber MS, Menge T, Lehmann-Horn K, et al. Current treatment strategies for multiple sclerosis - efficacy versus neurological adverse effects. *Curr Pharm Des* 2012; 18(2):209-19. PMID: 22229582.
6. Sorensen PS, Koch-Henriksen N, Ravnborg M, et al. Immunomodulatory treatment of multiple sclerosis in denmark: a prospective nationwide survey. *Mult Scler* 2006; Jun;12(3):253-64. PMID: 16764337.
7. Portaccio E, Zipoli V, Siracusa G, et al. Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. *Eur Neurol* 2008; 59(3-4):131-5. PMID: 18057899.
8. Tintore M, Sastre-Garriga J. New treatment measurements for treatment effects on relapses and progression. *J Neurol Sci* 2008; Nov 15;274(1-2):80-3. PMID: 18822433.
9. Koopman W. Needs assessment of persons with multiple sclerosis and significant others: using the literature review and focus groups for preliminary survey questionnaire development. *Axon* 2003; Jun;24(4):10-5. PMID: 12852337.
10. Viswanathan M, Berkman ND. Development of the RTI item bank on risk of bias and precision of observational studies. *J Clin Epidemiol* 2012; Feb;65(2):163-78. PMID: 21959223.
11. Treadwell JR, Reston JT, Singh S, et al. A framework for "best evidence" approaches in systematic reviews. . In: Quality AfHRa, ed. *Methods Research Report Vol AHRQ Publication No. 11-EHC046-EF*. Rockville, MD: Agency for Healthcare Research and Quality; 2011.
12. Turner R, Spiegelhalter D, Smith G, et al. Bias modelling in evidence synthesis. *J. R. Statis. Soc. A* 2009; 172(Part 1):21-47. PMID.
13. Berkman ND, Lohr K, Ansari M, et al. Grading the strength of a body of evidence when assessing health care interventions for the effective health care program of the Agency for Healthcare Research and Quality: An update. 290-2007-10056-I PbtR-UE-bPCuCN, trans. *Methods Guide for Comparative Effectiveness Reviews Vol AHRQ Publication No. 13(14)-EHC 130-EF*. November ed. Rockville, MD: Agency for Healthcare Research and Quality; 2013.
14. Atkins D, Chang S, Gartlehner G, et al. *Assessing the Applicability of Studies When Comparing Medical Interventions*. 2010 December. Available at: <http://www.effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayProduct&productID=603#2412>. Accessed AHRQ Publication No. 11-EHC019-EF.
15. Goodin DS, Reder AT, Ebers GC, et al. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFN-1b trial. *Neurology* 2012; Apr 24;78(17):1315-22. PMID: 22496198.
16. Reder AT, Ebers GC, Traboulsee A, et al. Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS. *Neurology* 2010; Jun 8;74(23):1877-85. PMID: 20530324.
17. Shirani A, Zhao Y, Karim ME, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. *Jama* 2012; Jul 18;308(3):247-56. PMID: 22797642.
18. Gold R, Rieckmann P, Chang P, et al. The long-term safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study. *Eur J Neurol* 2005; Aug;12(8):649-56. PMID: 16053475.

19. Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. *Lancet neurol* 2009; Nov;8(11):987-97. PMID: 19748319.
20. Patti F, Pappalardo A, Florio C, et al. Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head study. *Acta Neurologica Scandinavica* 2006; Apr;113(4):241-7. PMID: 16542163.
21. Rio J, Tintore M, Nos C, et al. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre. *Journal of Neurology* 2005; Jul;252(7):795-800. PMID: 15772741.
22. Rio J, Tintore M, Nos C, et al. Interferon beta in secondary progressive multiple sclerosis : daily clinical practice. *Journal of Neurology* 2007; Jul;254(7):849-53. PMID: 17361342.
23. Debouverie M, Moreau T, Lebrun C, et al. A longitudinal observational study of a cohort of patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate. *Eur J Neurol* 2007; Nov;14(11):1266-74. PMID: 17956447.
24. Ford C, Goodman AD, Johnson K, et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. *Mult Scler* 2010; Mar;16(3):342-50. PMID: 20106943.
25. Miller A, Spada V, Beerkircher D, et al. Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis. *Mult Scler* 2008; May;14(4):494-9. PMID: 18208875.
26. Confavreux C, Li DK, Freedman MS, et al. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. *Mult Scler* 2012; Sep;18(9):1278-89. PMID: 22307384.
27. Ford CC, Johnson KP, Lisak RP, et al. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. *Mult Scler* 2006; Jun;12(3):309-20. PMID: 16764344.
28. Johnson KP, Brooks BR, Ford CC, et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. *Mult Scler* 2000; Aug;6(4):255-66. PMID: 10962546.
29. Johnson KP, Brooks BR, Ford CC, et al. Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial. *Mult Scler* 2003; Dec;9(6):585-91. PMID: 14664471.
30. Johnson KP, Ford CC, Lisak RP, et al. Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data. *Acta Neurologica Scandinavica* 2005; Jan;111(1):42-7. PMID: 15595937.
31. Rio J, Porcel J, Tellez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. *Mult Scler* 2005; Jun;11(3):306-9. PMID: 15957512.
32. Prisms Study Group, the University of British Columbia MSMRIAG. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.[Erratum appears in *Neurology* 2001 Sep 25;57(6):1146]. *Neurology* 2001; Jun 26;56(12):1628-36. PMID: 11425926.
33. Uitdehaag B, Constantinescu C, Cornelisse P, et al. Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: Exploratory analyses from the PRISMS long-term follow-up study. *Therapeutic Advances in Neurological Disorders* 2011; //;4(1):3-14. PMID.
34. Mesaros S, Stojisavljevic N, Dujmovic-Basuroski I, et al. Long-term adherence to interferon-beta treatment in a cohort of RRMS patients in Belgrade, Serbia. *Clin Neurol Neurosurg* 2012; Oct;114(8):1145-8. PMID: 22425462.
35. Carmona O, Casado V, Moral E, et al. Interferon-beta1b in multiple sclerosis: effect on progression of disability and clinical markers of treatment response. *Eur Neurol* 2008; 60(6):279-84. PMID: 18824855.
36. Trojano M, Paolicelli D, Zimatore GB, et al. The IFNbeta treatment of multiple sclerosis (MS) in clinical practice: the experience at the MS Center of Bari, Italy. *Neurol Sci* 2005; Dec;26 Suppl 4:S179-82. PMID: 16388354.

37. Baker LM. A new method for studying patient information needs and information-seeking patterns. *Top Health Inf Manage* 1995; Nov;16(2):19-28. PMID: 10152475.
38. Basso MR, Candilis PJ, Johnson J, et al. Capacity to make medical treatment decisions in multiple sclerosis: a potentially remediable deficit. *J Clin Exp Neuropsychol* 2010; Dec;32(10):1050-61. PMID: 20446143.
39. Berger BA, Hudmon KS, Liang H. Predicting treatment discontinuation among patients with multiple sclerosis: application of the transtheoretical model of change. *J Am Pharm Assoc* (2003) 2004; Jul-Aug;44(4):445-54. PMID: 15372865.
40. Daugherty KK, Butler JS, Mattingly M, et al. Factors leading patients to discontinue multiple sclerosis therapies. *J Am Pharm Assoc* (2003) 2005; May-Jun;45(3):371-5. PMID: 15991759.
41. Dor A, Lage MJ, Tarrants ML, et al. Cost sharing, benefit design, and adherence: the case of multiple sclerosis. *Adv Health Econ Health Serv Res* 2010; 22:175-93. PMID: 20575233.
42. Gleason PP, Starner CI, Gunderson BW, et al. Association of prescription abandonment with cost share for high-cost specialty pharmacy medications. *J Manage Care Pharm* 2009; Oct;15(8):648-58. PMID: 19803554.
43. Johnson FR, Van Houtven G, Ozdemir S, et al. Multiple sclerosis patients' benefit-risk preferences: serious adverse event risks versus treatment efficacy. *Journal of Neurology* 2009; Apr;256(4):554-62. PMID: 19444531.
44. Prosser LA, Kuntz KM, Bar-Or A, et al. Patient and community preferences for treatments and health states in multiple sclerosis. *Mult Scler* 2003; Jun;9(3):311-9. PMID: 12814182.
45. Boeije HR, Janssens AC. 'It might happen or it might not': how patients with multiple sclerosis explain their perception of prognostic risk. *Soc Sci Med* 2004; Aug;59(4):861-8. PMID: 15177841.
46. Janssens AC, de Boer JB, van Doorn PA, et al. Expectations of wheelchair-dependency in recently diagnosed patients with multiple sclerosis and their partners. *Eur J Neurol* 2003; May;10(3):287-93. PMID: 12752403.
47. Visser LH, van der Zande A. Reasons patients give to use or not to use immunomodulating agents for multiple sclerosis. *Eur J Neurol* 2011; Nov;18(11):1343-9. PMID: 21496180.
48. Bischoff C, Schreiber H, Bergmann A. Background information on multiple sclerosis patients stopping ongoing immunomodulatory therapy: A multicenter study in a community-based environment. *Journal of Neurology* 2012; //;259(11):2347-53. PMID.
49. Hamann J, Mendel R, Schebitz M, et al. Can psychiatrists and neurologists predict their patients' participation preferences? *J Nerv Ment Dis* 2010; Apr;198(4):309-11. PMID: 20386262.
50. Hamann J, Neuner B, Kasper J, et al. Participation preferences of patients with acute and chronic conditions. *Health Expectations: An International Journal of Public Participation in Health Care & Health Policy* 2007; Dec;10(4):358-63. PMID: 2007-17117-006.
51. Heesen C, Kasper J, Kopke S, et al. Informed shared decision making in multiple sclerosis--inevitable or impossible? *J Neurol Sci* 2007; Aug 15;259(1-2):109-17. PMID: 17400253.
52. Heesen C, Kasper J, Segal J, et al. Decisional role preferences, risk knowledge and information interests in patients with multiple sclerosis. *Mult Scler* 2004; Dec;10(6):643-50. PMID: 15584489.
53. Heesen C, Kleiter I, Nguyen F, et al. Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists. *Mult Scler* 2010; Dec;16(12):1507-12. PMID: 20826527.
54. Heesen C, Kopke S, Richter T, et al. Shared decision making and self-management in multiple sclerosis--a consequence of evidence.[Erratum appears in *J Neurol*. 2008 Feb;255(2):309-10]. *Journal of Neurology* 2007; May;254 Suppl 2:II116-21. PMID: 17503119.
55. Kasper J, Kopke S, Fischer K, et al. Applying the theory of planned behaviour to multiple sclerosis patients' decisions on disease modifying therapy--questionnaire concept and validation. *BMC Med Inf Decis Mak* 2012; 12:60. PMID: 22747904.
56. Kasper J, Kopke S, Muhlhauser I, et al. Evidence-based patient information about treatment of multiple sclerosis--a phase one study on comprehension and emotional responses. *Patient Educ Couns* 2006; Jul;62(1):56-63. PMID: 16098706.
57. Kasper J, Kopke S, Muhlhauser I, et al. Informed shared decision making about immunotherapy for patients with multiple sclerosis (ISDIMS): a randomized controlled trial. *Eur J Neurol* 2008; Dec;15(12):1345-52. PMID: 19049552.

58. Mendel R, Traut-Mattausch E, Frey D, et al. Do physicians' recommendations pull patients away from their preferred treatment options? *Health Expect* 2011; Mar;15(1):23-31. PMID: 21323824.
59. Grytten N, Aarseth J, Espeset K, et al. Stoppers and non-starters of disease-modifying treatment in multiple sclerosis. *Acta Neurologica Scandinavica* 2013; Feb;127(2):133-40. PMID: 2013-02262-010.
60. Meyniel C, Spelman T, Jokubaitis VG, et al. Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome. *PLoS ONE* 2012; 7(6):e38661. PMID: 22768046.
61. Kremenchutzky M, Walt L. Perceptions of health status in multiple sclerosis patients and their doctors. *The Canadian Journal of Neurological Sciences / Le Journal Canadien Des Sciences Neurologiques* 2013; Mar;40(2):210-8. PMID: 2013-06076-015.
62. Thorne S, Con A, McGuinness L, et al. Health care communication issues in multiple sclerosis: an interpretive description. *Qual Health Res* 2004; Jan;14(1):5-22. PMID: 14725173.
63. Giordano A, Mattarozzi K, Pucci E, et al. Participation in medical decision-making: attitudes of Italians with multiple sclerosis. *J Neurol Sci* 2008; Dec 15;275(1-2):86-91. PMID: 18786682.
64. Lonergan R, Kinsella K, Duggan M, et al. Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started? *Mult Scler* 2009; Dec;15(12):1528-31. PMID: 19995848.
65. Kind P, Dolan P. The effect of past and present illness experience of the valuations of health states. *Medical Care* 1995; April;33(4 Suppl):AS255-63. PMID: 7723454.
66. Sackett D, Torrance G. The utility of different health states as perceived by the general public. *Journal of Chronic Disease* 1978; 31(11):697-704. PMID: 730825.
67. Ubel P, Loewenstein G, Schwartz N, et al. Misimagining the unimaginable: the disability paradox and health care decision making. *Health Psychology* 2005; Jul;24(4 Suppl):S57-62. PMID: 16045420.
68. Dolan P. Addressing misconceptions in valuing health. *Expert Rev Pharmacoecon Outcomes Res* 2013; Feb;13(1):1-3. PMID: 23402439.
69. Fischer J, LaRocca N, Miller D, et al. Recent developments in the assessment of quality of life in multiple sclerosis (MS). *Mult Scler* 1999; Aug;5(4):251-9. PMID: 10467384.
70. Cella D, Dineen K, Arnason B, et al. Validation of the functional assessment of multiple sclerosis quality of life instrument. *Neurology* 1996; Jul;47(1):129-39. PMID: 8710066.
71. Vickrey B, Hays R, Harooni R, et al. A health-related quality of life measure for multiple sclerosis. *Qual Life Res* 1995; June;4(3):187-206. PMID: 7613530.
72. National Institute for Health and Care Excellence (NICE). Multiple sclerosis--beta interferon and glatiramer acetate. Technology appraisal 32. Available at: www.nice.org.uk/Guidance/TA32. Accessed July 31, 2013.
73. Multiple Sclerosis Trust. Information, education, research and support. Available at: <http://www.msstrust.org.uk/atoz/risk-sharing-scheme.jsp>. Accessed July 26, 2014.
74. Boggild M, Palace J, Barton P, et al. Multiple sclerosis Risk-sharing Scheme: two year results of clinical cohort study with historical comparator. *BMJ* 2009; Dec 2;339:b4677. PMID: 19955128.

Introduction

Background

Condition

Multiple sclerosis (MS) is a potentially debilitating disease characterized by demyelination (deterioration of the protective myelin sheaths covering nerves in the brain and spinal cord) and axon loss within the central nervous system. The lesions created by the myelin destruction and resulting scar tissue interfere with normal transmission along nerve fibers within the brain and to and from the brain. This results in classic symptoms associated with MS. The condition affects 2.5 million individuals worldwide and approximately 400,000 in the United States.¹ Twice as many women as men are affected, and diagnosis usually occurs between the ages of 20 and 50.¹ Both symptoms and disease course are highly individualized, depending on where the lesions occur within the central nervous system and the type of MS. Clinically definite MS types include:

- Relapse-remitting MS (RRMS) is the most common form, affecting approximately 85 percent of patients. Patients typically are diagnosed in their 20s or 30s. Neurologic symptoms often present over a course of days, stabilize, and spontaneously resolve; however, over time permanent disability often develops and progresses with further relapses. Median times to disability progression (secondary progressive MS) range from 15 to 29 years.²
- Secondary progressive MS (SPMS) is characterized by worsening disability with or without relapses. Patients may have exacerbations, but the trend over time is a relatively steady progression of disease and disability.¹
- Primary progressive MS (PPMS) represents about 15 percent of patients and affects women and men about equally. This form has the worst prognosis and is characterized by gradual and progressive worsening without distinct relapses.¹
- Primary relapsing MS (PRMS) affects about 5 percent of patients. This form is usually initially diagnosed as PPMS due to a steady worsening of functioning and changed to PRMS when the patient experiences a relapse.

People with clinically isolated syndrome (CIS), a first neurological episode, may or may not go on to develop MS. CIS involves neurological symptoms such as optic neuritis and unilateral body weakness that last at least 24 hours and are caused by inflammation or demyelination in one (monofocal) or more (multifocal) sites in the central nervous system. In a cohort of 107 CIS patients followed for 20 years, 60 patients with three or more lesions (seen via magnetic resonance imaging [MRI]) converted to MS, while only seven with normal baseline MRI converted.³

Debate continues to surround the underlying etiology of MS. Most literature addresses MS as an autoimmune, inflammatory disease, and this understanding underlies current drug treatments.⁴ Others suggest that MS is best understood as a neurodegenerative disease, leading to autoimmune reaction to the neurodegenerative debris.⁵ Still others hypothesize that MS is a chronic metabolic disorder.⁶ Current disease-modifying treatments (DMTs) are aimed at modifying autoimmune activity, even though we do not yet know whether autoimmune activity is primary or secondary in MS pathology.

Treatment Strategies – and Their Discontinuation

MS cannot be cured with current therapies, and clinicians and patients face challenges balancing benefits and risks when choosing a treatment course.⁷ Current DMTs comprise immunomodulating and immunosuppressant medications, which aim to slow the progression of MS and relieve symptoms to improve quality of life. The working hypothesis is that reducing or preventing new lesions and their sequelae slows disease progression.

Given the unpredictable nature of MS relapses and progression, clinical trials for MS treatments are run for 2 to 3 years to allow for more accurate measurement of reductions in relapse rates and evidence of slowed disease progression. Table 1 provides a list of currently FDA approved DMTs.

Table 1. FDA approved disease modifying treatments for MS

Generic (Administration)	Manufacturer (Trade Name)	FDA-Approved Indication	FDA Warnings
Interferon beta-1a (IFNbeta-1a) (Injection: Avonex-weekly, Rebif-thrice weekly)	Biogen (Avonex [®])	May 17, 1996, for CIS and RRMS	Yes
	EMD Serono (Rebif [®])	March 7, 2002, for RRMS	Yes
Interferon beta-1b (IFNbeta-1b) (Injection every other day)	Bayer Healthcare Pharms (Betaseron [®])	July 23, 1993, for RRMS	Yes
	Novartis (Extavia [®])	August 14, 2009, for CIS and RRMS	Yes
Glatiramer acetate (Injection-daily)	Teva (Copaxone [®])	December 20, 1996, for RRMS	Yes
Mitoxantrone (IV)	Bedford; Hospira; Teva Parenteral; Fresenius; EMD Serono Inc., Kabi USA, Mylan Institutional; Onco Therapies LTD	2000 for RRMS, SPMS, PRMS	Yes, black box
Natalizumab (IV)	Biogen (Tysabri [®])	November 23, 2004, for RRMS	Yes, black box
Teriflunomide	Sanofi Aventis US (Aubagio) (leflunomide by Sanofi Aventis US as Arava for arthritis)	September 12, 2012, for RRMS	Yes, black box
Fingolimod (Oral)	Novartis (Gilenya)	September 21, 2010, RRMS	Yes
Dimethyl fumarate (Oral)	Biogen (Tecfidera)	March 27, 2013, RRMS	Yes

CIS = clinically isolated syndrome; FDA = U.S. Food and Drug Administration; IV = intravenous; MS= multiple sclerosis; PRMS=primary relapsing multiple sclerosis; RRMS = relapse-remitting multiple sclerosis; SPMS-secondary progressive multiple sclerosis

A 2013 Cochrane overview review and network analysis of 44 trials of DMTs for MS found moderate to high quality evidence that DMTs are effective against recurrence of relapses in RRMS during the first 24 months of treatment compared to placebo.⁸ The network analysis ranked natalizumab as the most effective drug, followed in order by IFNbeta-1a (Rebif), mitoxantrone, glatiramer acetate (Copaxone), and IFNbeta-1b (Betaseron). Confidence in the evidence dropped to moderate for direct comparisons of mitoxantrone and IFNbeta-1b versus placebo and very low for glatiramer acetate versus placebo. Included trials did not report relapse outcomes for RRMS at 3 years. Further, natalizumab and IFNbeta-1b were more effective than IFNbeta-1a in reducing the number of RRMS participants with disease progression as measured with surrogate markers. In patients with progressive MS, both pairwise and network analysis found no DMTs analyzed prevented disability progression over 2 or 3 years. The overview and network analysis were too recent to include the newest approved drugs such as fingolimod or dimethylfumarate.

Unfortunately, the efficacy level of MS treatments appears to correlate with the frequency and severity of side effects.⁹ The first-line treatments, the interferon drugs and glatiramer acetate, were modestly efficacious and side-effects were tolerable by many patients.⁸ Mitoxantrone, an escalation medication, has a lifetime maximum dosage due to severe cardiotoxicity.⁹ Natalizumab, the first monoclonal antibody, can induce a fatal progressive multifocal leukoencephalopathy (PML). Risk for PML increases with natalizumab use longer than 2 years, anti-JC virus antibody status, and prior use of immunosuppressive agents.¹⁰ People taking natalizumab may take a drug holiday or discontinue use completely if their risk factor increases assessed by a positive test for the anti-JCV antibody status.

Women considering pregnancy face special considerations for drug holidays. Women must weigh the possible risks of DMT exposure to the unborn fetus against the maternal risk of disease progression if she discontinues DMT. Neurologists commonly counsel a woman to discontinue her medications 3 months prior to trying to conceive, although rates of fetal exposure to DMTs vary greatly by country. While a Canadian study reported an exposure rate of 5 percent,¹¹ much higher rates have been reported by studies outside of North America. A Spanish study found 39 percent of pregnancies were exposed to DMTs,¹² and a Brazilian study found an exposure rate of 70 percent.¹³ Unfortunately, conception isn't always easily planned and the drug holiday may continue for much longer than anticipated, possibly years.

DMTs for MS are not intended for life-long use. However, with few exceptions (such as natalizumab use or intended pregnancy), patients who opt for DMT for MS may end up using it for several years to decades, as long as they tolerate the treatment and the DMT seems effective. Patients may switch between different DMTs in order to find one that is more effective or more tolerable, and studies have found high rates of switching between drugs.¹⁴ Some patients cannot tolerate any of the DMTs, but if a tolerable drug regime is determined, treatment generally continues until the individual reaches a disease course stage where DMTs no longer help. Such a point may be reached when a person is determined to be nonresponsive to the medication due to disease progression. The determination of when DMT is no longer helpful is challenging. Thus, major questions of interest are whether or not DMTs for MS alter the natural history of the disease in the long-run and when to discontinue DMT.

Scope and Key Questions

Scope of the Review

This review examines the long-term (more than 3 years) consequences of discontinuing DMT. We looked for evidence that directly assessed discontinuing versus continuing DMT, and also evidence for long-term (more than 3 years) benefits and harms for either continuing or discontinuing, since the decision to continue or discontinue can be informed by the benefits or harms directly linked to either course of action. This information would extend understanding beyond the short-term trials examined in the 2013 Cochrane review. We were also interested in the reasons for discontinuing treatment that were reported in the long-term studies.

We concentrated on outcomes relevant to the patient for decisionmaking, such as relapse rates and changes in disability level, rather than intermediate outcomes such as lab tests for neutralizing antibodies. MRI to identify MS-related lesions has been shown to correlate with short-term relapse rates, 6 months to 2 years.⁹ However, long-term MRI followup as a surrogate marker for relapse rates or, more importantly, disease progression, currently lacks evidence.¹⁵

Thus, we did not use MRI as a long-term outcome in this review. However, we included MRI as a short-term outcome in the subset of patients discontinuing natalizumab due to risk of PML.

People with MS commonly switch between the available DMTs depending on tolerance, presence of adverse effects, and perceived helpfulness of the treatment. The pertinent clinical question for switching medications is how to define the threshold of disease activity for changing medications. This important question is qualitatively different than that of when to stop DMTs completely. To adequately address the question of when to switch medication will likely require a review of both short- and long-term research. Therefore, questions related to switching between DMTs are outside the scope of this review.

The review also examines the evidence for patient values, beliefs, and preferences regarding discontinuing DMTs. Such information should support clinicians, patients, consumer advocates, and other decisionmakers in understanding the factors and processes that may inform decisions to discontinue treatment.

Key Questions

We synthesized the evidence in the published literature to address the following two key questions (KQ):

KQ1: What are the consequences of discontinuing disease-modifying treatments in adult patients?

- a. What is the evidence for benefits for continuing versus discontinuing treatment?
- b. What is the evidence for long-term harms?
- c. What reasons for discontinuation of disease-modifying treatments have been reported in long-term observational cohort studies?

KQ2: What are individual values, beliefs, and preferences regarding discontinuing disease-modifying treatments?

- a. What are patient and provider preferences for discontinuation of disease-modifying treatments?
- b. What are patient and provider preferences for participation in shared decisionmaking to discontinue disease-modifying treatments?


Figure 1 provides a conceptual framework that links the KQs. At the top it depicts the logic path both physicians and patients must travel when considering disease-modifying treatments:

- Does it work?
- What drug should I start with?
- When should I switch a patient to a new drug and what should that drug be?
- When should a patient discontinue disease-modifying treatment?

This logic path describes the context within which patients and clinicians make decisions about DMTs or, in the case of this review, discontinuation (KQ1). The lower part of the figure depicts the progression from an individual's internal decision context and process (such as preferences, values, knowledge, beliefs, and cognitive behaviors and habits) to an interpersonal decision context and processes between the physician and patient. The overlapping ovals representing the clinician and the patient indicate information shared between the two parties versus information and other cognitive processes specific to one individual. Any overlap depends in part on the level of sophistication a patient brings to the decisionmaking process and in part on

how well a physician understands a patient’s beliefs, values, goals, and preferences. For example, a patient newly diagnosed with MS in the novice phase of learning about MS would likely have a smaller overlap.¹⁶ The interaction between the physician and patient results in decisions that can vary in their level of concordance.

Figure 1. Conceptual framework for Key Questions



Organization of This Report

The report describes our review methods, including our search strategy, inclusion and exclusion criteria, approach to reviewing abstracts and full publications, and our method for extracting data and summarizing evidence. We also describe the approach to grading the quality of the literature and to evaluating the strength of the body of evidence.

The results section synthesizes the findings by KQ. For KQ1, we report the available evidence on consequences of discontinuing DMT, including long-term benefits and harms for DMTs. We also report the evidence regarding special cases of treatment discontinuation due to pregnancy and natalizumab discontinuation due to increased risk of PML. For KQ2, we present the empirical literature that populates the conceptual framework provided in Figure 1.

Methods

The methods for this review follow the methods established for the AHRQ Effective Health Care program. KQ1 uses methods suggested in the AHRQ Methods Guide for Effectiveness and Comparative Effectiveness Reviews (available at <http://www.effectivehealthcare.ahrq.gov/methodsguide.cfm>). Since KQ2 was not amenable to usual comparative effectiveness review (CER), we approached KQ2 using Technical Brief methodology. This section focuses on the elements of the protocol; certain methods map to the PRISMA checklist.¹⁷ All methods and analyses were determined *a priori*.

Topic Refinement and Review Protocol

Initially a panel of key informants comprised of MS researchers, clinicians, consumer advocates, and consumers gave input on the key questions (KQs). The draft KQs were then posted for public comment from May 31, 2013, through June 30, 2013, and revised as needed. We then drafted a protocol for the review and recruited a panel of technical experts to provide high-level content and methodological expertise during the development of the review. The Key Informants and members of the Technical Expert Panel (TEP) were required to disclose any financial conflicts of interest greater than \$10,000 and any other relevant business or professional conflicts. Any potential conflicts of interest were balanced or mitigated. Neither key informants nor members of the TEP performed analysis of any kind, nor did any of them contribute to the writing of this report. Members of the TEP were invited to provide feedback on an initial draft of the review protocol, which was then refined based on their input, reviewed by AHRQ, and posted for public access at the AHRQ Effective Health Care Website.


Role of the AHRQ Task Order Officer

The Task Order Officer (TOO) was responsible for overseeing all aspects of this project. The TOO helped to develop a common understanding among all parties involved in the project, resolved questions and ambiguities, and addressed our queries regarding the scope and processes of the project. The TOO reviewed the report for consistency, clarity, and to ensure that it conforms to AHRQ standards.

Analytic Framework

Figure 2 provides an analytic framework describing the treatment path and long-term benefits and harms of continuing versus discontinuing disease-modifying treatment for KQ1. The conceptual framework in Figure 1 provides a conceptual basis for KQ2 literature.

Figure 2. Analytic framework for discontinuing disease-modifying treatments for Multiple Sclerosis



DMT=disease modifying treatment; KQ=key question; MS=multiple sclerosis

Literature Search Strategy

Search Strategy

We used bibliographic database searching to identify previous randomized controlled trials and observational studies published from 1990 to August 2014 for studies enrolling adults with clinically isolated syndrome (CIS) or multiple sclerosis (MS). Relevant bibliographic databases for this topic include MEDLINE, the Cochrane Central Register of Controlled Trials (CENTRAL), PsychInfo, and Scopus. Our search strategy appears in Appendix A. The search strategy used relevant Medical Subject Headings and natural language terms to find studies on the topic. The concept search was supplemented with filters designed to select experimental designs. Bibliographic database searches were supplemented with backward citation searches of highly relevant systematic reviews.

We conducted additional grey literature searching to identify relevant completed and ongoing studies. Relevant grey literature resources include trial registries and FDA databases. We searched ClinicalTrials.gov, the International Controlled Trials Registry Platform (ICTRP), and Health Services Research Projects in Progress (HSRProj) for observational literature. Scientific information packet (SIP) letters and emails were sent to 11 identified relevant industry stakeholders requesting submission of published and unpublished information on their product(s). Four submissions were subsequently received and reviewed. Grey literature search results were used to identify studies, outcomes, and analyses not reported in the published literature that may further inform findings for key questions. Since we did not find randomized controlled trials (RCTs) of sufficient length to be included in this review, we were not able to assess publication and reporting bias using the grey literature.

Inclusion and Exclusion Criteria

We included studies based on the PICOTS (population, intervention, comparator, outcomes, timing, setting) framework outlined in Table 2 and further publication or study characteristics outlined in Table 3.

Table 2. Review PICOTS

PICOT	Included	Excluded
Population	Adults with CIS, RRMS, SPMS, PPMS, or PRMS using FDA-approved DMTs	Pediatric MS patients
Interventions used in long-term studies assessing discontinuing or continuing DMTs	DMTs IFNbeta-1a, IFNbeta 1b, glatiramer acetate, natalizumab, teriflunomide, fingolimod	Mitoxantrone – it has a lifetime use limit, so ultimately discontinuing is not a choice. (Dimethyl fumarate has not been approved long enough to generate long-term data.)
Comparator groups used in long-term studies assessing discontinuing or continuing DMTs	Patients who received placebo, FDA-approved DMTs, or patients who did not receive any DMT.	DMTs not FDA-approved
Outcomes and Concepts/ Topics of Interest	<p>KQ1 Patient-centered benefits compared with baseline: reduction in annualized relapse rate (at least one relapse); change in disability, change in EDSS, disease progression (determined by functional assessment); time to sustained disease progression Any reported adverse events Any reported reason for discontinuing treatment</p> <p>KQ2 Individuals' attitudes, values, preferences for discontinuing treatments and health states Perceptions of risk and seriousness of health states Factors and processes patients with MS and clinicians use in shared decisionmaking</p>	<p>KQ 1 Intermediate outcomes Exception: MRI as intermediate outcome exclusion was relaxed for patients discontinuing natalizumab due to changes in risk of PML, since the time frame was within the short-term 2-3 window.</p> <p>KQ2 Adherence to treatment plan</p>
Timing	Treatment and followup must be greater than 3 years. Exception: timing was relaxed for: <ul style="list-style-type: none"> • Women considering pregnancy or are pregnant • Patients discontinuing natalizumab due to changes in risk of PML 	
Setting	Outpatient	

CIS=clinically isolated syndrome; DMT=disease-modifying treatment; EDSS=Expanded Disability Status Scale; FDA=U.S. Food and Drug Administration; IV=intravenous; MS=multiple sclerosis; PML=progressive multifocal leukoencephalopathy; PPMS=primary progressive multiple sclerosis; PRMS=primary relapsing multiple sclerosis; RRMS=relapse-remitting multiple sclerosis; SPMS=secondary progressive multiple sclerosis

Table 3. Study inclusion criteria

Category	Criteria for Inclusion
Study Enrollment	Studies that enrolled adults with CIS, RRMS, SPMS, PPMS, or PRMS
Study Design	RCTs, nonrandomized controlled trials, prospective and retrospective cohort studies, case control studies, and case series were included for each population and treatment option.
Time of Publication	1990 forward. FDA-approved disease modifying drugs were only available in the U.S. after 1993.
Study Quality	All studies that met inclusion criteria were screened for eligibility. Studies that did not adequately report study information to allow abstraction of treatment and followup duration or that had indeterminable numerators and denominators for outcomes and adverse event were excluded.
Language of Publication	English language

CIS=clinically isolated syndrome; FDA=U.S. Food and Drug Administration; PPMS=primary progressive multiple sclerosis; PRMS=primary relapsing multiple sclerosis; RCT=randomized controlled trial; RRMS=relapse-remitting multiple sclerosis; SPMS=secondary progressive multiple sclerosis

Study Selection

Bibliographic database search results were exported to EndNote¹⁸ for screening studies relevant to our PICOTS framework and study-specific criteria. Titles and abstracts were reviewed by two independent investigators to identify studies meeting PICOTS framework and inclusion/exclusion criteria. All studies identified as relevant by either investigator underwent full-text screening. Two independent investigators screened full text to determine if inclusion criteria were met. Differences in screening decisions were resolved by consultation between investigators and, if necessary, a third investigator. We documented the inclusion and exclusion status of citations undergoing full-text screening. A bibliography of studies excluded at full text, and their reasons for exclusion, is provided in Appendix B.

Data Extraction

Studies that met inclusion criteria were distributed among investigators for data abstraction and risk of bias assessment. Two investigators abstracted relevant study, population demographic, and outcomes data. Data fields included author; year of publication; setting, subject inclusion and exclusion criteria; and study design characteristics. For KQ1, we also abstracted intervention and control characteristics (intervention components, timing, frequency, duration); followup duration; participant baseline demographics; type of CIS or MS, MS severity; descriptions and results of outcomes and adverse effects; reasons for discontinuation; and study funding source. Studies that only reported long-term benefits and harms aggregated across multiple disease modifying treatments (DMTs) were not abstracted. Such studies were accounted for, however, in the article flow-diagram and references are made available. Similarly, studies that did not meet minimum quality levels, or had incomplete reporting to allow analysis, were also accounted for and references made available. Evidence tables are provided in Appendix C.

For KQ2, we abstracted study aims, characteristics, and study findings. Relevant data were extracted directly into summary tables. Summary tables were reviewed and verified for accuracy by a second investigator.

Risk of Bias Assessment of Individual Studies

Because we found only observational literature for this review, we developed an instrument for assessing risk of bias for observational studies using the RTI Observational Studies Risk of Bias and Precision Item Bank for KQ1.¹⁹ We selected items most relevant in assessing risk of bias for

this topic, including participant selection, ascertainment, attrition, performance, and appropriateness of analytic methods.

Overall summary risk of bias assessments for each individual study were classified as low, moderate, or high based upon the collective risk of bias inherent in each domain and confidence that the results are believable given the study's limitations. Two investigators independently assessed the studies for risk of bias and consulted to reconcile any discrepancies. When agreement was not reached through consultation, a third party was consulted to reconcile the summary judgment. Information about risk of bias for individual studies is available in Appendix D. Following Technical Brief methods, risk of bias was not assessed for KQ2.

Data Synthesis

For KQ1, we summarized the results into evidence tables and qualitatively synthesized evidence for specific disease-modifying medications and unique population, duration of DMT, length of study followup, and outcomes combinations. Studies were grouped by length of followup to examine changes over time, if any, in outcomes and reasons for discontinuing disease modifying treatments. We used the best of the available evidence provided by the identified observational literature.²⁰ Our literature search found no RCTs of sufficient length and significant numbers of observational studies, and many observational studies were found on preliminary examination to have high risk of bias. So while all identified articles underwent abstraction, only the best evidence, based on those studies closest to an "ideal" study design²¹ (those studies with the lowest risk of bias) are included in the evidence synthesis.

We synthesized data on several outcomes. The Expanded Disability Status Scale (EDSS) is an ordinal measure assigned by clinical observation, with scores ranging from 0 (no evident disability) to 10 (death).²² The patient remains at a given score level until enough functional declines are observed to move one step on the scale; for example, from 4.0 to 4.5. A score of 4.5 indicates changes in a person's mobility. A score of 6.5 indicates a person requires bilateral and generally constant assistance (canes, crutches, braces, or people) to walk 20 meters without resting. Changes in EDSS are commonly used to calculate change in disability or progression of disease. Other measures included changes in the annual or annualized relapse rates from baseline.

For KQ2, we summarized the results into evidence tables and conducted a qualitative synthesis. We grouped the literature by mapping the included studies to the conceptual framework (Figure 1) and analyzed the study findings for emergent patterns for patient perspectives, clinician perspectives, and clinician/patient interpersonal interactions.

Strength of the Body of Evidence

The overall strength of evidence for select outcomes for KQ1 (relapse rate, change in disability, progression of disease, time to sustained disease progression) within each comparison were evaluated based on four required domains: (1) study limitations (internal validity); (2) directness (single, direct link between intervention and outcome); (3) consistency (similarity of effect direction and size); and (4) precision (degree of certainty around an estimate).²³ A fifth domain, reporting bias, was assessed when strength of evidence based upon the first four domains was moderate or high.²³ Based on study design and conduct, risk of bias was rated as low, medium, or high. Consistency was rated as consistent, inconsistent, or unknown/not applicable (e.g., single study). Directness was rated as either direct or indirect. Precision was rated as precise or imprecise. Other factors that may be considered in assessing strength of evidence include dose-response relationship,

the presence of confounders, and strength of association. Based on these factors, the overall evidence for each outcome was rated as:²³

- **High:** Very confident that estimate of effect lies close to true effect. Few or no deficiencies in body of evidence, findings believed to be stable.
- **Moderate:** Moderately confident that estimate of effect lies close to true effect. Some deficiencies in body of evidence; findings likely to be stable, but some doubt.
- **Low:** Limited confidence that estimate of effect lies close to true effect; major or numerous deficiencies in body of evidence. Additional evidence necessary before concluding that findings are stable or that estimate of effect is close to true effect.
- **Insufficient:** No evidence, unable to estimate an effect, or no confidence in estimate of effect. No evidence is available or the body of evidence precludes judgment.

Strength of evidence was not assessed for KQ2. This KQ was approached in a hypothesis-generating manner. Following Technical Brief methods, strength of evidence was not assessed for KQ2.

Applicability


Applicability of studies was determined according to the PICOTS framework. Study characteristics that may affect applicability include, but are not limited to, type of MS or CIS, unobserved differences in patient preferences, or country within which treatment is provided, given differences in international regulations and treatment preferences.²⁴

Results

Results of Literature Searches

We identified 4359 unique citations searching five bibliography databases (Figure 3) from 1990 to August 2014. After excluding articles at title and abstract, full texts of 198 articles were reviewed to determine final inclusion. Seven articles were added through hand search. Of the 61 articles retained for KQ1, 11 were specific to discontinuing natalizumab due to increased risk and 12 were specific to discontinuing due to pregnancy. Of the remaining 38 articles comprising 27 unique studies, only 16 studies contained complete information to allow for full analysis. All 38 articles were reviewed for information on reported reasons for discontinuation. For KQ2, 30 articles comprising 27 unique studies were included.

Figure 3. Disposition of studies identified for this review



NTZ= articles for discontinuing natalizumab. PG = articles for discontinuing due to pregnancy

Key Question 1. What are the consequences of discontinuing disease modifying treatments?

Description of Included Studies

Twenty-seven unique observational study populations were represented in 38 articles. (Detailed evidence tables in.) Studies were conducted in the United States,²⁵⁻³⁵ Canada,^{36,37} Ireland,^{38,39} Italy,^{14,40-45} Hungary,⁴⁶ Spain,⁴⁷⁻⁵¹ Sweden,^{52,53} Denmark,¹⁰ France,⁵⁴ Serbia,⁵⁵ and multiple international locations.⁵⁶⁻⁶⁰ Of these, only 16 studies (22 articles) provided sufficient detail to abstract treatment benefit information.^{14,27-33,35,37,41,45-47,49,50,53,54,56-61} Study comparison arms ranged from early versus delayed treatment, treatment types, treatment dosages, treatment continuers versus treatment stoppers, and treated versus untreated.

Table 4 displays the longest study followup period for each of the 27 studies, although some studies have companion articles that reported specific treatment types or outcome measures with shorter followup periods. The reporting set included all articles meeting all PICOT inclusion criteria. The analytic set used only studies that reported study information with adequate detail to allow abstraction of treatment and followup duration and outcome information. As is often seen in fields working on improving reporting, the articles in the analytic set tend to be newer, and thus tended to report longer followup periods because patient data was available longer. Table 4 presents the analytic set first by type of disease modifying treatment (DMT), followed by the remaining studies in the full reporting set but not the analytic set.

Table 4. MS study followup and treatment duration (mean unless otherwise noted)

Author, Year, Drug(s)	Duration:	1 Year	2 Years	3 Years	4 Years	5-6 Years	7-9 Years	≥10 Years	
Interferons									
Portaccio, 2008 ¹⁴	Followup				4.7y β -1a im, 6.0y β -1b				
	Treatment			β -1a im 3.1y , β -1b 3.3y					
Carmona, 2008 ⁴⁷	Followup					4.6y			
	Treatment					≤5y			
Kappos, 2009 ⁵⁷	Followup								
	Treatment			Delayed tx: med. 2.9y		Early tx: med. 5y			
Rio, 2007 ⁵¹	Followup					med. 5y (range 1-9)			
	Treatment	Mean, median treatment duration not stated. 36% stopped treatment during followup							
Bencsik, 2006 ⁴⁶	Followup					6y			
	Treatment					6y			
Patti, 2006 ⁴¹	Followup					6y			
	Treatment					6y			
Uitdehaag, 2011 ⁵⁸⁻⁶⁰	Followup					7-8 y after RCT enrollment			
	Treatment			96=3 y*			95=7y*		
Shirani, 2012 ³⁷	Followup				Contemporary untreated 4.5y	IFN β : 5.2y		Historical untreated. 10.5y	
	Tx: pt-yrs	Treatment was time-varying covariate in regression model.							
Goodin, 2012, ^{32,33}	Followup							21.1y	
	Treatment			RCT 3.3y	After RCT extension, treated by standard clinical practice.				
Teriflunomide									
Confavreux, 2012 ⁵⁶	Followup								
	Treatment						med. 7.1y (0.1-8.5)		
Glatiramer acetate									
Debouverie, 2007 ⁵⁴	Followup			3.5-8y					
	Treatment				med. 5y				
Ford, 2010 ²⁷⁻³¹	Followup							Up to 15y	
	Treatment				withdrawn 4.8y		mITT 8.6y	ongoing 13.6y	
Miller, 2008 ³⁵	Followup				Discontinued			Continuing	
	Treatment			Discontinued 3.5y(0.7-13y)				Cont15y(13- 22)	

Author, Year, Drug(s)	Duration:	1 Year	2 Years	3 Years	4 Years	5-6 Years	7-9 Years	≥10 Years
Multiple medications								
Rio, 2005 and 2006 ⁴⁸⁻⁵⁰	Followup				4y			
	Treatment			NR				
Tedeholm, 2013 ⁵³	Followup							12 y
	Treatment			Treated all DMT (interferons and glatiramer acetate) as single				
Bergamaschi, 2012 ⁴⁵	Followup							up to 35y
	Treatment		t	Treated all DMT as single class				
Interferons – not in analytic set								
Cunningham, 2010 ⁵²	Followup							
	Treatment		stoppers, switchers 1.2y	continuers ≥3y				
Mesaros, 2012 ⁵⁵	Followup			*3.5±2.1 yrs				
	Treatment			β1b 3.2±2 yr	β1a 3.7±2 yr			
O'Rourke, 2005 ³⁸	Followup		IFNβ-1a 1.6y	IFNβ-1a 3y	IFNβ-1a 4.5y			
	Treatment			varied by DMT				
O'Rourke, 2007 ³⁹	Followup			hist. controls 3y		5.1y		
	Treatment				8.5% stopped at 4.1y	NR		
Trojano, 2005 ⁴²	Followup					up to 6 y		
	Treatment				Results 4y			
Trojano, 2007 ⁴³	Followup					med 5.7 y.	up to 7 y	
	Treatment			Tx covered 75% of followed days				
Trojano, 2009 ⁴⁴	Followup						up to 7 y	
	Treatment			NR				
Bermel, 2010 and 2013 ^{25,26}	Followup							med.16.3y
	Treatment				stop 4.2y (0-15)			med.13.3y (3-15)
Multiple medications – not in analytic set								
Sorensen, 2006 ¹⁰	Followup				3.7y			
	Treatment			β-1b 3.8y, β-1a 2.7-3.7y, GA 1.8y				
Milanese, 2005 ⁴⁰	Followup					up to 5 y		
	Treatment		GA 1.6y	β-1a 2.3-3.2y	β-1b 3.5y			
Evans, 2012 ³⁶	Followup							up to 14y
	Treatment			med 6.3 yr any first-line DMT				

DMT=disease-modifying treatment; IFNβ=interferon beta; GA=glatiramer acetate; im=intramuscular; med=median; mITT=modified intention-to-treat; MS=multiple sclerosis; NR=not reported; RCT=randomized controlled trial; sc=subcutaneous; Tx=treatment; y=year

KQ1a. What is the evidence for benefits for continuing treatment versus discontinuing in patients with MS?

No studies directly assessed continuing versus discontinuing DMT in comparable populations. We therefore turned to literature examining benefits for continuing DMT long-term.

Sixteen observational studies from 24 articles on long-term benefits for DMT provided sufficient detail to abstract treatment benefit information.^{14,27-33,35,37,41,45-47,49-51,53,54,56-60} (Detailed evidence table are available in Appendix C.) Four studies were funded by industry,^{27,32,56,57} three by governmental funding,^{37,46,53} three reported not receiving funding,^{41,45,59} and six did not report funding sources.^{14,35,47,50,54,61}

Table 5 provides outcomes reported by type of DMT and the range of followup.

Key Points

- Low strength evidence from one moderate risk of bias study suggests long-term all-cause survival is higher for treatment naïve relapse-remitting MS (RRMS) patients who did not delay starting interferon beta 1b by 2 years and used DMTs for a longer duration than those who started later.
- Low strength evidence from one moderate risk of bias study suggests that interferon use did not change disability progression for RRMS patients.
- Insufficient evidence was available for long-term benefits for DMTs for secondary progressive MS (SPMS) patients, and most outcomes for RRMS patients. Except for those noted above, studies were high risk of bias, had small sample sizes, and reported effects were small in magnitude.

Table 5. Outcomes reported from unique studies included in the analytic set for long-term DMT use

Author	Type of MS at Baseline	Median or Mean Years to Final Assessment	All-cause Mortality Convert to SPMS	Progression	Annual Relapse Rate (ARR)	Strength of Evidence
INFB1a						
Uitdehaag, 2011 ⁵⁸⁻⁶⁰	RRMS	7-8	N (%) convert to SPMS	N (%) with EDSS progression; time to sustained 1-point EDSS progression	N (%) relapse-free; change in ARR from baseline, Annual relapse count by year;	Insufficient
INFB1b						
Kappos, 2009 ⁵⁷	CIS	5	Primary: time to clinically-definite MS	Change in EDSS from baseline		Insufficient
Carmona, 2008 ⁴⁷	RRMS	5.6	N (%) convert to SPMS	Change in EDSS from baseline; time to 1 –point EDSS progression	Change in ARR from baseline	Insufficient
Bencsik, 2006 ⁴⁶	RRMS, RPMS	6		Change in EDSS from baseline	Change in ARR from baseline	Insufficient
Rio, 2007 ⁵¹	SPMS	5		Time to 1-point increase in EDSS (or 0.5 points if above 6 at entry)	Change in ARR, % decrease in relapse rate	Insufficient
Goodin, 2012 ^{32,33}	RRMS	21	All-cause mortality: 250 mg arm vs. placebo – HR 0.532 (98% CI, 0.31-0.90) 50 mg arm vs placebo – HR 0.54 (95% CI, 0.32-0.92) favors treatment			Low
INFB mixed						
Portaccio, 2008 ¹⁴	RRMS	4.2				(Discontinuation or harms only reported)
Patti, 2006 ⁴¹	RRMS	≤6		Change in EDSS from baseline; progression by year to 6 years	Change in ARR from baseline	Insufficient
Shirani, 2012 ³⁷	RRMS	4.5-10.5	Time to sustained EDSS ≥6, No difference from contemporary	-	-	Low

Author	Type of MS at Baseline	Median or Mean Years to Final Assessment	All-cause Mortality Convert to SPMS	Progression	Annual Relapse Rate (ARR)	Strength of Evidence
			control (HR 1.30; 95% CI, : 0.92–1.83) or historical control (HR 0.77; 95% CI: 0.58–1.02)			
Glatiramer Acetate						
Debouverie, 2007 ⁵⁴	RRMS	3-8		Change in EDSS from baseline; % progression by at least 1-point EDSS	Change in ARR from baseline; mean ARR by year	Insufficient
Ford, 2010 ²⁷⁻³¹	RRMS	4.8-13.6	Proportion reaching EDSS 4, 6, 8; progression to SPMS	Change in EDSS from baseline	Change in ARR from baseline	Insufficient
Miller, 2008 ³⁵	RRMS	3.5-15	% changed from EDSS<4 to>4; EDSS <6 to >6	Change in EDSS from baseline	ARR over time	Insufficient
Teriflunomide						
Confavreux, 2012 ⁵⁶	RRMS, SPMS	7.1		Change in EDSS from baseline	Change in ARR from baseline	Insufficient
Multiple drugs						
Rio, 2005 ⁴⁸⁻⁵⁰	RRMS	5	Proportion relapse-free; proportion reaching EDSS of 6	% sustained disability progression	Change in ARR from baseline; proportion with decrease in ARR	Insufficient
Tedeholm, 2013 ⁵³	RRMS	12	Time to SPMS			Insufficient
Bergamaschi, 2012 ⁴⁵	RRMS	20	Proportion converting to SPMS			Insufficient

CIS=clinically isolated syndrome; DMT=disease modifying treatment; EDSS=extended disability scale score; FU=followup; IFN β =interferon beta; GA=glatiramer acetate; LTFU=long-term followup; med=median; MS=multiple sclerosis; NR=not reported; RRMS=relapse remitting multiple sclerosis; SD=standard deviation; SPMS=secondary-progressive multiple sclerosis; y=year

Detailed Synthesis

Variation among the included studies on patient populations, interventions, outcome measurements, and time frames, precluded meaningful pooling. Risk of bias for all but two studies was also high. Selection bias, attrition, and lack of accounting for patient populations over time accounted for the greatest threat to risk of bias. Only two studies provide a low strength of evidence for two benefit outcomes measured long-term for interferons.

One moderate risk of bias study examined all-cause mortality over a 21 year period for 366 patients who had enrolled in a randomized controlled trial (RCT) (98.4 percent of the original RCT participants) testing interferon beta-1b for treatment naïve RRMS patients in 11 clinics in North America.³² The study's strength lies in the nearly complete followup of patients and the objective outcome measure. The missing patients were evenly spread across the study arms at two each. After the 2-year RCT, participants used DMTs according to patient and physician discretion, but analysis was based on RCT intention to treat. Participants in the treatment arms showed lower all-cause mortality compared to the placebo arm, with the 250 mg arm slightly lower than the 50 mg arm. The survival rate for the placebo arm was consistent with survival rates reported in MS natural history studies. Median treatment duration for the three groups ranged between 7 years for the placebo group, 14 years for the 50 mg arm, and 12 years for the 250 mg arm. Patients assigned to placebo had both later starts and shorter exposure to DMTs. Thus, the study cannot distinguish between the effects of early use and the effects of long-term use.

Three studies examined the effects of DMTs on disease progression measured by conversion to SPMS.^{37,45,53} While the studies were not pooled due to heterogeneity of treatments and methodological approaches, they represent on-target studies that directly attempt to evaluate the effects of DMTs on the long-term patient goal of delaying, or possibly preventing, progressing to SPMS, a more severe disease state. Thus, while only one study provided at least low strength of evidence findings, all three are presented in more detail.

One moderate risk of bias study examined the association between interferon beta use and progression to sustained Expanded Disability Status Scale (EDSS) of 6 for 2656 RRMS patients in Canada.³⁷ Three arms were used: a treatment cohort followed for 5.1 years (interquartile range, 3 to 7 years), a contemporary cohort followed 4 years (interquartile range, 2.1 to 6.4 years), and a historical cohort (drawn from pre-interferon period) followed 10.8 years (interquartile range, 6.3 to 14.7 years). The strength of the study by Shirani et al. lies in the almost complete capture of MS patients since patients were unable to obtain DMTs other than from the participating clinic, and the multiple statistical approaches used to test for association, including use of comorbidities (Charlson score) and socioeconomic status along with age, sex, disease duration, and EDSS. Propensity score adjustments did not substantially change the results. The study did not find statistically significant differences in hazard rates for reaching EDSS 6 for either contemporary or historical cohort comparisons. Analyses used a time-dependent treatment variable and accounted for changing treatment status over time to address immortal time bias, a special form of selection bias. The study does not report the percent of patients prescribed different DMTs, or patients with neutralizing antibodies.

One high risk of bias study used selected patients' data from a Swedish MS registry, also using both a contemporary and historical cohort as comparisons.⁵³ Adjusting for sex, age at MS symptom onset, whether onset was monofocal or polyfocal, and location of lesions, the study did not find a statistically significant difference in time to SPMS conversion for DMT (interferons

and glatiramer acetate) treated versus a historical control of untreated patients. The reported results are consistent with Shirani et al. However, significant concerns regarding selection bias of the treatment and contemporary groups and treatment by indication determined the study's high risk of bias.

A second study published only as an e-publication ahead of print used Bayesian techniques to model propensity for treatment – Bayesian risk estimate for MS (BREMS) – and then Bayesian modeling to estimate effects for DMT use in aggregate.⁴⁵ The study reports that the technique they used allowed for typical switching and start/stop usage. However, there is insufficient information to assess model quality, and guidelines for model risk of bias are still new to the field and have not yet been translated to systematic review use; thus the risk of bias remains unclear. Bergamaschi et al. found that a smaller proportion of patients using DMTs (the vast majority of patients used interferons or glatiramer acetate) converted to SPMS compared to the historical control. This result is inconsistent with the other two studies.

Insufficient evidence exists to address long-term benefits for glatiramer acetate, teriflunomide, and natalizumab for either RRMS or SPMS, as well as other important MS outcomes for interferon beta for RRMS beyond all-cause mortality or 5-year disability progression for interferon beta.

KQ1b. What is the evidence for long-term harms?

Eleven of the 16 unique studies reported harms in sufficient detail for abstraction.^{14,27-33,35,41,49-51,54,56-60} (Detailed evidence table in Appendix C.) Only one of the studies was moderate risk of bias;³² all others were rated as high risk of bias.

Table 6 provides categories of harms reported by type of DMT and the range of followup.

Key Points

- Limited low strength evidence suggests harms over the long term (up to 16 years for interferon, 22 years for glatiramer acetate, and 8.5 years for teriflunomide) do not differ from short-term harms.
- The majority of discontinuation tends to occur in the short-term (2 to 3 years from start).
- Broad variation in harms reporting precludes informative aggregation and summary.

Table 6. Harms reported from unique studies included in the analytic set

DMT	Number of Studies Total N Followup	Any Adverse Event	At Least One Serious Adverse Event	Treatment Discontinuation for Adverse Event	Comparator Groups	Reported Results
IFN β -1a ⁵⁸	1 N=429 4 y-	Most common AEs: Injection site reactions, headache, flu-like symptoms	NR	NR	No	No difference from short-term events
IFN β -1b ^{33,57}	2 N=746 5 – 16 y	Most common AEs: Injection site reactions, depression, flu-like symptoms, headache	21% to 24%	Discontinuation rates “high” but numbers not reported	No	No difference from short-term events Frequency declined over 16 y time in continuers
IFN β mixed ^{14,41,50}	3 N=587 4 - 8 y	Most common AEs: Injection site reactions, depression, flu-like symptoms, headache.	NR	3% during LT FU. Discontinue for serious AE more likely to happen early in treatment course (1 y)	No	Headache more likely for β -1a, injection site reactions for β -1b, no other differences between type of IFN β Majority of discontinuation occur early/short term.
INF β mixed ⁵¹ SPMS	1 N=146 5 y	NR	NR	3.4%, although timing isn't clear	No	Majority of discontinuation occur early/short term.
Glatiramer Acetate ^{27,35,54}	3 N=483 4y – 22 y	Only one reported overall rates: 87.3% Most common AE: injection site reactions	NR	Only one reported overall rates: 4.9% in long-term extension	No	Majority of discontinuation occur early/short term No difference from short-term events
Teriflunomide ⁵⁶	1 N=147 8.5 y followup	98% of 7 mg dose and 100% of 14 mg dose experienced treatment emergent AE	36% of 7 mg dose and 29% of 14 mg dose	13.6% of 7 mg dose and 13.6% of 14 mg dose for AE	One comparison to general population rates for cancer	No difference from short-term events

AEs=adverse events; DMT=disease modifying treatment; FU=followup; IFN β =interferon beta; GA=glatiramer acetate; im=intramuscular; LTFU=long-term followup; med=median; mg=milligram; MS=multiple sclerosis; NR=not reported; RRMS=relapse remitting multiple sclerosis; sc=subcutaneous remitting multiple sclerosis; SD=standard deviation; SPMS=secondary-progressive multiple sclerosis; y=year

Detailed Synthesis

The included studies used a wide range of reporting methods and adverse event categories that precluded simple aggregation over the studies. The most commonly reported adverse events were injection site reactions, flu-like symptoms, depression, and headache. Serious adverse events were generally not reported, although two studies gave rates of about 25 percent to 30 percent of participants. Discontinuations tended to occur during the first or second year of the study. When reported, discontinuation rates during long-term followup were low, about 3 percent to 4 percent. However, the studies generally did not separate discontinuation rates due to adverse events from total discontinuation rates, which would also include perceived lack of efficacy and other reasons not necessarily related to adverse events or side effects. Further, all studies lost participants to attrition. Dropouts from observational studies are more likely to bias reporting towards lack of adverse events. Patients on long-term treatment are self-selected for positive outcomes, even though this may be due to any combination of treatment effects and benign disease course. The studies also did not use large enough patient populations to adequately detect rare events.

The Cochrane overview of reviews of RCTs by Filippini et al. provides another basis for comparing short-term and long-term harms.⁸ They assessed treatment discontinuation for any reason as acceptability of treatment. The included RCTs were generally 2 to 3 years followup. They assessed treatment harms as counts of participants with (1) at least one adverse event, (2) at least one serious adverse event as defined by the author of the primary study, (3) withdrawal due to adverse event at any time during the followup period, (4) serious infections as defined by the authors of the primary study, and (5) a new diagnosis of leukemia, lymphoma, or any other type of cancer during the followup period.⁸ They found, similar to our results, that studies tended to report number of adverse events rather than number of participants reporting adverse events, and that the range of adverse events and reporting methods was too diverse to allow for data aggregation. Filippini et al. found no statistically significant differences in serious adverse events, serious infections, or cancer between treatment and placebo groups. However, participants in treatment groups were more likely to withdraw from the studies than placebo groups (OR 2.41, 95% CI, 1.92 to 3.03).

Natalizumab Discontinuation or Drug Holiday

Eleven observational studies (one moderate and 10 high risk of bias) addressed the risks of rebound disease activity with natalizumab treatment interruption. (Detailed evidence tables in Appendix C.) Studies were conducted in the United States,^{62,63} Canada,⁶⁴ Germany,^{65,66} France,⁶⁷ Italy,⁶⁸ Denmark,⁶⁹ Australia,⁷⁰ and Spain.^{71,72} Three studies were funded by industry,^{63,64,68} one was funded by a combination of government, nongovernmental, and industry,⁷⁰ two were unfunded,^{62,72} and five did not report funding sources.^{65-67,69,71}

Eight of the 11 included annualized relapse rate and MRI measures to assess rebound,^{62,64-70} while three included MRI measures only.^{63,71,72} Reported reasons for natalizumab interruption were drug holiday in five studies,^{63,64,68,71,72} mostly drug holiday or not clearly reported in two studies,^{62,65,70} and mixed reasons in three studies.^{66,67,69} Five of the eight studies included RRMS patients only,^{62,66-68,71} while the others were mixed or unspecified. Sample size ranged from 13 to 48, with three exceptions: Sorensen (n=375),⁶⁹ Jokubaitis (n=536),⁷⁰ and O'Connor (n=949).⁶⁴

Mean duration of natalizumab treatment ranged from 12 to 32.4 months, while treatment interruption ranged from median 2.6 to mean 11.3 months. Other DMT use during the

natalizumab interruption was heterogeneous. DMT was not administered during the treatment interruption in three studies,^{63,67,72} glatiramer acetate was used in two studies,^{65,68} fingolimod in three studies,^{66,69,70} mixed DMTs in three studies,^{62,64,69} and pulsed steroids in one study,⁷¹ although only two studies administered DMTs to all MS patients.^{68,71} All^{63,65-67} or most patients used DMTs prior to natalizumab, with details not reported^{62,68,72} or not analyzed.⁶⁹ Three studies did not report prior DMT use,^{70,71,73} one of which compared patients who switched from natalizumab to fingolimod with cohorts who switched to fingolimod from first-line DMT or no treatment.⁷⁰

Table 7 provides definitions of rebound reported in the studies.

Key Points

- Overall, evidence is insufficient for whether the rebound phenomenon exists due to the high risk of bias and small study sample sizes.
- Operational definition of rebound lacks consensus. Rebound is subjectively measured and not clearly defined in studies.
- Evidence is lacking for rebound based on the best available evidence of one large study with moderate risk of bias.
- Studies that reported cases of rebound had high risk of bias, mostly small sample size, were mixed in providing DMTs during the interruption, and did not account for DMT use prior to natalizumab.

Table 7. Natalizumab rebound definitions

Study Location Risk of Bias	Reported Rebound	Definition of Rebound/Severe Flare
ARR and MRI measures		
Jokubaitis, 2014 ⁷⁰ Australia and International Moderate	None	Quantified: compared ARR pre- and post-natalizumab; also compared ARR and distribution of severe relapse among those who switched to fingolimod from natalizumab, first-line, or no DMT
O'Connor, 2011 ⁷³ Canada High	None	Quantified: comparison to placebo: peak mean ARR during treatment interruption was not higher than the placebo group
Havla, 2013 ⁶⁶ Germany High	3/13	Quantified: Sustained EDSS worsening (>1 EDSS steps) and widespread disease activity (>1 GELs) on MRI
Havla, 2011 ⁶⁵ Germany High	4/13	Subjective: severe relapse with sustained EDSS worsening and widespread disease activity on MRI
Kaufman, 2011 ⁶² United States High	None	Subjective: severe relapse as has been reported by others subjective: clinically severe flare and mean 16 GELs (range 6-40))
Kerbrat, 2011 ⁶⁷ France High	4/27	Subjective: severe relapse and 20+ GELs (range 23-50)
MRI measures only		
Rossi, 2013 ⁶⁸ Italy High	None	Subjective: MRI parameters were not consistent with rebound of disease activity
Sorensen, 2014 ⁶⁹ Denmark, High	83/375 or 42/375*	Quantified: Higher individual relapse rate after cessation of NTZ than before NTZ
Borriello, 2012 ⁷¹ Spain	2	Subjective: severe disabling relapse and a large number of GELs

Study Location Risk of Bias	Reported Rebound	Definition of Rebound/Severe Flare
High		
Borriello, 2011 ⁷² Spain High	None	Subjective: disease activity worsens beyond pre-treatment severity
Miravalle, 2011 ⁶³ United States High	1	Subjective: NR for observational study design

ARR=annualized relapse rate; EDSS=Expanded Disability Status Scale; GELs=gadolinium-enhancing lesions; MRI=magnetic resonance imaging; NR=not reported; *excluding 51 patients treated with mitoxantrone prior to natalizumab

Detailed Synthesis

Determining whether rebound exists requires comparing disease activity prior to receiving natalizumab and disease activity after interrupting treatment. The comparisons need to examine people who discontinued natalizumab due to risk of progressive multifocal leukoencephalopathy (PML) rather than lack of treatment efficacy, compare pre and post measures on an individual level if rebound is heterogeneous, and account for other medications used both prior to natalizumab and after treatment interruption. None of the studies met these criteria.

One study addressed the issue of prior treatment by comparing patients who switched from natalizumab to fingolimod with patients who started fingolimod after interferon beta, glatiramer acetate or treatment naïve.⁷⁰ Although this study did not examine individual level outcomes or treatment prior to natalizumab, mean ARR did not increase pre- and post-natalizumab among the 89 patients who used natalizumab followed by fingolimod. Additionally, comparison of quarterly relapse rates for each 3-month period in the 15 months before and 9 months after fingolimod initiation found no differences between the natalizumab to fingolimod and first-line DMT to fingolimod cohorts. No differences were found between any of the three cohorts except that during the 3-6 month period after beginning fingolimod, relapse rates were significantly lower among the treatment naïve cohort (with only one relapse across the cohort) compared with the post-natalizumab cohort. Relapse severity was assessed by comparing relapse treatment (ambulatory, hospitalization, or none) across the cohorts. Fifteen percent of relapses required hospitalization, and these relatively severe relapses were distributed evenly across the three cohorts and across the full observation period, with no evidence of rebound observed during the transition from natalizumab to fingolimod.

One large (n=949) industry-funded high risk-of-bias study examined 8 months of treatment interruptions gathered from large clinical trials.⁶⁴ About 13 percent of patients used other DMTs during the interruption. Peak mean ARR following natalizumab discontinuation remained below the on-study placebo ARR. However, ARR and magnetic resonance imaging (MRI) outcomes were assessed only as averages, with no examination of pre and post measures for individual patients. Sampling of MRI outcomes was limited. Of the 949 study participants who underwent natalizumab treatment interruption, 339 had baseline MRI measures, and followup MRI during treatment interruption ranged from a sample of 147 at 2 - 3 months after discontinuation to 60 participants at 6 or more months after discontinuation, the time period with peak MRI activity.

Three small, high risk-of-bias studies also reported no rebound. One study examined only mean ARR, with no MRI outcomes or individual pre/post ARR comparisons in 48 patients, some of which used other DMTs during the interruption.⁶² One study of patients who did not use DMTs during the interruption did not report ARR outcomes after treatment interruption and included a sample of less than 20 with complete MRI data.⁷² One industry-funded study reported

that the mean number of gadolinium-enhancing lesions (GELs) was significantly higher prior to natalizumab treatment compared with after natalizumab discontinuation in 40 patients. However, all patients were switched to glatiramer acetate, to which they had been treatment naïve, and thus the study lacked a true comparison group.⁶⁸

In contrast, six high risk of bias (five small) studies reported cases of rebound disease activity. Four studies used subjective rebound definitions.^{63,65,67,71} All studies did not account for prior use of DMTs and lacked the quantitative detail necessary to generate confidence in the study findings.^{63,65-67,69,71} Two studies each reported four rebounds and one reported three rebounds despite small sample sizes (n=13, 27, 36) but lacked quantitative detail on reported MRI outcomes.⁶⁵⁻⁶⁷ Prior to natalizumab, all patients in both studies used some type of DMT (details not reported). During the interruption, patients in one study used no DMTs.⁶⁷ In the other two studies, some patients used DMTs while others did not, with all of the reported rebounds occurring in the group taking no DMTs during the interruption.^{65,66} In all four studies reporting ARR, mean ARR did not increase after natalizumab interruption compared with prior to natalizumab treatment. Two other studies did not report ARR after natalizumab interruption.^{63,71} One found no median change in MRI outcomes and reported two cases of rebound despite pulsed steroids use in all patients.⁷¹ DMT use prior to natalizumab was not reported; 18 of 23 patients had used mitoxantrone. One study found significantly higher mean GELs among the 12 patients with GELs after natalizumab interruption and described one case of rebound.⁶³ All patients used DMTs prior to natalizumab, with details not reported, and none during the interruption. One large study reported 83 rebounds based on individual-level comparison of ARR pre- and post-natalizumab. However, this study did not account for the sample's high disease activity at baseline, included individuals who stopped natalizumab due to treatment failure, and did not address prior DMT (except to report 42 rebounds after excluding patients who had been on mitoxantrone prior to natalizumab).

Since pre-treatment disease activity tends to return following natalizumab interruption, comparisons that do not account for DMTs used prior to natalizumab are insufficient. Studies found some evidence that those with higher disease activity prior to natalizumab were more likely to relapse after natalizumab interruption. In one study, those with three or more relapses in the year prior to natalizumab treatment were twice as likely to experience relapse following natalizumab interruption (p=0.04) compared with those with fewer relapses prior to natalizumab.⁶⁸ In this study, 88 percent of the total sample (n=40) were on interferon beta prior to natalizumab, and all received glatiramer acetate during the treatment interruption. Two studies reported trends toward higher ARR prior to natalizumab among those who relapsed during interruption.^{63,65} One study found that relapse on fingolimod was predicted by the number of relapses during the 6 months prior to fingolimod, regardless of whether patients started fingolimod after natalizumab discontinuation or after first-line treatment or treatment naïve, and among the natalizumab to fingolimod cohort, relapses on fingolimod were not predicted by relapse rates prior to natalizumab.⁷⁰

Pregnancy Drug Holiday

Twelve observational studies (all high risk of bias) addressed the benefits and risks to mothers and fetuses of treatment discontinuation due to pregnancy or intended pregnancy. (Detailed evidence tables in Appendix C.) Published from 2005 to 2012, these 12 studies comprised 11 cohort studies comparing DMT-exposed to unexposed pregnancies, and one large case series, and ranged in size from 14 to 425 DMT exposed pregnancies. The case series was

drawn from a global drug safety database, included 425 pregnancies exposed to IFNbeta-1a with prospectively recorded outcomes.⁷⁴ Studies were conducted in Sweden,^{74,75} Italy,⁷⁶⁻⁷⁸ Canada,^{11,79} Brazil,¹³ and Germany,⁸⁰⁻⁸² and one was an international study with data from the United Kingdom, Brazil, Argentina, and Mexico.⁸³ Two studies were funded by industry,^{74,75} two by governmental organizations,^{11,82} three reported that no specific funding was received for the study,^{80,81,83} and five did not report funding sources.^{12,13,76-79}

Definitions of exposed versus unexposed differed (Table 8). Of the 12 studies, 10 reported on IFNbeta (14-88 exposed pregnancies),^{11,13,74-77,79,80,82,83} six reported on GA (6 - 41 exposed pregnancies),^{11,13,78,81-83} and one reported on natalizumab (35 exposed pregnancies).⁸⁰ Of the 10 studies reporting results for IFN exposure, 2 studies reported on IFNbeta-1a,^{74,75} and 8 studies did not report results by specific IFNbeta preparation.

Table 8. Studies reporting pregnancy outcomes by drug

DMT	Total Number of Studies Total N	Spontaneous Abortion	Fetal Death	Preterm Delivery	Postpartum Relapse Rate
IFNβ1a (sc or im)	2 N=466	2	2	1	0
IFN mixed	8 N=373	6	6	5	2
GA	6 N=156	4	5	3	2
NTZ	1 N=35	1	1	1	1

DMT=disease-modifying treatment; IFNβ=interferon beta; GA=glatiramer acetate; im=intramuscular; NR=not reported; sc=subcutaneous; NTZ=natalizumab

Key Points

- Overall, high risk of bias and small sample sizes rendered the evidence insufficient to address the risks of fetal exposure to DMT during pregnancy in women with MS or the risks to the mother from the drug holiday.
- Women who discontinued DMT to attempt pregnancy but did not conceive were not observed as comparison groups, nor were data gathered or grouped by time on drug holiday prior to and during pregnancy.
- IFNbeta-1a exposure did not impact spontaneous abortion rates based on the best available evidence from one high risk-of-bias study.

Detailed Synthesis

The studies were not pooled for several reasons: (1) the outcomes are relatively rare events and the studies were not appropriately powered, (2) comparison groups were heterogeneous due to lack of reporting specific types of IFNbeta, and (3) definitions of exposure differed.

Maternal risks and benefits of discontinuation were investigated by examining post-partum relapse rate. Improvement in relapse rates during pregnancy is well established.⁸⁴ Women who discontinue DMT with the intention of becoming pregnant risk increased relapses between discontinuation and pregnancy, as well as post-partum. Given that the studied populations are those who became pregnant, none of the studies capture what happens to women who discontinue DMT but do not become pregnant. Therefore, no research has observed whether such women are at increased risk of relapse. A German study using a retrospective survey found

that women stopped DMT due to intended pregnancy for a mean of 4 years,⁸⁵ thus the period a woman with MS remains untreated is not insignificant.

Maternal Outcomes

Three small, high risk-of-bias studies reported data on the outcome of post-partum maternal relapse rate.^{80,81,83} These studies were limited by sample size and aggregation of DMTs. One study reported on natalizumab with prospective data and found no significant difference but a trend toward fewer post-partum relapses among the exposed.⁸⁰ One study reported on glatiramer acetate and aggregated IFNbeta with mixed prospective and retrospective data and found exposed women had a lower postpartum relapse rate during the first trimester after delivery compared with the unexposed group ($p < 0.05$).⁸¹ One study reported on DMT in aggregate and found women receiving any DMT at least 8 weeks during pregnancy had a significantly lower relapse rate following delivery compared with those receiving no DMT at least 3 months prior to pregnancy, with no significant differences between the exposed and unexposed groups in relapse rates during the year prior to pregnancy or during pregnancy.⁸³ However, the study timing and details of the postpartum relapse rates were not clearly reported.

Fetal Outcomes

All 12 studies reported on fetal outcomes. Two studies on IFNbeta-1a, including a large case series, found that rates of spontaneous abortion did not differ significantly from population estimates.^{74,75} Neither study reported a significant difference in fetal death from population estimates. One small, high risk-of-bias study reported no difference in preterm delivery between the exposed and unexposed groups.⁷⁵

Of the six studies reporting on spontaneous abortions in pregnancies exposed to aggregated IFN, one small, high risk-of-bias study found significantly higher rates of spontaneous abortion among the exposed group.⁷⁹ This study used multivariate analysis with mixed models on an inappropriately small sample, and the population was heterogeneous, including women with non-MS diseases in both the exposed and unexposed groups. In the exposed group, the two mothers without MS discontinued DMT at 21 and 38 weeks of gestation, while the 14 mothers with MS discontinued during the first trimester.

One small, high risk-of-bias study found no overall difference in spontaneous rates between the exposed and unexposed groups. The reported rate of spontaneous abortion was statistically significantly higher among those exposed to IFNbeta 1b compared with exposure to IFNbeta 1a, glatiramer acetate, or the control group without MS (rates in these groups ranged from 3.9 percent to 9.1 percent, with as few as one or two events per group. However, the result was not significant compared with the MS control group (9.8 percent).⁸² General population estimates of spontaneous abortion are 10 to 20 percent.⁸⁶ This outcome is subject to surveillance bias; spontaneous abortions may be unobserved, contributing to the low rates reported by many of the included studies.

No studies on IFNbeta found significant differences in fetal death rates. One small, high risk-of-bias study found an increased risk of preterm delivery with exposure to IFNbeta, based on propensity score adjustment.⁷⁶ The study did not report the percentage of nonoverlapping subjects that were dropped from the analysis.

Six small, high risk-of-bias studies on glatiramer acetate and one small, high risk-of-bias study of natalizumab reported no significantly higher rates of spontaneous abortion, fetal death, or preterm delivery among exposed pregnancies.

A published systematic review on DMT during pregnancy among women with MS rated the evidence level and quality as good across most IFNbeta outcomes and fair for glatiramer acetate and natalizumab.⁸⁷ However, the review based the ratings on one small study, did not report maternal outcomes, and inappropriately used an instrument for assessing systematic reviews to assess individual study risk of bias. Two other systematic reviews on pregnancy did not assess study quality or risk of bias and performed meta-analysis without regard to underpowered sample sizes or heterogeneity (such as pooling spontaneous and elective abortions).^{84,88} Several recent reviews have summarized FDA categorization for DMTs including oral drugs with or without current FDA approval as treatment for MS, along with early data from clinical trial registries.^{89,90}

KQ1c. What reasons for discontinuation of disease modifying treatments have been reported in long-term observational cohort studies?

Twenty of the 27 articles in the full reporting set reported reasons for discontinuing treatment. (Detailed evidence table in Appendix C.) Table 9 provides a summary of the number of articles reporting discontinuations by categories.

Key Points

- The broad variation in discontinuation reporting prevented useful aggregation of studies.
- All studies reported one or more adverse events and inefficacy or progression of disability as reasons to discontinue.
- Patient reasons for discontinuing DMT were not explored.

Table 9. Studies reporting reasons for discontinuing medication

DMT	Total Number of Studies	Adverse Event	Inefficacy or Progression of Disability*	Intended Pregnancy	Long-term Stable MS	Death	Protocol Violation**	Patient Decision
Glatiramer acetate	3	3	3	2	1	1	2	3
Teriflunomide	1	1	1	0	0	1	1	1
Interferon beta-1a	1	1	1	1	0	1	0	1
Interferon beta-1b	4	4	4	3	0	3	2	3
Interferon beta mixed	7	7	7	5	1	1	0	5
DMT mixed	3	3	3	3	0	1	0	3

*Category includes counts of both discontinuation based on clinician evaluation of disease progression and patient evaluation of lack of efficacy. **Protocol violations are from studies that were RCT extensions.

Detailed Synthesis

As was seen with harms, the wide range of reporting methods and discontinuation categories prohibited detailed quantitative aggregation over the studies. Most articles reported numerous reasons for discontinuations. An article was categorized as reporting lack of efficacy or progression of disability based on study author definitions and use of the specific terms. In this category we included both physicians' and patients' perceptions of lack of efficacy, and it was often unclear who was the source of such a determination. Progression of disability was also study author defined but included articles that provided objective measures of progression such

as a one-step increase in the EDSS. Protocol violations was included as a category since several studies were open label surveillance extensions of RCTs. Unfortunately, the category of most interest, the patient's decision to discontinue, remained largely unexplored by the study authors. Minimal text was generally provided for this category, such as "by own will,"^{51,55} "withdrew consent."^{35,57} or "voluntary withdrawal."^{42,47,49} One study labeled patients stopping DMT for "no discernable reason, without discussion with their neurologists" as noncompliant.³⁸

Key Question 2. What are individuals' values, beliefs, and preferences regarding discontinuing disease modifying treatments?

Description of Included Studies

The 25 included unique studies (28 total articles) represented a wide range of study aims. Designs ranged from factor analysis of questionnaires to experimental psychology lab tests to trials of shared decisionmaking interventions. Study locations were international, including the United States,⁹¹⁻⁹⁸ Netherlands,⁹⁹⁻¹⁰¹ Germany,¹⁰²⁻¹¹² Norway,¹¹³ a consortium of European countries,¹¹⁴ Canada,^{115,116} Italy,¹¹⁷ and Ireland.¹¹⁸ The included studies, organized by the KQ sub-questions and relevant section of the conceptual framework, are shown in Figure 1.

Overarching Key Point

Given the complexity of understanding preferences and behaviors, and the wide range of study designs used over a small literature set, all KQ2 key points should be viewed as preliminary.


KQ2a. What are patients' and providers' preferences for discontinuation of disease modifying treatments in patients?

Literature for this KQ sub-question is categorized as intrapersonal or interpersonal literature. Intrapersonal literature examines preferences, values, knowledge, beliefs, and other behaviors of people with MS to improve our understanding of the inputs that may enter on a personal level into deciding whether or not to discontinue DMTs. The interpersonal literature addresses the relationship between patients and providers, and the preferences each brings to the encounters and decisions.

Intrapersonal Literature

We found few studies to populate the intrapersonal portion of Figure 1 (reproduced in Figure 4). Table 10 provides information on the 14 studies that addressed intrapersonal factors in the values and preferences literature. The literature tended to examine attitudes and cognition rather than patient knowledge and how that knowledge impacted decisions. Studies examined risk expectation, preferences for DMT treatment and treatment trade-offs, knowledge of cost factors, reasons for using or discontinuing DMTs, and theoretical approaches to understanding decisionmaking and behavior processes. Study designs varied widely, including survey questionnaires, qualitative interviews, preferences, elicitation techniques, prospective cohorts, cross-sectional analysis of claims data, and one RCT.¹¹⁹ Four studies received industry funding,^{93,97,114,119} five did not report funding sources,^{94,95,102,109,113} one was unfunded,⁹⁶ and four received governmental or nongovernmental funds.⁹⁸⁻¹⁰¹

Figure 4. Intrapersonal factors



Key Points

- Patients overestimated risk of wheelchair use in the intermediate term but underestimated it for life-time risk. This underestimation may indicate the uncertainty felt by MS patients when contemplating their personal trajectories rather than lack of knowledge (two studies).
- Patients are likely to use heuristics in risk assessments (one study).
- With training, patients can improve risk understanding and sense of informed choice (one study).
- Quantified preference studies suggest patients are willing to make risk trade-offs for benefits only to the point where the discomfort from side effects and treatment are equal to or worse than the disease symptoms (two studies).
- Increasing out-of-pocket cost reduces DMT purchases (two studies).
- Common reasons for discontinuing include side-effects, perceived lack of efficacy against disease progression or uncertainty regarding efficacy, administration method and frequency, and cost (five studies).
- MS patients tended to take responsibility for the decision to discontinue (three studies), while viewing their neurologist as the driver for decisions regarding choice of DMT (one study).
- Psychological models of behavior support the presence of rational processes contributing to patient decisionmaking (two studies).

Table 10. Included studies for intrapersonal literature

First Author, Year Country Funder	Study Aim	Population	Design	Study Author Findings
Janssens, 2003 ¹⁰⁰ Netherlands Nongovernmental	Quantify expectations of wheelchair dependency in newly diagnosed MS patients and partners	101 MS patients diagnosed within previous 2 years, mean diagnosis time 8 months, 70% female, only 10% current DMT users; 78 partners	Survey questionnaire and neurological exams; compared perceived risk to actual at 2 years, 10 years, and lifetime; differences by clinical characteristics	<ul style="list-style-type: none"> • Both groups overestimate 2 and 10 year, but underestimate lifetime risk. • Patients with more functional limitation perceived lower seriousness for wheelchair use. • Concordance between patient and partner was moderate.
Boeije, 2004 ⁹⁹ Netherlands Nongovernmental	Examine how patients explain perception of prognostic risk	85 MS patients included in Janssens, 2003 who were interviewed	Qualitative; one-on-one interviews in patients' homes	<ul style="list-style-type: none"> • Uncertainty of future progression was predominant factor in risk perception. • Patients discriminated over time in the perception of absolute risk. • Use of heuristics was clearly evident.
Kopke, 2014 ¹¹⁹ Germany Industry	Evaluate efficacy of an evidence-based patient information program; increase informed choice in MS patients	192 RRMS or CIS enrolled in RCT evaluating effectiveness of education program for informed decision making based on theory of planned behavior	RCT of complex intervention including education program presenting best available evidence regarding diagnostic testing, prognosis, and early DMT therapy. Control received stress management program by trained psychologist. Outcomes: Multidimensional measure of informed choice	<ul style="list-style-type: none"> • Intervention arm more likely to demonstrate good risk knowledge after 4 weeks than control ($p < 0.001$) • Intervention arm more likely to achieve informed choice after 6 months compared with control (OR 0.2, 95% CI 0.1 to 0.4)
Prosser, 2003 ⁹⁸ U.S. Nongovernmental	Examine preferences for MS disability states and three DMTs. Also compare differences in utility weights between MS and healthy community	62 RRMS patients, median age 38, 79% female; 67 healthy community respondents, similar to U.S. population but more educated and fewer children	Computer-based survey using standard gamble methods to elicit and quantify preferences for health states as input to a modeling project	<ul style="list-style-type: none"> • Patients discontinue DMT when side effects and discomfort from treatment are equal to or worse than disease symptoms. • Patients assigned higher utilities to MS-related health states and treatment states than community respondents. • Ratings diverged as health states worsened. For the EDSS 8 health state, there was very little overlap between patient and community respondents.

First Author, Year Country Funder	Study Aim	Population	Design	Study Author Findings
Johnson, 2009 ⁹⁷ U.S. Industry	Examine willingness to accept a life-threatening adverse event in exchange for improvement	651 MS patients drawn from consumer advocacy and industry website lists, and participants in a clinical trial; similar to national MS sample	Computer-based survey using choice-format stated preferences, also known as discrete choice experiment or conjoint analysis, to elicit and quantify preferences for health states	<ul style="list-style-type: none"> • Delay in years to progression was the most important factor in willingness to accept risk, followed by risk of severe adverse event; relapse rate was least important. • Respondents were willing to trade higher risk for greater benefit. • Maximum acceptable risk was relatively insensitive to SES or patient experience with MS.
Dor, 2010 ⁹⁵ U.S. Not reported	Examine the impact of copayments or coinsurance on reducing adherence	1974 MS patients with prescription or procedure codes for IFN or GA (MedStat MarketScan Commercial Claims and Encounters database of private sector health data)	Two-stage least squares model using secondary data; copayment vs. coinsurance and effects on medication possession ratio; patients with copay matched to patients with coinsurance.	<ul style="list-style-type: none"> • Increases in coinsurance associated with decreased adherence. 10% increase in cost sharing led to an 8.6% decline in adherence. (monthly price range \$44 to \$1162) • Copayment, which is inherently more price stable than coinsurance, did not show an effect. (monthly price range \$37 to \$42)
Gleason, 2009 ⁹⁶ U.S. No external funds	Examine the relationship between DMT abandonment and out-of-pocket expenses	2791 MS patients with continuous enrollment and new to DMT (BlueCross BlueShield database, Midwestern and southern)	Cochran-Armitage test for trend and multivariate logistic regression; defined prescription abandonment as never taking possession of DMT	<ul style="list-style-type: none"> • Abandonment rate increased with increasing out-of-pocket cost. (p<0.001) • 5.7% abandonment rate at monthly cost of \$100 or less • OR between 6.1 and 7.3 for expense groups greater than \$200/claim (1 in 4 MS patients abandoned DMT at \$200/claim)
Visser, 2011 ¹⁰¹ Netherlands Dutch MS Foundation	Examine patient perception regarding decisions and reasons for using or not using DMT	1403 MS patients recruited through Dutch National MS Foundation and MS nurses (89% response rate) Includes 41% RRMS, 31% SPMS, 19% benign MS, 9% PPMS	Survey questionnaire, descriptive statistics; patients categorized by never used, stopped using, currently on 1 st DMT, currently on switched DMT	<ul style="list-style-type: none"> • Patients attributed the decisive role in starting (70%) or changing (66%) DMT to the neurologist, but claimed the decisive role for stopping (62%). • 1/3 of current DMT users were uncertain DMT had a beneficial effect. • Reasons for stopping: side-effects, uncertainty of benefit, administration method, aggravation of signs and symptoms, frequency of administration, and phase of disease

First Author, Year Country Funder	Study Aim	Population	Design	Study Author Findings
Bischoff, 2012 ¹⁰² Germany Not reported	Examine reasons for discontinuation; who made and what influenced decision	396 MS patients discontinuing DMT in last 3 months, 75% female; 40 clinics; includes 54 SPMS on DMT	Telephone standardized questionnaire, descriptive statistics	<ul style="list-style-type: none"> • Mean duration of DMT was 30.5 months, ± 32.1. • Positive expectations from therapy declined from 59% to 49% at discontinuation. • 75% claimed responsibility for decision; no outside influence. (Half were willing to restart.) • Reasons for stopping: not wanting to be reminded of MS, side effects, loss of efficacy, adverse events (same in all DMTs)
Grytten, 2013 ¹¹³ Norway Not reported	Examine psychosocial factors of nonstarters and stoppers of DMT	424 RRMS respondents (84%), 69% female	Survey questionnaire, descriptive statistics and multivariate regression; patients categorized by never used, stopped using, currently on 1 st DMT, currently on switched DMT.	<ul style="list-style-type: none"> • Patient decision to stop 37%, Patient/MD decision to stop 45%, MD decision to stop 18%. • Risk of stopping increased with high education. • Psychosocial factors not significant. • Significant factors: lack of efficacy, tolerability, adverse events.
Meyniel, 2012 ¹¹⁴ International Industry	Assess factors leading to first treatment discontinuation	2314 CIS patients from 44 centers; MSBase Incident Study; 1247 started DMT (followed 2.7 years, during which 90% converted to definite MS)	Prospective cohort, multivariate survival analysis for factors predicting stopping	<ul style="list-style-type: none"> • 40% stopped within the observation period. • Significant factors for stopping: female, increasing EDSS, and using IFN. • Stopping varied by country • Not significant: MRI features, age, time to treatment, relapse on treatment
Daugherty, 2005 ⁹⁴ U.S. Not reported	Examine patient reported factors for discontinuing treatment	108 MS patients prescribed DMT at a Midwest university neurology clinic.	Telephone questionnaire, descriptive statistics; a priori discontinuation reason categories.	<ul style="list-style-type: none"> • Adverse events 52% • Physician-documented disease progression 40% • Perception of drug ineffectiveness 20% • Cost 4%.
Berger, 2004 ⁹³ U.S. Industry	Assess extent to which Transtheoretical Model of Change predicts discontinuation	530 (of 946, 56%) MS patients in Biogen Alliance program prescribed Avonex (INF beta 1a) 79% currently on Avonex	Survey, split into current, previous, or never users; factor analysis of readiness stages, decisional balance (pros and cons), self-efficacy; regression for predictors including cognitive impairment, injection info, demographics	<ul style="list-style-type: none"> • Predictors of use: average pros of DMT, average cons of DMT for decisional balance, education, and level of disability. • Model predicted 82% of discontinuers, 81% continuers.

First Author, Year Country Funder	Study Aim	Population	Design	Study Author Findings
Kasper, 2012 ¹⁰⁹ Germany Not reported	Use theory of planned behavior to describe decision process for intention to use DMT; test evidence-based education intervention	192 RRMS enrolled in RCT evaluating effectiveness of education program for informed decision making	Survey; validation study of measures of planned behavior factors; logistic regression using intention, attitude, subjective social norms, perceived behavioral beliefs, expectations, and values	<ul style="list-style-type: none"> Planned behavior questionnaire explained 68% of variance in intention to use DMT.

CIS=clinically isolated syndrome; DMT=disease modifying treatment; EDSS=extended disability scale score; GA=glatiramer acetate; IFN=interferon; MS=multiple sclerosis; MD=medical doctor; PML=Progressive multifocal leukoencephalopathy; QoL-quality of life; RRMS-relapse remit multiple sclerosis; SES=socioeconomic status

Detailed Discussion

Risk

Risk is fundamental to decisionmaking. Expectations regarding an uncertain future can figure heavily in both rational thought processes and emotional appraisals. Risk expectations have particular salience for people with MS due to the enormous prognostic uncertainty regarding the disease course. One mixed-methods study, using quantitative survey data and interviews, along with a neurological clinical examination, looked at perceptions of risk of future wheelchair use.^{99,100} The study did not directly examine individual choice to use or discontinue DMT, but it provides empirical literature regarding MS patient perceptions of risk. These perceptions would presumably factor into decisions regarding DMT use.

MS patients within 2 years of having been diagnosed tend to overestimate risk of becoming wheelchair-bound in the short and immediate term but underestimate the lifetime risk.¹⁰⁰ The authors chose this particular risk factor because wheelchair use is one of the most major and well-recognized consequences of MS. In 101 MS patients, 2-year expected risk was 22.5 percent versus 5-10 percent actual, 10-year expected risk was 38.8 percent versus 20-25 percent actual, and lifetime risk was estimated at 54 percent versus 70 - 80 percent actual. People with more functional limitations were less concerned about wheelchair use than people with fewer functional limitations ($p < 0.01$). This may reflect that MS patients with higher mobility impairment view wheelchair use as an improvement in mobility, while those with higher mobility view it as a significant loss.

Followup interviews with 85 MS patients indicated the use of heuristics—or cognitive shortcuts—to simplify complex judgments.⁹⁹ The enormous uncertainty of the MS disease course was the predominant explanation for risk perceptions. One-third of MS patients in the quantitative study perceived their 10-year and lifetime risk of wheelchair use to be 50 percent. However, all but one patient indicating a 50 percent risk gave reasons such as “I’ve no idea,” or “it might happen or it might not.” This indicates that their response was based more on uncertainty about their prognosis rather than on a belief that the risk was actually 50 percent.

MS patients’ risk comprehension can be improved with education. An RCT with 192 RRMS or CIS patients receiving a 4 hour education program including MS basics, diagnostics, prognostic studies, therapeutic options, and pros and cons of DMT retained improved risk understanding after 4 weeks.¹¹⁹

Quantified Preferences

Patients' preferences for different health states are addressed by two studies using different methodological approaches to estimate or model the trade-offs contributing to the preferences.^{97,98} While some of the findings may seem evident, such as the importance of delaying disease progression, other findings are cautionary. MS patients placed more value on disabled health than did study participants without MS. Further, their preferences change over time and do so differentially for different quality of life domains.

One study used standard gamble to elicit preferences, or utilities, for health states.⁹⁸ The standard gamble measures the risk patients are willing to take for a better outcome and the value they attach to their current health state. Patients are asked to gamble between their current certain health state and an uncertain outcome that has a probability P of full health and a corresponding probability 1-P of death.¹²⁰ For this study, MS patients were asked to choose between a chronic

treatment or a one-time treatment with some chance of perfect health and some risk of immediate death. Three treatment profiles were created to mimic IFNbeta-1A, IFNbeta-1b, and glatiramer acetate. The treatment descriptions did not include information on the rare but potentially serious adverse events of treatments. Respondents indicated they would discontinue DMT when the severity of side effects and discomfort from treatment are equal to or worse than disease symptoms. This creates a challenge when MS patients are early in the disease course. Such a person may not yet be experiencing significant disease symptoms, but considering treatment with negative quality of life consequences today in exchange for the possibility of delaying disease symptoms and disability. The differing preferences between MS patients and healthy people underscore that the hypothetical nature of the gamble and highlight the fact that choices made in a hypothetical situation differ from actual decisions and behaviors.

Choice-format stated-preference, also known as discrete choice experiments or conjoint analysis, was used to quantify the relative preferences MS patients assigned to various treatment attributes.⁹⁷ This technique can estimate the maximum risk patients are willing to accept in trade for treatment benefits. This study included several major risks associated with DMTs, including death or severe disability from PML, death from liver failure, and death from leukemia. These risks were traded against different 5-year annualized relapse rates and years to disease progression. The study claimed the maximum acceptable risk estimates for the levels of benefit observed in clinical trials were higher than the observed risk but did not provide the data necessary for the comparison. The study design tried to reduce respondent burden, given the number of trade-offs to assess, and tested for result validity through mathematical rules and logic validity tests. However, as with the standard gamble, the hypothetical nature of the questions fails to inform us about actual choices. Further, respondents may have lacked the numeracy skills to fully appreciate the information provided and evaluate their choices accordingly. Heuristics may also have come into play. Although the heuristics may not have differed substantially from the actual cognitive behaviors of the decision process, heuristics itself is not consistent with the assumption of rational processes underlying this preference elicitation technique.

Cost as a Contributor to Discontinuing

Costs, especially out-of-pocket costs, have a serious impact on a patient's decision to discontinue DMT. Two studies examined the effect of out-of-pocket costs on MS patients choosing not to fill prescriptions for DMTs.^{95,96} Both studies found increasing costs related to decreasing possession of DMTs. Both studies considered patient demographics (age, sex, geographic region). One study relied on zip codes to represent education and income levels.⁹⁵ The other study matched patients by demographics plus employment status and employer industry; it also included general health status as assessed by the Charlson score and other comorbid conditions.⁹⁶ MS patients with copayments rather than coinsurance did not exhibit a relationship between increasing cost and medication possession but still showed variation in medication possession. This finding underscores that finances are not the only factor responsible for DMT discontinuation.

Stated Reasons and Predictors for Discontinuing

Stated reasons and predictors for discontinuing DMT were examined in five studies.^{94,101,102,113,114} Four studies used surveys,^{94,101,102,113} while one used prospective cohort data.¹¹⁴ While all studies converged on common reasons to discontinue—side-effects, perceived lack of efficacy, aggravation of signs and symptoms/disease progression, and administration

method and frequency—surveys allowing open responses, rather than *a priori* discontinuation categories, found more nuanced responses. For example, patients who said they did not want to be reminded of the disease were not responding to fear of injections; patients injecting the DMT weekly were more likely to express this desire than patients injecting several times weekly or daily.¹⁰² Rather, these patients were expressing the psychological response to being confronted with the disease at the time of injection. As another example, uncertainty of DMT benefit is qualitatively different than perceived lack of benefit.¹⁰¹

Who Makes the Decision to Discontinue?

The majority of patients took responsibility for the decision to discontinue, a finding similar in three studies that reported 62 percent,¹⁰¹ 75 percent,¹⁰² and even up to 82 percent if unilateral patient and patient/physician shared categories are combined.¹¹³

Tests of Psychological Theories

Two studies used theories or models of behavior to explore patient preferences for DMT.^{93,109} The Theory of Planned Behavior, an expectancy-value model, assumes that behavior reflects past experiences and anticipated barriers. A person's intent to perform a specific behavior depends on the individual's favorable or unfavorable attitudes toward the behavior, perceived pressure to comply to social norms regarding the behavior, and perceived ease or difficulty of performing the behavior.¹²¹ In contrast, the Transtheoretical Model of Change assumes that behavior change is a six-step process, and people move through precontemplation, contemplation, preparation, action (new behavior for fewer than 6 months), maintenance (longer than 6 months), and termination.¹²² This model incorporates concepts from numerous influential theories in psychology, including motivational theory, social learning theory, self-efficacy theory, conflict decisionmaking theory, the health belief model, and the theory of reasoned action.


Kasper and colleagues¹⁰⁹ identified domains in a questionnaire based on the Theory of Planned Behavior. These domains predicted 68 percent of the variance in the intention to use DMTs in 192 patients with RRMS enrolled in an evidence-based education intervention for informed decisionmaking, suggesting rational processes contribute to decisionmaking regarding DMTs. The assessed domains included attitudes, social norms, and beliefs regarding the perceived ease or ability of the patient to perform expected behaviors. The questionnaire also incorporated emotional appraisals of DMTs, through questions such as “the risk I would be taking by putting off immunotherapy for too long frightens me.” However, the study examined intention to use DMT, not the actual behavior.

Rational processes also contributed to decisionmaking when modeled using the Transtheoretical Model of Change.⁹³ Along with level of education and disability, average pros and average cons of DMT use, specifically IFNbeta-1a in this case, predicted 81 percent of discontinuation. The study authors determined an equation for calculating an individual's likelihood of discontinuing treatment. Very simply, as patients lose confidence in the DMT's ability to prevent or slow disease progression, they move closer to discontinuing. The study was conducted by one firm to develop a company-based program to promote treatment persistence, so generalizability of the findings is uncertain.

Interpersonal Literature

We found much less literature to populate the interpersonal portion of Figure 1 (reproduced in Figure 5). Table 11 provides information on the three studies that addressed interpersonal factors in the values and preferences literature. Interpersonal concerns include the knowledge, values, beliefs, and preferences that both the patient and physician bring to a decisionmaking encounter, and also the extent to which this information is shared between the two. Communication issues also are important at the interpersonal level. Study designs included survey questionnaires and qualitative interviews. One study received industry funding,¹¹⁵ one was unfunded,¹⁰⁷ and one received nongovernmental funds.¹¹⁶

Figure 5. Interpersonal factors



Key Points

- MS patients and their physicians can differ significantly in their perceptions of the relative importance of health states and risks (two studies).
- Physicians and patients must communicate in order to clarify differences in perceptions and preferences (one study).

Table 11. Included studies for interpersonal literature

First Author, Year Country Funder	Study Aim	Population	Design	Study Author Findings
Heesen, 2010 ¹⁰⁷ Germany Not funded	Assess risk tolerance of MS patients and treating physicians for natalizumab adverse events	69 MS patients from a university clinic (average EDSS = 4), 192 affiliated neurologists	Survey to investigate prerequisites for shared decisionmaking (part of an intervention study of shared decisionmaking). A 3-page information leaflet on natalizumab was provided to both groups. Test and correlation statistics	<ul style="list-style-type: none"> • 49% of physicians would stop natalizumab for a PML risk of 2 per 10,000; only 17% of patients would do so (p<0.001). • Both groups overestimated natalizumab treatment effects. • Similar to risk perceptions, patients were more strongly in favor of continuing than physicians, who were more ambivalent
Kremenchutsky, 2013 ¹¹⁵ Canada Biogen	Compare neurologist and MS patient perceptions of MS related health status	99 MS patient and neurologist pairs. 6 clinics in Ontario and Alberta; excluded patients receiving natalizumab or IFNbeta marketed by Biogen	Survey questionnaire using standard gamble methods to elicit and quantify preferences for health states to assess communication	<ul style="list-style-type: none"> • Significant differences between patient and provider perceptions of relapse frequency and QoL; patients rate as worse. • Little concordance on identified important health domains; providers identify physical functioning while patients emphasize mental health
Thorne, 2004. ¹¹⁶ Canada Nongovernmental	Describe healthcare communication issues	12 long-term MS patients, 7 unemployed due to disability; prior to illness, 6 had been professionals, 3 health care professions	In-depth, loosely structured interviews, recorded, transcribed, and analyzed using NVivo software.	<ul style="list-style-type: none"> • Provides table of helpful and unhelpful communication specifics

EDSS=extended disability scale score; MS=multiple sclerosis; PML=Progressive multifocal leukoencephalopathy; QoL-quality of life

Detailed Discussion

Differences Between Patient and Physician Perceptions

MS patients and their physicians may differ in their perceptions of the relative importance of health states and risks. Two studies examined these differences, one using a survey,¹⁰⁷ the other using the standard gamble to quantify preferences.¹¹⁵ Standard gamble was described briefly in the section on intrapersonal literature. Both studies found differences between patient and physician relative assessments of risks and health states. The lack of concordance carried into preferences to discontinue DMT for given risk levels for serious adverse events, in this case, discontinuing natalizumab for given risk levels for PML.¹⁰⁷ Patients had a more negative perception of MS than physicians and were willing to tolerate greater risk of PML. Physicians tended to value health states more highly than patients, and emphasized physical health states, while patients gave greater relative weight to mental health.¹¹⁵ With only 6 neurologists for the 99 patients in this study, generalizability is low. Further, the MS patients were recently diagnosed and thus had limited experience with their condition. Possibly, the discord between physician and MS patients would have lessened with a more experienced group of long-term MS patients. However, these studies highlight the need for good communication between physician and patient for successful shared decisionmaking.

One study examined communication issues from the perspective of the patient using qualitative interviews of 12 long-term MS patients.¹¹⁶ While the study was not strictly related to DMT use and discontinuation, we include it in this section as a resource for communication based on empirical research. The table of communication tips from that study is recreated in Table 12.

Table 12. Helpful and unhelpful communications in MS


Coping Focus	Helpful Communication	Unhelpful Communication
Managing Fear	Timely, relevant, accurate information	Withholding information Using statistics Sugar coating
	Validating patient experience	Dismissing patient claims
	Planned appointments to discuss test results, ongoing management, and followup	Waiting for referrals and appointments
Taking Charge	Assistance from health care professionals	Feeling alone and isolated in managing MS
	Providing as much information as possible – more is better than less	Inaccurate or outdated information
	Convenient access to medical professionals	Difficulty accessing medical services
Crafting a Life	Acknowledging the limits of medical science	Belief that medical science has all the answers
	MS is only one aspect of their life	MS is their life
	Validating symptoms	Minimizing symptoms
	Ongoing interest	Giving up
	Willingness to learn and explore alternative therapeutic options	Inflexibility in thinking and researching
Respecting the patient as a competence and knowledgeable partner	Condescension Platitudes Reprimanding	

Table from Thorne, 2004¹¹⁶

KQ2b. What are patients' and providers' preferences for participation in shared decisionmaking to discontinue disease modifying treatments?

Literature for this KQ sub-question relates to shared decisionmaking for patients and providers. All but one of the identified studies populate the center box in the shared decisionmaking portion of Figure 1 (reproduced in Figure 6). Table 13 provides information on the five studies addressing shared decisionmaking from the patient side, four addressing the physician side, and a test of a decision aid to improve shared decisionmaking. Study designs included survey questionnaires, experimental psychology, third party observation of physician shared decisionmaking skills, and a randomized controlled trial of the decision aid. Six studies received governmental or nongovernmental funding,^{91,92,104,105,110,117,123} three did not report funding,^{103,112,118} and one was unfunded.⁹¹

Figure 6. Shared decisionmaking factors



Key Points

- MS patients may bring different information-seeking orientations to shared decisionmaking processes (one study).
- Mildly cognitively impaired MS patients show a significantly reduced capacity to understand treatment disclosures, but understanding may be brought back to the level of healthy controls through repetition and recognition cuing (one study).
- The large majority of people with MS prefer a collaborative or active participation role in treatment decisions (three non-U.S. studies).
- Physicians cannot reliably predict patient preferences for an active participation role and may inadvertently pull patients away from their preferred treatment (two studies).
- Both patient and third party observers rated physicians as showing limited skill at involving patients in shared decisionmaking (one study).
- Providing balanced, evidence-based information alone is not sufficient to alter decisionmaking processes to help patients achieve their preferred participation role (one study).

Table 13. Included studies for shared decisionmaking literature

First Author, Year Funder	Study Aim	Population	Design	Study Author Findings
Patient SDM				
Baker, 1995 ⁹¹ U.S. Not reported	Test if general orientation and length of MS affects interest in and desire for (1) more information about MS, (2) general or specific information	1. 160 women with MS 2. 95 women with MS	Survey questionnaire to identify monitors vs. information blunters, comparative tests of 1. Interest in and amount wanted for 29 MS topics 2. Relevance of information	<ul style="list-style-type: none"> • Monitors want both general and specific information from the beginning. • Blunters want information for some topics only after having MS for period of time.
Basso, 2010 ⁹² U.S. Governmental and nongovernmental	Assess whether aspects of neurocognition correspond with understanding treatment disclosures, and if disclosure understanding can be enhanced	Experimental: 36 people with MS; 24 unimpaired, 12 cognitively compromised Control: 16 adult community participants without MS	Experimental psychology lab Measures of new learning, executive function, attention Understanding of treatment disclosures scale. Significance tests and correlations	<ul style="list-style-type: none"> • Lower new learning and executive function correlated with poor understanding of treatment disclosures; understanding about 60% of control group mean. • Repetition and cuing improved understanding of cognitively compromised back to the level of control adults • MS patients without cognitive impairments understood information as well as the control group.
Giordano, 2008 ¹¹⁷ Italy Nongovernmental	Assess preferences of Italians with MS regarding participating in treatment decisions	129 people with stable MS, 71% female, 69% RRMS, average EDSS 3.5.	Survey using Control Preference Scale. Sex, age, disease duration, EDSS score, education level, whether on DMT, length of followup time at clinic.	<ul style="list-style-type: none"> • 61% preferred a collaborative role, 33% passive role, 6% active. • Sex, age, disease duration, EDSS score, and whether on DMT were not associated with preferred role. • Those with ≥5 years followup time at the clinic were more likely to prefer passive.
Hamann, 2007 ¹⁰⁴ Germany Governmental	Assess if decisionmaking participation preferences vary by chronicity of disease	1393 German patients with hypertension (164), depression (230), breast cancer (178), Schizophrenia (120) RRMS (105), Minor traumas (596)	Pooled preferences from SDM trials. Examined age, gender, education, diagnosis, and autonomy preference index scale Descriptive and test statistics	<ul style="list-style-type: none"> • MS patients significantly more likely to have higher preferences for participation than other patient groups (p <0.001)
Heesen, 2007 ^{105,106,108} Germany Governmental	Assess decision role preferences and MS risk knowledge	113 RRMS and 100 PPMS patients randomly selected from MS database	Survey questionnaire (performed during decision aid development) Descriptive and test statistics	<ul style="list-style-type: none"> • 79% (132/168) prefer an active role in decisionmaking. • Patients on INF had higher knowledge (risk calculation ability) than those not on INF. • People who preferred an active role had higher knowledge

First Author, Year Funder	Study Aim	Population	Design	Study Author Findings
Provider SDM				
Hamann, 2010 ¹⁰³ Germany Not reported	Examine how accurately neurologists and psychiatrists can predict patient participation preferences	203 patients; 102 MS patients, 66% female, mean MS duration 10 years; 101 schizophrenia. 51 providers	Survey questionnaire Autonomy preference index scale. Descriptive and test statistics	<ul style="list-style-type: none"> Physicians tended to over predict patient preference for participation Physicians correctly predicted 74% of preferences, but agreement between physician and patient was overall poor. Participation preferences depended on the physicians' and patients' expertise with MS
Pietrolongo, 2013 ¹²³ Italy Nongovernmental	Assess physician shared decisionmaking from third party observer and patient perspectives	88 MS patients, 10 physicians	Audio recordings of first consultations rated using Observing Patient Involvement in Shared Decision Making tool	<ul style="list-style-type: none"> Physicians were rated as showing limited skills at patient involvement by both patients and third party observers; patients rated physicians higher than the third party observer.
Mendel, 2011 ¹¹² Germany Not funded	Examine if physicians influence patients away from their preferred treatment option.	102 MS patients, 66% female, mean MS duration 10 years	Fictitious clinician recommendation contrary to stated preference Stated choice, satisfaction with choice	<ul style="list-style-type: none"> 26% of MS patients followed the physician's advice, but were less satisfied with their choice.
Lonergan, 2009 ¹¹⁸ Ireland Not reported	Assess utilization of DMT in patients with SPMS and PPMS, and examine approaches by physicians to counsel discontinuation in SPMS	336 Irish patients with MS living in urban southeast Dublin, and rural counties Wexford and Donegal. 26 neurologists in Europe, North America, and New Zealand	Survey questionnaires to physicians. Patients recruited through clinical services and MS Society, medical chart review for utilization.	<ul style="list-style-type: none"> 27% of patients with EDSS >6.5 were using DMT and were PPMS or SPMS, 99% of which were in rural locations. 15 physicians made an effort to stop treatment; 2 never stopped prescribing, and 11 generally continued DMT. Despite stated preference to stop, most did not insist to avoid affecting the relationship.
Decision Aids				
Kasper, 2008 ^{110,111} Germany Government	Evaluate effects of a patient decision aid to improve achieving a preferred role in decisionmaking and DMT use	297 MS patients considering or reconsidering DMT. 14% CIS, 53% RRMS, 19% SPMS, 11% PPMS. Recruited from community, consumer advocate group, MS clinic. Experimental: 150, Control: 147	RCT of evidence-based decision aid. Control received standard treatment information. Outcomes: Achieved participation role preference; treatment choice	<ul style="list-style-type: none"> No differences between groups on role preference or treatment choice. 50% of patients achieved preferred role. Patients tended to use shared decisionmaking as an actual role. 18% of patients reconsidering treatment chose to interrupt treatment. Experimental group was more critical of DMT use than control group.

CIS=clinically isolated syndrome; DMT=disease modifying treatment; EDSS=extended disability scale score; MS=multiple sclerosis; PPMS=primary progressive multiple sclerosis; RCT=randomized controlled trial; RRMS=relapse remitting multiple sclerosis; SDM=shared decisionmaking; SPMS=secondary progressive multiple sclerosis

Detailed Discussion

Patients in Shared Decisionmaking

Two studies examined information-seeking and information-processing, necessary steps in shared decisionmaking.^{91,92} The type and timing of information sought by women with MS differed depending on the individual orientation toward information—whether the person was a monitor or blunter of information.⁹¹ Monitors prefer a high information input before a stressful event and suffer less psycho-physiological arousal when they have information while blunters prefer less information and suffer more arousal when they have a high information input. A person's tendency toward monitoring or blunting differed according to time from diagnosis: monitors wanted information early while blunters' preference for information that was specific increased with the time they had MS. This was a small study of women with MS, so the applicability of the findings is highly constrained. However, it does suggest that patients bring different orientations to the information search aspect of shared decisionmaking.

Cognitively compromised MS patients had impaired understanding of treatment disclosures in one study using experimental psychology lab methods.⁹² Cognitively unimpaired MS patients understood treatment disclosures as well as people without MS. Among those with cognitive impairment, probing for understanding, repeating information, and recognition cuing brought understanding performance back to the level of the healthy control group. The cognitively impaired group was relatively small and the impairment was generally mild rather than severe, thus limiting applicability. Yet, the mildly compromised MS patient may be less likely to be recognized as having reduced decisional capacity for informed consent and shared decisionmaking.

Three studies from Italy and Germany examined patient preferences for participating in shared decisionmaking.^{104,105,117} Overall, the large majority of people with MS preferred an active participatory role in treatment decisions (68 percent to 79 percent). People with MS were significantly more likely than people with hypertension, major depression, breast cancer, or schizophrenia to prefer an active role.¹⁰⁴ Those who preferred an active role also tended to have higher knowledge regarding risk.¹⁰⁵ The applicability of these studies to MS patients in the United States is difficult to judge without U.S. studies for comparison.

Physicians in Shared Decisionmaking

Two studies examined physician ability to predict MS patient preferences to participate in treatment decisions. Both studies used the same MS patient population in Germany.^{103,112} Physicians tended to overestimate patient preference for participation overall, and individual predictions correlated poorly to individual patient preferences.¹⁰³ In a test using fictitious clinician's recommendations, 26 percent of MS patients followed the fictitious recommendation and chose the treatment option that went against their initial preferences.¹¹² A third study found both third party observers and patients rated physicians as showing limited skill at involving patients in shared decisionmaking.¹²³

One study surveyed an international sample of physicians regarding their experience with discontinuing DMT when it is no longer effective.¹¹⁸ While primarily influenced by absence of relapses and evidence of disease progression, EDSS scores in the 6.0 to 8.0 range were cited as indicators of likely lack of efficacy, although reimbursement policies in several countries were also influential. Most physicians noted the challenge of negotiating discontinuing a DMT that is

well-tolerated even if it appeared to the physician to lack efficacy. Physicians tended to defer to patient preferences for discontinuing, noting the importance of a good patient-physician relationship. Several mentioned that patients expressed insecurity with discontinuing.

Decision Aids for Shared Decisionmaking

Simply providing patients with balanced information did not in itself alter the decisionmaking process, although providing evidence-based information to MS patients improved assessment of information, with the experimental group more critical of DMTs than the control group.^{110,111} In one RCT of a decision aid to improve patient achievement of their preferred participation role, MS patients had a high preference rate for active or autonomous decisionmaking roles, 79 percent at baseline and 81 percent at followup in the experimental group. Actual participation roles, however, tended toward shared decisionmaking styles. In an applied context, 27 percent of the patients with stated preferences for autonomy participated at a shared level. No major differences were seen in achieving preferred roles between the intervention and control groups at followup. Across the groups, half of the MS patients reported an actual participation role other than their preferred role.

Patients and assessors were masked as to whether the patient received the decision aid or standard information packet. Patients were asked to not directly discuss the details of the information they received with their physicians. It is not possible to determine if factors related to the masking itself may have resulted in patients feeling constrained in communicating with their physician.

Discussion

Overview

MS patients and providers have little information to guide decisions to discontinue DMT. There was no literature that directly compared continuing versus discontinuing DMT in comparable populations. There was sparse information available to address one part of the decisionmaking picture faced by providers and patients, which are long-term benefits and harms. Of 27 unique studies identified, only 16 provided sufficient information to adequately assess outcomes and risk of bias. As summarized in Table 14, low-strength evidence was found for increased all-cause mortality for patients who started interferon beta 1b 2 years earlier than the comparators, but no differences between treated and comparator groups in time to progression to secondary progressive MS (SPMS) (as measured by sustained Expanded Disability Status Scale (EDSS) greater than 6). Similarly, overall long-term harms were found to be no different than short-term harms. Low-strength evidence implies low confidence in the findings and the expectation that future research could change the findings. Evidence is insufficient to assess long-term benefits and harms for all other patient populations, type of DMT, or outcome.

Table 14. Summary of KQ1 Findings for which evidence was found

DMTs Used in Long-term Studies Assessing Discontinuing or Continuing DMTs	Number of Studies Number of Participants	Findings	Strength of Evidence
All cause survival			
Interferon beta 1b	1 study n=366 RRMS	All-cause mortality: 250 mg arm vs. placebo – HR 0.532 (98% CI, 0.31 to 0.90) 50 mg arm vs. placebo – HR 0.54 (95% CI, 0.32 to 0.92) favors treatment	Low (moderate risk of bias, unknown consistency)
Time to progression to SPMS			
Mixed Interferon	1 study n=2656 RRMS	No difference from contemporary or historical control	Low (moderate risk of bias, unknown consistency)
Overall Harms			
Interferon, glatiramer acetate, teriflunomide	3 studies n=746 RRMS interferon beta 1b, 16y; 46 RRMS glatiramer acetate, 22 y; 131 RRMS, 16 SPMS, teriflunomide, 8.5y	Long-term harms not different than short term (qualitative finding)	Low (high risk of bias, consistent, indeterminate precision)

DMT=disease modifying treatment; HR=hazard ratio; RRMS=relapse remitting multiple sclerosis; SPMS=secondary-progressive multiple sclerosis; y=year

The current literature did not examine whether long-term benefits for DMTs remain after a patient converts to SPMS. Such a finding would refute the practice of discontinuing current DMTs once a patient converts. However, given that mitoxantrone (with a maximum life-time dose limit) is the only FDA-approved DMT for SPMS, there is little to suggest a long-term study past conversion to SPMS would be constructive. This assumption is supported by a recent systematic review and meta-analysis of 3082 SPMS patients, which found interferon beta did not reduce disability progression, and while there was a slight reduction in number of patients who

had relapses during the 3 years, more treated than placebo patients dropped out due to adverse events.¹²⁴

For the special cases of natalizumab and planned pregnancy discontinuations, evidence was insufficient to answer whether discontinuation is problem-free. Evidence from eight studies was insufficient to answer whether rebound due to discontinuing natalizumab exists. Studies lacked quantitative definitions of rebound, were high risk of bias, small sample sizes, and potential plausible confounders for post-natalizumab annualized relapse rates. Similarly, evidence from 12 studies was insufficient to address risks of fetal exposure to DMT during pregnancy in women with MS or the risks to the mother for the drug holiday due to study high risk of bias and small sample sizes. Further, women who discontinued DMT to attempt pregnancy who didn't conceive were not observed as comparison groups, nor were data gathered or grouped by time on drug holiday prior to and during pregnancy.

In the absence of evidence, providers and patients are left with little to inform their preferences and guide their decisions regarding when to discontinue treatments. The majority of included studies reported reasons for patients discontinuing treatments, but the information provided was without detail. Adverse events and inefficacy or progression of disability were two expected categories. Other possible reasons for discontinuation, such as a patient's desire to try alternative medicine approaches, perceived risk of long-term use, or financial concerns such as out of pocket costs or loss of insurance, are not noted. The "patient decision" category for discontinuing was consistently unexplored.

Key Question 2 aimed to delve into what is known about patient and provider preferences. While the literature was sparse, with only 28 studies available to populate the conceptual map provided in Figure 1, each of the three major conceptual areas was at least partially represented. No study directly asked why people are not willing to discontinue when treatment is no longer effective, but taken as a whole the literature set provides some insight.

Overall, one can weave together the general themes found in the KQ2 literature. Even though physicians cannot reliably predict patient preferences for shared decisionmaking, and often have different perceptions of the relative importance of health status or acceptable risks, when it comes to the decision to discontinue DMT, the patient is the driving voice in the decision, and this preference and role are generally unchallenged by the physician. In some DMT discontinuations, the balance of shared decisionmaking may shift to discordance between the physician and patient, with the physician deferring to patient preferences for continuing or discontinuing treatment. The quantified preferences work by Prosser and colleagues⁹⁸ illustrates a paradox, where patients are less likely to prefer DMT during the early course of the disease, when disease symptoms are lower than the side effects of the DMT, and more likely to use it at later stages of the disease when the side effects are less than disease symptoms. This behavior is counter to the hypothesis under which DMTs are assumed to work – reducing relapses early in the disease course to prevent or delay disease progression. Without more solid evidence for the long-term net benefits, or the thresholds at which treatment is no longer effective in preventing disease progression, the decision to discontinue treatment remains preference sensitive.

The preferences literature underscores the complexity of the topic and the processes underlying decisionmaking. Both rational and nonrational processes were found to be at play, and neither had primacy over the other. Cost was a factor in both self-report and through observation of purchasing behavior. Cognitive deficits impairing decisional capacity may be overcome with adequate cuing. Information is a necessary component of decisionmaking, yet nonrational factors can influence what information is sought at what time.

Preferences, values, and beliefs are highly variable, may change over time, and are linked to the nature of the patients' relationships with their doctors. There may well be differences based on age, sex, race, class, and other factors. A patient's preference position between "treat my MS at any cost/comfort from knowledge of receiving treatment" and "need strong evidence that the medication will help and be worth the cost/side effects" may change over time and as the disease changes.

Changing perceptions regarding health states was common across different parts of the intrapersonal literature. Risk perceptions and quantified preferences (which are risk-based as well) both suggested that people with longer MS experience assigned higher values to, or viewed as less serious, disabled states. This is a finding consistent with other research into how people value different health states. Many people overestimate their aversion to hypothetical states of disability and hence eliminate treatment options that might lead to such disability, especially if it could be long-term.¹²⁵⁻¹²⁸ The hypothetical disutilities for these states are consistently higher than those for persons actually experiencing the state.

Issues

Several challenges impede the ability to gather evidence to inform decisions to discontinue DMTs. First, the potential differential effectiveness of DMTs for different patient subpopulations is unclear, due both to lack of studies examining the questions as well as the use of study designs that are unsatisfactory. Whether DMTs for clinically isolated syndrome (CIS) patients is effective remains an open question. DMTs may offer little benefit in exchange for side effects and potential harms for patients with a benign MS course. Conversely, who is at risk of worsened disease activity (such as a rebound effect or overshoot) when DMTs are discontinued, possibly prematurely? We cannot currently predict early or benign disease courses.

Second, similar to determining which CIS patients will convert to MS, or which MS patients have a benign disease course without use of DMTs, the transition from relapse-remitting MS (RRMS) to SPMS is difficult to ascertain and therefore poses challenges in the decision to discontinue treatment. There are no clear biomarkers and no distinct boundaries for the transition. Further, how does one differentiate between a "stable" RRMS, one which may be induced by DMTs preventing relapses, and SPMS? Currently, EDSS changes or a score of 6 or 7 and clinical judgment are generally used. However, patients who may be "close" to SPMS but "stable" may look similar, and without clear clinical markers to differentiate, both provider and patient are left with uncertainty.

This observation leads to the third major challenge, measuring disability. The EDSS is the most commonly used scale in research, in part because it is the longest standing. Because the EDSS is largely driven by mobility assessment, available research is generally silent on potential benefits of DMT other than ambulation, such as upper limb function and cognitive impairments. Other validated measures of health status in MS which incorporate more function domains include the MSQOL-54, the Functional Assessment of Multiple Sclerosis (FAMS), and the Multiple sclerosis Quality-of-Life Inventory (MSQLI).¹²⁹⁻¹³¹ Since the EDSS is often used as a validation standard, cross-walks between the EDSS and other scales are already somewhat established to assist with aggregating findings across studies for mobility disability and possibly inform transitions to SPMS. However, as seen in KQ2, given that people with MS can value health domains differently than physicians (or perhaps researchers),¹¹⁵ the broader range of disability assessment should be pursued regardless of any potential limitations comparing results with studies that used the EDSS exclusively.

Without adequate measures of quality of life, balancing the benefits of treatments against harms becomes challenging, especially across different drug regimens. DMTs are not benign with regard to side effects and risk profiles. Quality of life benefits of treatment are offset by quality of life decreases due to side effects and risk profiles are important. Such research is often done within the context of cost-benefit analysis,^{7,132-143} a methodology with its own set of strengths and limitations.

Much remains to be done to understand patient preferences. Emerging but useful information was available to explore KQ2, but no study directly asked the question about preference for discontinuing treatment or explored why patients are unwilling to discontinue when treatment is no longer effective. Lonergan and colleagues approached the question tangentially, asking physicians about how they counsel patients when considering discontinuation.¹¹⁸ Providers who are involved with such counseling sessions would also benefit from research that separates understanding of preferences, which may be clear to the patient, and the mixed feelings such preferences may generate, ranging from fear or grief related to “giving up” on the disease to relief for no longer carrying the burden of DMTs.

Newly approved drugs, such as fingolimod, and drugs in the development pipeline are emphasizing oral administration to improve medication uptake and adherence to treatment programs. Self-injection can be a deterrent to patients with MS starting first-line DMTs and “shot-fatigue” is a significant factor for adherence. Oral medications will certainly have implications for preferences for continuing and discontinuing DMTs.

Future Research

Since only three areas of evidence for KQ1 were sufficient to provide answers with low strength of evidence, essentially all questions related to KQ1 would benefit from further study. The utility of studies for estimating long-term treatment effectiveness in MS can be improved by using prospective, population-based designs with appropriate comparators and standardized data collection methods. Study cohorts must be better characterized with respect to demographic and clinical characteristics, as well as other potential factors that may influence outcome such as socioeconomic status, access to care, health behaviors, and comorbidities. Near-complete patient retention with regularly scheduled patient visits is also necessary. Accounting for treatment effects would improve with better models to predict disability outcomes in MS., including disentangling the young versus old from the new versus long-term disease presence, since the two overlap. Techniques to adjust for selection bias such as regression analysis or propensity scores are more easily accomplished with rich datasets. With regard to the question of discontinuing for pregnancy, appropriate comparison groups need to include women who discontinued DMT to attempt pregnancy but didn’t conceive.

A prospective 10-year observational study based on the United Kingdom’s MS risk sharing scheme is underway to evaluate the effectiveness of the first DMTs, interferon and glatiramer acetate. After NICE recommended against DMTs in 2002,¹⁴⁴ a pricing scheme was negotiated with participating pharmaceutical companies whereby the drug prices would be reduced if patient outcomes were lower than expected,¹⁴⁵ thus the United Kingdom National Health Service and the pharmaceutical companies shared the financial risk for cost-effective treatment. The initial 2-year results published in 2009 found patient outcomes were worse than predicted;¹⁴⁶ 4-, 6-, and 8-year data have been collected and are being analyzed using an updated modelling methodology. This research initiative should help inform the long-term benefits of these first-line

treatments and may suggest improvements to current MS registries or methods that may make analysis of such registries more fruitful.

KQ2 covered a broad array of relevant topics, and investigator-driven research remains a likely source for innovative and interesting approaches to continued exploration. The AutoMS project, an international consortium of six European locations and Australia, was formed in 2010 to explore MS patient preferences for shared decisionmaking. Confirming the generalizability of their findings to the United States would be beneficial. Well-designed qualitative and survey research, perhaps as a mixed-methods study, aimed at directly asking the question why people are not willing to discontinue when treatment is no longer effective would be also useful.

Limitations

Literature on preferences is not indexed to permit easy identification of relevant articles. Search strategies to capture the diffuse literature used natural language as keywords. While we tested multiple terms before settling on the final algorithm, it is likely that relevant articles were missed, and thus the included literature set must be viewed as comprehensive but not exhaustive. Likewise, setting the review scope to exclude adherence literature – as adherence by definition connotes a decision to continue DMT use – may have precluded some relevant literature that looked at lack of adherence as a de facto decision to discontinue use.

References

1. Hilas O, Patel P, Lam S. Disease modifying agents for multiple sclerosis. *Open Neurol J* 2010; May;4:15-24.
2. Hurwitz B. Analysis of current multiple sclerosis registries. *Neurology* 2011; Jan 4;76(1 Suppl 1):S7-13. PMID: 21205683.
3. Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. *Brain* 2008; Mar;131(Pt 3):808-17. PMID: 18234696.
4. Nylander A, Hafler DA. Multiple sclerosis. *J Clin Invest* 2012; Apr 2;122(4):1180-8. PMID: 22466660.
5. Stys PK, Zamponi GW, van Minnen J, et al. Will the real multiple sclerosis please stand up? *Nat Rev Neurosci* 2012; Jul;13(7):507-14. PMID: 22714021.
6. Corthals AP. Multiple sclerosis is not a disease of the immune system. *Q Rev Biol* 2011; Dec;86(4):287-321. PMID: 22384749.
7. Daumer M, Neuhaus A, Herbert J, et al. Prognosis of the individual course of disease: the elements of time, heterogeneity and precision. *J Neurol Sci* 2009; Dec;287 Suppl 1:S50-5. PMID: 20106349.
8. Filippini G, Del Giovane C, Vacchi L, et al. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. *Cochrane Database Syst Rev* 2013; 6:CD008933. PMID: 23744561.
9. Weber MS, Menge T, Lehmann-Horn K, et al. Current treatment strategies for multiple sclerosis - efficacy versus neurological adverse effects. *Curr Pharm Des* 2012; 18(2):209-19. PMID: 22229582.
10. Sorensen PS, Koch-Henriksen N, Ravnborg M, et al. Immunomodulatory treatment of multiple sclerosis in denmark: a prospective nationwide survey. *Mult Scler* 2006; Jun;12(3):253-64. PMID: 16764337.
11. Lu E, Dahlgren L, Sadovnick A, et al. Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs. *Mult Scler* 2012; Apr;18(4):460-7. PMID: 21914689.
12. De Las Heras V, De Andres C, Tellez N, et al. Pregnancy in multiple sclerosis patients treated with immunomodulators prior to or during part of the pregnancy: a descriptive study in the Spanish population. *Mult Scler* 2007; Sep;13(8):981-4. PMID: 17623725.
13. Finkelsztejn A, Frago YD, Ferreira ML, et al. The Brazilian database on pregnancy in multiple sclerosis. *Clin Neurol Neurosurg* 2011; May;113(4):277-80. PMID: 21159421.
14. Portaccio E, Zipoli V, Siracusa G, et al. Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. *Eur Neurol* 2008; 59(3-4):131-5. PMID: 18057899.
15. Tintore M, Sastre-Garriga J. New treatment measurements for treatment effects on relapses and progression. *J Neurol Sci* 2008; Nov 15;274(1-2):80-3. PMID: 18822433.
16. Koopman W. Needs assessment of persons with multiple sclerosis and significant others: using the literature review and focus groups for preliminary survey questionnaire development. *Axon* 2003; Jun;24(4):10-5. PMID: 12852337.
17. Moher D, Altman DG, Liberati A, et al. PRISMA statement. *Epidemiology* 2011; Jan;22(1):128; author reply PMID: 21150360.
18. [computer program]. Version.
19. Viswanathan M, Berkman ND. Development of the RTI item bank on risk of bias and precision of observational studies. *J Clin Epidemiol* 2012; Feb;65(2):163-78. PMID: 21959223.
20. Treadwell JR, Reston JT, Singh S, et al. A framework for "best evidence" approaches in systematic reviews. . In: Quality AfHRa, ed. *Methods Research Report Vol AHRQ Publication No. 11-EHC046-EF*. Rockville, MD: Agency for Healthcare Research and Quality; 2011.
21. Turner R, Spiegelhalter D, Smith G, et al. Bias modelling in evidence synthesis. *J. R. Statis. Soc. A* 2009; 172(Part 1):21-47.
22. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). *Neurology* 1983; Nov;33(11):1444-52. PMID: 6685237.

23. Berkman ND, Lohr K, Ansari M, et al. Grading the strength of a body of evidence when assessing health care interventions for the effective health care program of the Agency for Healthcare Research and Quality: An update. 290-2007-10056-I PbtR-UE-bPCuCN, trans. Methods Guide for Comparative Effectiveness Reviews Vol AHRQ Publication No. 13(14)-EHC 130-EF. November ed. Rockville, MD: Agency for Healthcare Research and Quality; 2013.
24. Atkins D, Chang S, Gartlehner G, et al. Assessing the Applicability of Studies When Comparing Medical Interventions. 2010 December. Available at: <http://www.effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayProduct&productID=603#2412>. Accessed AHRQ Publication No. 11-EHC019-EF.
25. Bermel RA, Weinstock-Guttman B, Bourdette D, et al. Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study. *Mult Scler* 2010; May;16(5):588-96. PMID: 20167591.
26. Bermel RA, You X, Foulds P, et al. Predictors of long-term outcome in multiple sclerosis patients treated with interferon. *Ann Neurol* 2013; Jan;73(1):95-103. PMID: 23378325.
27. Ford C, Goodman AD, Johnson K, et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. *Mult Scler* 2010; Mar;16(3):342-50. PMID: 20106943.
28. Ford CC, Johnson KP, Lisak RP, et al. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. *Mult Scler* 2006; Jun;12(3):309-20. PMID: 16764344.
29. Johnson KP, Brooks BR, Ford CC, et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. *Mult Scler* 2000; Aug;6(4):255-66. PMID: 10962546.
30. Johnson KP, Brooks BR, Ford CC, et al. Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial. *Mult Scler* 2003; Dec;9(6):585-91. PMID: 14664471.
31. Johnson KP, Ford CC, Lisak RP, et al. Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data. *Acta Neurologica Scandinavica* 2005; Jan;111(1):42-7. PMID: 15595937.
32. Goodin DS, Reder AT, Ebers GC, et al. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFN-1b trial. *Neurology* 2012; Apr 24;78(17):1315-22. PMID: 22496198.
33. Reder AT, Ebers GC, Traboulsee A, et al. Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS. *Neurology* 2010; Jun 8;74(23):1877-85. PMID: 20530324.
34. Ebers GC, Reder AT, Traboulsee A, et al. Long-term follow-up of the original interferon-beta 1b trial in multiple sclerosis: design and lessons from a 16-year observational study. *Clin Ther* 2009; Aug;31(8):1724-36. PMID: 19808131.
35. Miller A, Spada V, Beerkircher D, et al. Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis. *Mult Scler* 2008; May;14(4):494-9. PMID: 18208875.
36. Evans C, Tam J, Kingwell E, et al. Long-term persistence with the immunomodulatory drugs for multiple sclerosis: a retrospective database study. *Clin Ther* 2012; Feb;34(2):341-50. PMID: 22296946.
37. Shirani A, Zhao Y, Karim ME, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. *Jama* 2012; Jul 18;308(3):247-56. PMID: 22797642.
38. O'Rourke KE, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. *Mult Scler* 2005; Feb;11(1):46-50. PMID: 15732266.
39. O'Rourke K, Walsh C, Antonelli G, et al. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis. *Mult Scler* 2007; Apr;13(3):336-42. PMID: 17439902.

40. Milanese C, Beghi E, Giordano L, et al. A post-marketing study on immunomodulating treatments for relapsing-remitting multiple sclerosis in Lombardia: preliminary results. *Neurol Sci* 2005; Dec;26 Suppl 4:S171-3. PMID: 16388352.
41. Patti F, Pappalardo A, Florio C, et al. Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head study. *Acta Neurologica Scandinavica* 2006; Apr;113(4):241-7. PMID: 16542163.
42. Trojano M, Paolicelli D, Zimatore GB, et al. The IFNbeta treatment of multiple sclerosis (MS) in clinical practice: the experience at the MS Center of Bari, Italy. *Neurol Sci* 2005; Dec;26 Suppl 4:S179-82. PMID: 16388354.
43. Trojano M, Pellegrini F, Fuiani A, et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. *Ann Neurol* 2007; Apr;61(4):300-6. PMID: 17444502.
44. Trojano M, Pellegrini F, Paolicelli D, et al. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. *Ann Neurol* 2009; Oct;66(4):513-20. PMID: 19847899.
45. Bergamaschi R, Quaglini S, Tavazzi E, et al. Immunomodulatory therapies delay disease progression in multiple sclerosis. *Mult Scler* 2012; published online May 31:1-9. PMID: 22653657.
46. Bencsik K, Fuvesi J, Friczka-Nagy Z, et al. Short communication: treatment of relapsing-remitting multiple sclerosis 96 patients with IFN-beta 1b: results of a 6-year follow-up. *J Interferon Cytokine Res* 2006; Feb;26(2):96-100. PMID: 16487029.
47. Carmona O, Casado V, Moral E, et al. Interferon-beta1b in multiple sclerosis: effect on progression of disability and clinical markers of treatment response. *Eur Neurol* 2008; 60(6):279-84. PMID: 18824855.
48. Rio J, Nos C, Tintore M, et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. *Ann Neurol* 2006; Feb;59(2):344-52. PMID: 16437558.
49. Rio J, Porcel J, Tellez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. *Mult Scler* 2005; Jun;11(3):306-9. PMID: 15957512.
50. Rio J, Tintore M, Nos C, et al. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre. *Journal of Neurology* 2005; Jul;252(7):795-800. PMID: 15772741.
51. Rio J, Tintore M, Nos C, et al. Interferon beta in secondary progressive multiple sclerosis : daily clinical practice. *Journal of Neurology* 2007; Jul;254(7):849-53. PMID: 17361342.
52. Cunningham A, Gottberg K, von Koch L, et al. Non-adherence to interferon-beta therapy in Swedish patients with multiple sclerosis. *Acta Neurologica Scandinavica* 2010; Mar;121(3):154-60. PMID: 20055771.
53. Tedeholm H, Lycke J, Skoog B, et al. Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs. *Mult Scler* 2013; 19(6):765-74. PMID: 23124789.
54. Debouverie M, Moreau T, Lebrun C, et al. A longitudinal observational study of a cohort of patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate. *Eur J Neurol* 2007; Nov;14(11):1266-74. PMID: 17956447.
55. Mesaros S, Stojisavljevic N, Dujmovic-Basuroski I, et al. Long-term adherence to interferon-beta treatment in a cohort of RRMS patients in Belgrade, Serbia. *Clin Neurol Neurosurg* 2012; Oct;114(8):1145-8. PMID: 22425462.
56. Confavreux C, Li DK, Freedman MS, et al. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. *Mult Scler* 2012; Sep;18(9):1278-89. PMID: 22307384.
57. Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. *Lancet neurol* 2009; Nov;8(11):987-97. PMID: 19748319.
58. Gold R, Rieckmann P, Chang P, et al. The long-term safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study. *Eur J Neurol* 2005; Aug;12(8):649-56. PMID: 16053475.

59. Uitdehaag B, Constantinescu C, Cornelisse P, et al. Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: Exploratory analyses from the PRISMS long-term follow-up study. *Therapeutic Advances in Neurological Disorders* 2011; //;4(1):3-14.
60. Prisms Study Group, the University of British Columbia MSMRIAG. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.[Erratum appears in *Neurology* 2001 Sep 25;57(6):1146]. *Neurology* 2001; Jun 26;56(12):1628-36. PMID: 11425926.
61. Barbero P, Verdun E, Bergui M, et al. High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study. *J Neurol Sci* 2004; Jul 15;222(1-2):13-9. PMID: 15240190.
62. Kaufman MD, Lee R, Norton HJ. Course of relapsing-remitting multiple sclerosis before, during and after natalizumab. *Mult Scler* 2011; Apr;17(4):490-4. PMID: 21135017.
63. Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. *Archives of Neurology* 2011; Feb;68(2):186-91. PMID: 20937940.
64. O'Connor P, Devonshire V, Canadian Network of MSC. The use of disease-modifying agents in multiple sclerosis--by the Canadian Network of MS Clinics. *Can J Neurol Sci* 2008; May;35(2):127-32. PMID: 18574923.
65. Havla J, Gerdes LA, Meinl I, et al. De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate. *Journal of Neurology* 2011; Sep;258(9):1665-9. PMID: 21431380.
66. Havla J, Tackenberg B, Hellwig K, et al. Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis. *Journal of Neurology* 2013; May;260(5):1382-7. PMID: 23266894.
67. Kerbrat A, Le Page E, Leray E, et al. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients. *J Neurol Sci* 2011; Sep 15;308(1-2):98-102. PMID: 21665227.
68. Rossi S, Motta C, Studer V, et al. Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab. *Eur J Neurol* 2013; Jan;20(1):87-94. PMID: 2012-34812-013.
69. Sorensen PS, Koch-Henriksen N, Petersen T, et al. Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. *Journal of Neurology* 2014; 261(6):1170-7.
70. Jokubaitis VG, Li V, Kalincik T, et al. Fingolimod after natalizumab and the risk of short-term relapse. *Neurology* 2014; Apr 8;82(14):1204-11. PMID: 24610329.
71. Borriello G, Prosperini L, Mancinelli C, et al. Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study. *Eur J Neurol* 2012; May;19(5):783-7. PMID: 22054236.
72. Borriello G, Prosperini L, Marinelli F, et al. Observations during an elective interruption of natalizumab treatment: a post-marketing study. *Mult Scler* 2011; Mar;17(3):372-5. PMID: 21148264.
73. O'Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. *Neurology* 2011; May 31;76(22):1858-65. PMID: 21543733.
74. Sandberg-Wollheim M, Alteri E, Moraga MS, et al. Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy. *Mult Scler* 2011; Apr;17(4):423-30. PMID: 21220368.
75. Sandberg-Wollheim M, Frank D, Goodwin TM, et al. Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. *Neurology* 2005; Sep 27;65(6):802-6. PMID: 16093457.
76. Amato MP, Portaccio E, Ghezzi A, et al. Pregnancy and fetal outcomes after interferon-exposure in multiple sclerosis. *Neurology* 2010; Nov 16;75(20):1794-802. PMID: 21079181.
77. Patti F, Cavallaro T, Lo Fermo S, et al. Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis? *Journal of Neurology* 2008; Aug;255(8):1250-3. PMID: 18677640.

78. Giannini M, Portaccio E, Ghezzi A, et al. Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. *BMC Neurol* 2012; 12:124. PMID: 23088447.
79. Boskovic R, Wide R, Wolpin J, et al. The reproductive effects of beta interferon therapy in pregnancy: A longitudinal cohort. *Neurology* 2005; 65(6):807-11.
80. Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. *Mult Scler* 2011; Aug;17(8):958-63. PMID: 21613333.
81. Hellwig K, Haghikia A, Rockhoff M, et al. Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. *Therapeutic advances in neurological disorders* 2012; 5(5):247-53.
82. Weber-Schoendorfer C, Schaefer C. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. *Mult Scler* 2009; Sep;15(9):1037-42. PMID: 19692433.
83. Fragoso YD, Boggild M, MacIas-Islas MA, et al. The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis. *Clinical Neurology and Neurosurgery* 2013; //;115(2):154-9.
84. Finkelsztejn A, Brooks JB, Paschoal FM, Jr., et al. What can we really tell women with multiple sclerosis regarding pregnancy? A systematic review and meta-analysis of the literature. *Bjog* 2011; Jun;118(7):790-7. PMID: 21401856.
85. Hellwig K, Brune N, Haghikia A, et al. Reproductive counselling, treatment and course of pregnancy in 73 German MS patients. *Acta Neurologica Scandinavica* 2008; Jul;118(1):24-8. PMID: 18205883.
86. Regan L, Rai R. Epidemiology and the medical causes of miscarriage. *Best Pract Res Clin Obstet Gynaecol* 2000; Oct;14(5):839-54. PMID: 11023804.
87. Lu E, Wang BW, Guimond C, et al. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. *Neurology* 2012; Sep 11;79(11):1130-5. PMID: 22933738.
88. Fragoso YD, Fragoso SD, Finkelsztejn A, et al. Systematic review versus internet search: considerations about availability and reliability of medical information regarding pregnancy in women with multiple sclerosis. *Rev* 2012; Dec;15(4):896-903. PMID: 23515783.
89. Cree BA. Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. *Mult Scler* 2013; Jun;19(7):835-43. PMID: 23319073.
90. Houtchens MK, Kolb CM. Multiple sclerosis and pregnancy: therapeutic considerations. *Journal of Neurology* 2013; May;260(5):1202-14. PMID: 22926165.
91. Baker LM. A new method for studying patient information needs and information-seeking patterns. *Top Health Inf Manage* 1995; Nov;16(2):19-28. PMID: 10152475.
92. Basso MR, Candilis PJ, Johnson J, et al. Capacity to make medical treatment decisions in multiple sclerosis: a potentially remediable deficit. *J Clin Exp Neuropsychol* 2010; Dec;32(10):1050-61. PMID: 20446143.
93. Berger BA, Hudmon KS, Liang H. Predicting treatment discontinuation among patients with multiple sclerosis: application of the transtheoretical model of change. *J Am Pharm Assoc (2003)* 2004; Jul-Aug;44(4):445-54. PMID: 15372865.
94. Daugherty KK, Butler JS, Mattingly M, et al. Factors leading patients to discontinue multiple sclerosis therapies. *J Am Pharm Assoc (2003)* 2005; May-Jun;45(3):371-5. PMID: 15991759.
95. Dor A, Lage MJ, Tarrants ML, et al. Cost sharing, benefit design, and adherence: the case of multiple sclerosis. *Adv Health Econ Health Serv Res* 2010; 22:175-93. PMID: 20575233.
96. Gleason PP, Starner CI, Gunderson BW, et al. Association of prescription abandonment with cost share for high-cost specialty pharmacy medications. *J Manage Care Pharm* 2009; Oct;15(8):648-58. PMID: 19803554.
97. Johnson FR, Van Houtven G, Ozdemir S, et al. Multiple sclerosis patients' benefit-risk preferences: serious adverse event risks versus treatment efficacy. *Journal of Neurology* 2009; Apr;256(4):554-62. PMID: 19444531.
98. Prosser LA, Kuntz KM, Bar-Or A, et al. Patient and community preferences for treatments and health states in multiple sclerosis. *Mult Scler* 2003; Jun;9(3):311-9. PMID: 12814182.

99. Boeije HR, Janssens AC. 'It might happen or it might not': how patients with multiple sclerosis explain their perception of prognostic risk. *Soc Sci Med* 2004; Aug;59(4):861-8. PMID: 15177841.
100. Janssens AC, de Boer JB, van Doorn PA, et al. Expectations of wheelchair-dependency in recently diagnosed patients with multiple sclerosis and their partners. *Eur J Neurol* 2003; May;10(3):287-93. PMID: 12752403.
101. Visser LH, van der Zande A. Reasons patients give to use or not to use immunomodulating agents for multiple sclerosis. *Eur J Neurol* 2011; Nov;18(11):1343-9. PMID: 21496180.
102. Bischoff C, Schreiber H, Bergmann A. Background information on multiple sclerosis patients stopping ongoing immunomodulatory therapy: A multicenter study in a community-based environment. *Journal of Neurology* 2012; //;259(11):2347-53.
103. Hamann J, Mendel R, Schebitz M, et al. Can psychiatrists and neurologists predict their patients' participation preferences? *J Nerv Ment Dis* 2010; Apr;198(4):309-11. PMID: 20386262.
104. Hamann J, Neuner B, Kasper J, et al. Participation preferences of patients with acute and chronic conditions. *Health Expectations: An International Journal of Public Participation in Health Care & Health Policy* 2007; Dec;10(4):358-63. PMID: 2007-17117-006.
105. Heesen C, Kasper J, Kopke S, et al. Informed shared decision making in multiple sclerosis--inevitable or impossible? *J Neurol Sci* 2007; Aug 15;259(1-2):109-17. PMID: 17400253.
106. Heesen C, Kasper J, Segal J, et al. Decisional role preferences, risk knowledge and information interests in patients with multiple sclerosis. *Mult Scler* 2004; Dec;10(6):643-50. PMID: 15584489.
107. Heesen C, Kleiter I, Nguyen F, et al. Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists. *Mult Scler* 2010; Dec;16(12):1507-12. PMID: 20826527.
108. Heesen C, Kopke S, Richter T, et al. Shared decision making and self-management in multiple sclerosis--a consequence of evidence.[Erratum appears in *J Neurol*. 2008 Feb;255(2):309-10]. *Journal of Neurology* 2007; May;254 Suppl 2:III116-21. PMID: 17503119.
109. Kasper J, Kopke S, Fischer K, et al. Applying the theory of planned behaviour to multiple sclerosis patients' decisions on disease modifying therapy--questionnaire concept and validation. *BMC Med Inf Decis Mak* 2012; 12:60. PMID: 22747904.
110. Kasper J, Kopke S, Muhlhauser I, et al. Evidence-based patient information about treatment of multiple sclerosis--a phase one study on comprehension and emotional responses. *Patient Educ Couns* 2006; Jul;62(1):56-63. PMID: 16098706.
111. Kasper J, Kopke S, Muhlhauser I, et al. Informed shared decision making about immunotherapy for patients with multiple sclerosis (ISDIMS): a randomized controlled trial. *Eur J Neurol* 2008; Dec;15(12):1345-52. PMID: 19049552.
112. Mendel R, Traut-Mattausch E, Frey D, et al. Do physicians' recommendations pull patients away from their preferred treatment options? *Health Expect* 2011; Mar;15(1):23-31. PMID: 21323824.
113. Grytten N, Aarseth J, Espeset K, et al. Stoppers and non-starters of disease-modifying treatment in multiple sclerosis. *Acta Neurologica Scandinavica* 2013; Feb;127(2):133-40. PMID: 2013-02262-010.
114. Meyniel C, Spelman T, Jokubaitis VG, et al. Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome. *PLoS ONE* 2012; 7(6):e38661. PMID: 22768046.
115. Kremenutzky M, Walt L. Perceptions of health status in multiple sclerosis patients and their doctors. *The Canadian Journal of Neurological Sciences / Le Journal Canadien Des Sciences Neurologiques* 2013; Mar;40(2):210-8. PMID: 2013-06076-015.
116. Thorne S, Con A, McGuinness L, et al. Health care communication issues in multiple sclerosis: an interpretive description. *Qual Health Res* 2004; Jan;14(1):5-22. PMID: 14725173.
117. Giordano A, Mattarozzi K, Pucci E, et al. Participation in medical decision-making: attitudes of Italians with multiple sclerosis. *J Neurol Sci* 2008; Dec 15;275(1-2):86-91. PMID: 18786682.

118. Loneragan R, Kinsella K, Duggan M, et al. Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started? *Mult Scler* 2009; Dec;15(12):1528-31. PMID: 19995848.
119. Köpke S, Solari A, Khan F, et al. Information provision for people with multiple sclerosis. John Wiley & Sons, Ltd. 2014. Available at: <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008757.pub2/abstract> <http://onlinelibrary.wiley.com/store/10.1002/14651858.CD008757.pub2/asset/CD008757.pdf?v=1&t=hybuweer&s=91dd5cefeff1f9a01769f0742e42ae5e4987ff60>.
120. Torrance G. Measurement of health state utilities for economic appraisal. *Journal of Health Economics* 1985; 5(1-30).
121. Fishbein M, Ajzen I. Belief, attitude, intention and behaviour: An introduction to theory and research. Reading, MA: Addison-Wesley; 1975.
122. Prochaska J, Velicer W. The transtheoretical model of health behavior change. *American Journal of Health Promotion* 1997; Sep-Oct;12(1):38-48.
123. Pietrolongo E, Giordano A, Kleinfeld M, et al. Decision-making in multiple sclerosis consultations in Italy: third observer and patient assessments. *PLoS ONE* 2013; 8(4):e60721. PMID: 23565270.
124. La Mantia L, Vacchi L, Rovaris M, et al. Interferon beta for secondary progressive multiple sclerosis: a systematic review. *Journal of Neurology, Neurosurgery and Psychiatry* 2013; 84(4):420-6. PMID: 22952326.
125. Kind P, Dolan P. The effect of past and present illness experience of the valuations of health states. *Medical Care* 1995; April;33(4 Suppl):AS255-63. PMID: 7723454.
126. Sackett D, Torrance G. The utility of different health states as perceived by the general public. *Journal of Chronic Disease* 1978; 31(11):697-704. PMID: 730825.
127. Ubel P, Loewenstein G, Schwartz N, et al. Misimagining the unimaginable: the disability paradox and health care decision making. *Health Psychology* 2005; Jul;24(4 Suppl):S57-62. PMID: 16045420.
128. Dolan P. Addressing misconceptions in valuing health. *Expert Rev Pharmacoecon Outcomes Res* 2013; Feb;13(1):1-3. PMID: 23402439.
129. Fischer J, LaRocca N, Miller D, et al. Recent developments in the assessment of quality of life in multiple sclerosis (MS). *Mult Scler* 1999; Aug;5(4):251-9. PMID: 10467384.
130. Cella D, Dineen K, Arnason B, et al. Validation of the functional assessment of multiple sclerosis quality of life instrument. *Neurology* 1996; Jul;47(1):129-39. PMID: 8710066.
131. Vickrey B, Hays R, Harooni R, et al. A health-related quality of life measure for multiple sclerosis. *Qual Life Res* 1995; June;4(3):187-206. PMID: 7613530.
132. Prosser L, Kuntz KM, Bar-Or A, et al. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. *Value Health* 2004; 7(5):554-68. PMID: 15367251.
133. Thompson J, Noyes K, Dorsey E, et al. Quantitative risk-benefit analysis of natalizumab. *Neurology* 2008; 71(5):357-64. PMID: 18663181.
134. Tappenden P, McCabe C, Chilcott J, et al. Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population. *Value Health* 2009; Jul-Aug;12(5):657-65. PMID: 19508662.
135. Parkin D, McNamee P, Jacoby A, et al. A cost-utility analysis of interferon beta for multiple sclerosis. *Health Technol Assess* 1998; 2(4):iii-54. PMID: 9580870.
136. Kendrick M, Johnson KI. Long-term treatment of multiple sclerosis with interferon-beta may be cost effective. *Pharmacoeconomics* 2000; Jul;18(1):45-53. PMID: 11010603.
137. Earnshaw SR, Graham J, Oleen-Burkey M, et al. Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis. *Appl Health Econ Health Policy* 2009; 7(2):91-108. PMID: 19731967.
138. Chilcott J, McCabe C, Tappenden P, et al. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis. *BMJ* 2003; Mar 8;326(7388):522; discussion PMID: 12623909.

139. Casado V, Martinez-Yelamos S, Martinez-Yelamos A, et al. Direct and indirect costs of Multiple Sclerosis in Baix Llobregat (Catalonia, Spain), according to disability. *BMC Health Serv Res* 2006; 6:143. PMID: 17078879.
140. Brown MG, Kirby S, Skedgel C, et al. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? *Neurology* 2007; Oct 9;69(15):1498-507. PMID: 17699802.
141. Bell C, Graham J, Earnshaw S, et al. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. *J Manage Care Pharm* 2007; Apr;13(3):245-61. PMID: 17407391.
142. Becker RV, 3rd, Dembek C. Effects of cohort selection on the results of cost-effectiveness analysis of disease-modifying drugs for relapsing-remitting multiple sclerosis. *J Manage Care Pharm* 2011; Jun;17(5):377-81. PMID: 21657808.
143. Bakhshai J, Bleu-Laine R, Jung M, et al. The cost effectiveness and budget impact of natalizumab for formulary inclusion. *J Med Econ* 2010; Mar;13(1):63-9. PMID: 20028199.
144. National Institute for Health and Care Excellence (NICE). Multiple sclerosis--beta interferon and glatiramer acetate. Technology appraisal 32. Available at: www.nice.org.uk/Guidance/TA32. Accessed July 31, 2013.
145. Multiple Sclerosis Trust. Information, education, research and support. Available at: <http://www.mstrust.org.uk/atoz/risk-sharing-scheme.jsp>. Accessed July 26, 2014.
146. Boggild M, Palace J, Barton P, et al. Multiple sclerosis Risk-sharing Scheme: two year results of clinical cohort study with historical comparator. *BMJ* 2009; Dec 2;339:b4677. PMID: 19955128.

Abbreviations

ARR	Annual relapse rate
BREMS	Bayesian risk estimate for MS
CENTRAL	Cochrane Central Register of Controlled Trials
CER	Comparative effectiveness review
CIS	Clinically isolated syndrome
DMT	Disease-modifying treatment
EDSS	Expanded Disability Status Scale
FAMS	Functional Assessment of Multiple Sclerosis
GEL	Gadolinium-enhancing lesion
HSRProj	Health Services Research Projects in Progress
ICTRP	International Controlled Trials Registry Platform
KQ	Key question
MRI	Magnetic resonance imaging
MS	Multiple sclerosis
MSQLI	Multiple Sclerosis Quality-of-Life Inventory
MSQOL	Multiple sclerosis quality of life
PICOTS	Population, intervention, comparator, outcomes, timing, setting
PML	Progressive multifocal leukoencephalopathy
PPMS	Primary progressive MS
PRMS	Primary relapsing MS
RCT	Randomized controlled trial
RRMS	Relapse-remitting MS
SIP	Scientific information packet
SPMS	Secondary progressive MS
TEP	Technical Expert Panel
TOO	Task Order Officer

Appendix A. Search Algorithms

For KQ1, we searched Medline via Ovid, Cochrane Libraries, and Scopus, modifying the Medline searches for the other databases.

KQ1. MS/Drug Holiday:

Database: Ovid MEDLINE

Search Strategy:

-
- 1 exp multiple sclerosis/dt, th, im
 - 2 drug holiday\$.mp.
 - 3 discontinu\$.mp.
 - 4 halt\$.mp.
 - 5 cessat\$.mp.
 - 6 interrupt\$.mp.
 - 7 stop\$.mp.
 - 8 2 or 3 or 4 or 5 or 6 or 7
 - 9 1 and 8

KQ1. MS/Immunomodulation:

Database: Ovid MEDLINE(R)

Search Strategy:

-
- 1 exp multiple sclerosis/dt, th, im (16589)
 - 2 exp immunomodulation/ (229961)
 - 3 exp immunosuppressive agents/ (235978)
 - 4 exp immunologic techniques/ (1168203)
 - 6 1 and 2 (1184)
 - 7 1 and 3 (1831)
 - 8 1 and 4 (2881)
 - 9 6 or 7 or 8 (4864)

KQ1. MS/Drug Names:

Database: Ovid MEDLINE(R)

Search Strategy:

-
- 1 Multiple Sclerosis, Relapsing-Remitting/dt, im, th [Drug Therapy, Immunology, Therapy]
 - 2 exp Interferon-beta/
 - 3 interferon beta.mp.
 - 4 glatiramer acetate.mp.
 - 5 natalizumab.mp.
 - 6 teriflunomide.mp.
 - 7 3 or 4 or 5 or 6
 - 8 1 and 7

- 9 limit 8 to (addresses or autobiography or bibliography or biography or classical article or comment or editorial or historical article or interactive tutorial or lectures or news or newspaper article or patient education handout)
- 10 8 not 9
- 11 limit 10 to (english language and humans and yr="1990 -Current")

For KQ2, we searched Medline via Ovid, Cochrane Libraries, PsychiInfo, and CINAHL, modifying the Medline searches for the other databases.

KQ2. MS/Patient Preference:
 Database: Ovid MEDLINE(R)
 Search Strategy:

-
- 1 exp multiple sclerosis/dt, th, im
 - 2 exp patient preference/
 - 3 exp attitude to health/
 - 4 exp physician-patient relations/
 - 5 exp decision making/
 - 6 exp choice behavior/
 - 7 exp decision support techniques/
 - 8 exp personal autonomy/
 - 9 exp patient participation/
 - 10 decision [making.mp](#).
 - 11 decision [support.mp](#).
 - 12 risk communication\$.mp.
 - 13 shared decision\$.mp.
 - 14 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13
 - 15 1 and 14
 - 16 exp health knowledge, attitudes, practice/
 - 17 exp *multiple sclerosis/
 - 18 16 and 17
 - 19 15 or 18
 - 20 exp multiple sclerosis/px
 - 21 14 and 20
 - 22 19 or 21

Appendix B. Excluded Studies

(reason for exclusion appears at the end of each reference)

1. Barbero P, Verdun E, Bergui M, et al. High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study. *Journal of the Neurological Sciences* 2004 Jul 15; 222(1-2):13-9 (*timing*).
2. Boz C, Oger J, Gibbs E, et al. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study.[Erratum appears in *Mult Scler*. 2008 May;14(4):575]. *Multiple Sclerosis* 2007 Nov; 13(9):1127-37 (*outcomes*).
3. Castillo-Trivino T, Mowry EM, Gajofatto A, et al. Switching multiple sclerosis patients with breakthrough disease to second-line therapy. *PLoS ONE [Electronic Resource]* 2011; 6(2):e16664 (*not on topic*).
4. Chan KH, Tsang KL, Ho PW, et al. Clinical outcome of relapsing remitting multiple sclerosis among Hong Kong Chinese. *Clinical Neurology & Neurosurgery* 2011 Oct; 113(8):617-22 (*outcomes*).
5. Clanet M, Kappos L, Hartung HP, et al. Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study. *Multiple Sclerosis* 2004 Apr; 10(2):139-44 (*drug: non-US dose*).
6. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon -1a at 5-year follow-up of CAMMS223 clinical trial. *Neurology* 2012 Apr 3; 78(14):1069-78 (*drug not included*).
7. Coppola G, Lanzillo R, Florio C, et al. Long-term clinical experience with weekly interferon beta-1a in relapsing multiple sclerosis. *European Journal of Neurology* 2006 Sep; 13(9):1014-21 (*timing*).
8. De Las Heras V, De Andres C, Tellez N, et al. Pregnancy in multiple sclerosis patients treated with immunomodulators prior to or during part of the pregnancy: a descriptive study in the Spanish population. *Multiple Sclerosis* 2007 Sep; 13(8):981-4 (*outcomes not by drug*).
9. Dubois BD, Keenan E, Porter BE, et al. Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre. *Journal of Neurology, Neurosurgery & Psychiatry* 2003 Jul; 74(7):946-9 (*timing*).
10. Ebers GC, Reder AT, Traboulsee A, et al. Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study. *Clinical Therapeutics* 2009 Aug; 31(8):1724-36 (*design*).
11. Fazekas F, Baumhackl U, Berger T, et al. Decision-making for and impact of early immunomodulatory treatment: the Austrian Clinically Isolated Syndrome Study (ACISS). *European Journal of Neurology* 2010 Jun 1; 17(6):852-60 (*not on topic*).
12. Fernandez Liguori N, Klajn D, Acion L, et al. Epidemiological characteristics of pregnancy, delivery, and birth outcome in women with multiple sclerosis in Argentina (EMEMAR study). *Multiple Sclerosis* 2009 May; 15(5):555-62 (*outcomes not by drug*).
13. Fernández O, Oreja-Guevara C, Arroyo R, et al. Natalizumab treatment of multiple sclerosis in Spain: Results of an extensive observational study. *Journal of Neurology* 2012 //; 259(9):1814-23 (*outcomes*).
14. Fernandez-Fernandez O, Garcia-Trujillo L, Guerrero-Fernandez M, et al. The effectiveness of glatiramer acetate in clinical practice: an observational study. *Revista de Neurologia* 2012 Jan 1; 54(1):1-9 (*timing*).
15. Flechter S, Vardi J, Pollak L, et al. Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up. *Journal of the Neurological Sciences* 2002 May 15; 197(1-2):51-5 (*timing*).
16. Giovannoni G, Rhoades RW. Individualizing treatment goals and interventions for people with MS. *Current Opinion in Neurology* 2012 Feb; 25 Suppl:S20-7 (*not on topic*).
17. Grimaldi LM, Prosperini L, Vitello G, et al. MRI-based analysis of the natalizumab therapeutic window in multiple sclerosis. *Multiple Sclerosis* 2012 Sep; 18(9):1337-9 (*outcomes*).

18. Grytten N, Aarseth J, Espeset K, et al. Health-related quality of life and disease-modifying treatment behaviour in relapsing-remitting multiple sclerosis-A multicentre cohort study. *Acta Neurologica Scandinavica* 2012 Dec; 126(Suppl 195):51-7 (*design*).
19. Hamann J, Mendel R, Reiter S, et al. Why do some patients with schizophrenia want to be engaged in medical decision making and others do not? *Journal of Clinical Psychiatry* 2011 Dec; 72(12):1636-43 (*not on topic*).
20. Heesen C, Solari A, Giordano A, et al. Decisions on multiple sclerosis immunotherapy: new treatment complexities urge patient engagement. *Journal of the Neurological Sciences* 2011 Jul 15; 306(1-2):192-7 (*not on topic*).
21. Hill S, Filippini G, Synnot A, et al. Presenting evidence-based health information for people with multiple sclerosis: the IN-DEEP project protocol. *BMC Medical Informatics & Decision Making* 2012; 12:20 (*not on topic*).
22. Holmen C, Piehl F, Hillert J, et al. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. *Multiple Sclerosis* 2011 Jun; 17(6):708-19 (*outcomes*).
23. Horakova D, Kalincik T, Dolezal O, et al. Early predictors of non-response to interferon in multiple sclerosis. *Acta Neurologica Scandinavica* 2012 Dec; 126(6):390-7 (*intervention unclear*).
24. Isaksson AK, Ahlstrom G. Managing chronic sorrow: experiences of patients with multiple sclerosis. *Journal of Neuroscience Nursing* 2008 Jun; 40(3):180-91 (*not on topic*).
25. Janssens AC, van Doorn PA, de Boer JB, et al. Perception of prognostic risk in patients with multiple sclerosis: the relationship with anxiety, depression, and disease-related distress. *Journal of Clinical Epidemiology* 2004 Feb; 57(2):180-6 (*not on topic*).
26. Jokubaitis VG, Spelman T, Lechner-Scott J, et al. The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform. *PLoS ONE* 2013 //; 8(3) (*selective reporting of discontinuation*).
27. Jordy SS, Tilbery CP, Fazzito MM. Immunomodulator therapy migration in relapsing remitting multiple sclerosis: a study of 152 cases.[Erratum appears in *Arq Neuropsiquiatr*. 2008 Jun;66(2A):292]. *Arquivos de Neuro-Psiquiatria* 2008 Mar; 66(1):11-4 (*intervention unclear*).
28. Kalincik T, Horakova D, Dolezal O, et al. Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort. *Clinical Neurology & Neurosurgery* 2012 Sep; 114(7):940-6 (*intervention unclear*).
29. Kasper J, Heesen C, Kopke S, et al. Patients' and observers' perceptions of involvement differ. Validation study on inter-relating measures for shared decision making. *PLoS ONE [Electronic Resource]* 2011; 6(10):e26255 (*not on topic*).
30. Kopke S, Kasper J, Muhlhauser I, et al. Patient education program to enhance decision autonomy in multiple sclerosis relapse management: a randomized-controlled trial. *Multiple Sclerosis* 2009 Jan; 15(1):96-104 (*not on topic*).
31. Lebrun C, Debouverie M, Jeannin S, et al. Impact of disease-modifying treatments in North African migrants with multiple sclerosis in France. *Multiple Sclerosis* 2008 Aug; 14(7):933-9 (*intervention unclear*).
32. Lode K, Larsen JP, Bru E, et al. Patient information and coping styles in multiple sclerosis. *Multiple Sclerosis* 2007 Jul; 13(6):792-9 (*not on topic*).
33. Magraner MJ, Coret F, Navarre A, et al. Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study. *Journal of Neurology* 2011 Oct; 258(10):1805-11 (*design*).
34. Mancardi GL, Amato MP, D'Alessandro R, et al. Natalizumab: a country-based surveillance program. *Neurological Sciences* 2008 Sep; 29 Suppl 2:S235-7 (*outcomes*).
35. Margolis JM, Fowler R, Johnson BH, et al. Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study. *BMC Neurology* 2011; 11:122 (*timing*).

36. Melin A, Outteryck O, Collongues N, et al. Effect of natalizumab on clinical and radiological disease activity in a French cohort of patients with relapsing-remitting multiple sclerosis. *Journal of Neurology* 2012 Jun; 259(6):1215-21 (*not on topic*).
37. Milanese C, La Mantia L, Palumbo R, et al. A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients. *Journal of Neurology, Neurosurgery & Psychiatry* 2003 Dec; 74(12):1689-92 (*timing*).
38. Minden S, Hoaglin D, Jureidini S, et al. Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study. *Multiple Sclerosis* 2008 Jun; 14(5):640-55 (*design*).
39. O'Connor P, Devonshire V, Canadian Network of MSC. The use of disease-modifying agents in multiple sclerosis--by the Canadian Network of MS Clinics. *Canadian Journal of Neurological Sciences* 2008 May; 35(2):127-32 (*design*).
40. Oger J, Francis G, Chang P, et al. Prospective assessment of changing from placebo to IFN beta-1a in relapsing MS: the PRISMS study. *Journal of the Neurological Sciences* 2005 Oct 15; 237(1-2):45-52 (*timing*).
41. Ollendorf DA, Castelli-Haley J, Oleen-Burkey M. Impact of co-prescribed glatiramer acetate and antihistamine therapy on the likelihood of relapse among patients with multiple sclerosis. *Journal of Neuroscience Nursing* 2008 Oct; 40(5):281-90 (*timing*).
42. Onesti E, Bagnato F, Tomassini V, et al. Interferon beta treatment of MS in the daily clinical setting: a 3-year post-marketing study. *Neurological Sciences* 2003 Dec; 24(5):340-5 (*timing*).
43. Panitch H, Goodin D, Francis G, et al. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. *Journal of the Neurological Sciences* 2005 Dec 15; 239(1):67-74 (*timing*).
44. Paolillo A, Pozzilli C, Giugni E, et al. A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta. *European Journal of Neurology* 2002 Nov; 9(6):645-55 (*drug: non-US dose*).
45. Pickin M, Cooper CL, Chater T, et al. The Multiple Sclerosis Risk Sharing Scheme Monitoring Study--early results and lessons for the future. *BMC Neurology* 2009; 9:1 (*not on topic*).
46. Portaccio E, Zipoli V, Siracusa G, et al. Switching to second-line therapies in interferon-beta-treated relapsing-remitting multiple sclerosis patients. *European Neurology* 2009; 61(3):177-82 (*not on topic*).
47. Pozzilli C, Prosperini L, Sbardella E, et al. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience. *Neurological Sciences* 2005 Dec; 26 Suppl 4:S174-8 (*design*).
48. Prosperini L, Gianni C, Leonardi L, et al. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. *Multiple Sclerosis* 2012 Jan; 18(1):64-71 (*outcomes*).
49. Prunty M, Sharpe L, Butow P, et al. The motherhood choice: themes arising in the decision-making process for women with multiple sclerosis. *Multiple Sclerosis* 2008 Jun; 14(5):701-4 (*not on topic*).
50. Prunty MC, Sharpe L, Butow P, et al. The motherhood choice: a decision aid for women with multiple sclerosis. *Patient Education & Counseling* 2008 Apr; 71(1):108-15 (*not on topic*).
51. Putzki N, Yaldizli O, Maurer M, et al. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries. *European Journal of Neurology* 2010 Jan; 17(1):31-7 (*design*).
52. Reynolds MW, Stephen R, Seaman C, et al. Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs. *Journal of Medical Economics* 2010 Mar; 13(1):90-8 (*timing*).
53. Rinaldi F, Seppi D, Calabrese M, et al. Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: Clinical and magnetic resonance imaging findings. *Multiple Sclerosis* 2012 //; 18(11):1640-3 (*design*).

54. Rovaris M, Comi G, Rocca MA, et al. Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial. *Multiple Sclerosis* 2007 May; 13(4):502-8 (*outcomes*).
55. Rudick RA, Cutter GR, Baier M, et al. Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients. *Multiple Sclerosis* 2005 Dec; 11(6):626-34 (*outcomes*).
56. Rudick RA, Lee JC, Cutter GR, et al. Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight-year follow-up. *Archives of Neurology* 2010 Nov; 67(11):1329-35 (*outcomes*).
57. Ruggieri RM, Settipani N, Viviano L, et al. Long-term interferon-beta treatment for multiple sclerosis. *Neurological Sciences* 2003 Dec; 24(5):361-4 (*timing*).
58. Russo P, Paolillo A, Caprino L, et al. Effectiveness of interferon beta treatment in relapsing-remitting multiple sclerosis: an Italian cohort study. *Journal of Evaluation in Clinical Practice* 2004 Nov; 10(4):511-8 (*timing*).
59. Sangalli F, Moiola L, Bucello S, et al. Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study. *Neurological Sciences* 2011 Jan; 31 Suppl 3:299-302 (*outcomes*).
60. Schwartz CE, Coulthard-Morris M, Cole B, et al. The quality-of-life effects of interferon beta-1b in multiple sclerosis. An extended Q-TWiST analysis. *Archives of Neurology* 1997; 54:1475-80 (*not on topic*).
61. Schwartz CE, Sprangers MA, Oort FJ, et al. Response shift in patients with multiple sclerosis: an application of three statistical techniques. *Quality of Life Research* 2011 Dec; 20(10):1561-72 (*not on topic*).
62. Schwid SR, Goodman AD, Weinstein A, et al. Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial. *Journal of the Neurological Sciences* 2007 Apr 15; 255(1-2):57-63 (*outcomes*).
63. Siger M, Durko A, Nicpan A, et al. Discontinuation of interferon beta therapy in multiple sclerosis patients with high pre-treatment disease activity leads to prompt return to previous disease activity. *Journal of the Neurological Sciences* 2011 Apr 15; 303(1-2):50-2 (*timing*).
64. Sindic CJ, Seeldrayers P, Vande Gaer L, et al. Long-term follow up of glatiramer acetate compassionate use in Belgium. *Acta Neurologica Belgica* 2005 Jun; 105(2):81-5 (*design*).
65. Smeltzer SC. Reproductive decision making in women with multiple sclerosis. *Journal of Neuroscience Nursing* 2002 Jun; 34(3):145-57 (*not on topic*).
66. Solari A, Ferrari G, Radice D. A longitudinal survey of self-assessed health trends in a community cohort of people with multiple sclerosis and their significant others. *Journal of the Neurological Sciences* 2006 Apr 15; 243(1-2):13-20 (*not on topic*).
67. Somerset M, Campbell R, Sharp DJ, et al. What do people with MS want and expect from health-care services? *Health Expectations* 2001 Mar; 4(1):29-37 (*not on topic*).
68. Stuve O, Cravens PD, Frohman EM, et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. *Neurology* 2009 Feb 3; 72(5):396-401 (*outcomes*).
69. Tedeschi G, Amato MP, D'Alessandro R, et al. The pharmacovigilance program on natalizumab in Italy: 2 years of experience. *Neurological Sciences* 2009 Oct; 30 Suppl 2:S163-5 (*outcomes*).
70. Thorne S, Paterson B, Russell C. The structure of everyday self-care decision making in chronic illness. *Qualitative Health Research* 2003 Dec; 13(10):1337-52 (*not on topic*).
71. Tilbery CP, Mendes MF, Oliveira BE, et al. Immunomodulatory treatment in multiple sclerosis: experience at a Brazilian center with 390 patients. *Arquivos de Neuro-Psiquiatria* 2006 Mar; 64(1):51-4 (*timing*).
72. Tomassini V, Paolillo A, Russo P, et al. Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. *Journal of Neurology* 2006 Mar; 253(3):287-93 (*drug: non-US dose*).

73. Tremlett H, Oger J. Adherence from across the pond: Six years of experience with beta-interferons for multiple sclerosis. *Pharmaceutical Journal* 2003 //; 271(7274):649-53 (*timing*).
74. Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. *Neurology* 2003 Aug 26; 61(4):551-4 (*timing*).
75. Tur C, Tintore M, Vidal-Jordana A, et al. Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision. *Multiple Sclerosis* 2012 Aug; 18(8):1193-6 (*not on topic*).
76. Tworok S, Nippert I, Scherer P, et al. Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population. *Current Medical Research & Opinion* 2007 Jun; 23(6):1209-15 (*design*).
77. Vazirinejad R, Lilley JM, Ward CD. The 'Impact on Participation and Autonomy': acceptability of the English version in a multiple sclerosis outpatient setting. *Multiple Sclerosis* 2003 Dec; 9(6):612-5 (*not on topic*).
78. Veugelers PJ, Fisk JD, Brown MG, et al. Disease progression among multiple sclerosis patients before and during a disease-modifying drug program: a longitudinal population-based evaluation. *Multiple Sclerosis* 2009 Nov; 15(11):1286-94 (*timing*).
79. Vlahiotis A, Sedjo R, Cox ER, et al. Gender differences in self-reported symptom awareness and perceived ability to manage therapy with disease-modifying medication among commercially insured multiple sclerosis patients. *Journal of Managed Care Pharmacy* 2010 Apr; 16(3):206-16 (*not on topic*).
80. Werneck LC, Lorenzoni PJ, Radunz VA, et al. Influence of treatment in multiple sclerosis disability: an open, retrospective, non-randomized long-term analysis. *Arquivos de Neuro-Psiquiatria* 2010 Aug; 68(4):511-21 (*intervention unclear*).
81. West TW, Cree BA. Natalizumab dosage suspension: are we helping or hurting? *Annals of Neurology* 2010 Sep; 68(3):395-9 (*design*).
82. Zwibel HL, Copolymer-1 Treatment Study Principal I. Glatiramer acetate in treatment-naive and prior interferon-beta-1b-treated multiple sclerosis patients. *Acta Neurologica Scandinavica* 2006 Jun; 113(6):378-86 (*timing*).

Appendix C. Evidence Tables

Appendix Table C1. Evidence table for KQ1 (not natalizumab interruption or pregnancy) studies	C-2
Appendix Table C2. Analytic set outcomes	C-5
Appendix Table C3. Analytic set harms	C-7
Appendix Table C4. Discontinuation details by study (if reported) from full reporting set ..	C-10
Appendix Table C5. Studies of natalizumab discontinuation.....	C-12
Appendix Table C6. Outcomes for studies of natalizumab discontinuation	C-14
Appendix Table C7. Studies of women with MS who experienced pregnancy and their fetuses	C-16
Appendix Table C8. Fetal outcomes for DMT exposure and maternal outcomes for drug holiday	C-18
References for Appendix C.....	C-23

Appendix Table C1. Evidence table for KQ1 (not natalizumab interruption or pregnancy) studies

Study Country	Study Aim	Patient Population	Drugs Study Design	Duration: Treatment, Followup	Comparison(s)
Bencsik, 2006 ¹ Hungary	To evaluate long-term efficacy	36: 34 RRMS, 2 RPMS mean age 36.0	IFN β -1b Case series	Tx: 6y Fu: 6y	By duration of therapy
Bermel, 2013 ^{2,3} United States	To evaluate long-term tolerability, efficacy	172 RRMS (122 living, 14 died, 24 unknown) 78% F mean age 35.8	IFN β -1a Open-label extension	Tx: med. 13.3y (mean 12.1, range 3–15) Fu: med. 16.3y	56 currently receiving IFN β -1a im vs. 66 not; by EDSS quartile
Bergamaschi 2012 ⁴ Italy	To investigate disability progression	1178 RRMS	Mixed IFN β and glatiramer acetate	Tx: NR FU: median 16.5y	Treated vs untreated by Bayesian risk quartile
Carmona, 2008 ⁵ Spain	To investigate early prognostic markers, efficacy	115 RRMS 68% F	IFN β -1b Prospective cohort with historical control	Tx: NR Fu: mean 4.6y (range 0.5-7.1), med 5.6y	115 treated, 44 untreated historic cohort
Confavreux, 2012 ⁶ North America and Europe	To evaluate tolerability, efficacy	147: 131 RRMS, 16 SPMS mean age 40	Teriflunomide Open-label extension of RCT	Tx: mean 5.6y, med. 7.1 (SD 2.7, range 0.05-8.5) Fu: up to 8.5y	52 7mg 40 14mg 29 pl.+7mg 26 pl.+14mg
Cunningham, 2010 ⁷ Sweden	To explore stopping, switching, continuing.	259 MS 71% F	IFN β mixed Cohort study	Tx: 3y+ continuers, 1.2y stoppers, 1.2y switchers Fu: NR	80 tx at least 3y, 38 stopped, 141 switched
Debouverie, 2007 ⁸ France	To evaluate long-term safety, efficacy	205 RRMS 77% F mean age 38.5	GA Case series	Tx: med. 5y Fu: 3.5-8y	By tx duration
Evans, 2012 ⁹ Canada	To describe long-term DMT persistence	1896 MS 75% F mean age 42.5	Mixed Cohort study	Tx: med. 2.9y initial DMT, med. 6.3y any first-line DMT Fu: up to 14y	By specific drug
Ford, 2010 ¹⁰⁻¹⁴ United States	To evaluate long-term safety, efficacy	232 mITT, 100 ongoing cohort, mITT: 73% F mean age 35.5	GA Cohort study	Tx: mITT mean 8.6y (SD 5.2), ongoing mean 13.6y (SD 1.3) Fu: up to 15y	232 mITT, 100 ongoing, 131 withdrawn
Goodin, 2012, ¹⁵⁻¹⁷ 11 North American centers	To investigate effect of early tx on survival	366 identified of 372 RRMS	IFN β -1b Long term followup	Tx: NR Fu: 21y	149 treated 123 placebo
Kappos, 2009 ¹⁸ North America and Europe	To compare early vs. delayed tx	418 MS	IFN β -1b Open-label extension of RCT	Tx: med. 5y early tx, med. 3y delayed tx Fu: 5y	261 early tx, 157 delayed tx

Study Country	Study Aim	Patient Population	Drugs Study Design	Duration: Treatment, Followup	Comparison(s)
Mesaros, 2012 ¹⁹ Serbia	To assess frequency and reasons for stopping	290 RRMS 71% F mean age 38.0 EDSS at least 3.5	IFN β -1a, IFN β -1b Cohort study	Tx: IFN β -1a mean 3.7y, IFN β -1b mean 3.2y Fu: up to 6y, mean 3.5y	169 IFN β -1a sc, 121 IFN β -1b
Milanese 2005 ²⁰ Italy	To compare long-term efficacy	294 RRMS	IFN β -1a, IFN β -1b, GA Case series 20/26 centers	Tx mean: IFN β -1b 3.5y, IFN β -1a 2.3-3.2y, GA 1.6y Fu: up to 5y	By specific drug
Miller, 2008 ²¹ United States	To evaluate long-term safety, efficacy	46 RRMS	GA Followup of compassionate use - case series	Tx: med. 12y (range 1- 22y) Fu: NR	18 continuing, 28 discontinued
O'Rourke, 2005 ²² Ireland	To investigate DMT discontinuation	394: 246 RRMS, 148 SPMS mean age 38	IFN β mixed Cohort study	Tx: NR Fu: med. 4.1y (up to 8y)	246 RRMS, 148 SPMS; by specific drug, by reasons for discon.
O'Rourke, 2007 ²³ Ireland	To evaluate efficacy, prognostic markers	175 RRMS 72% F	IFN β mixed Cohort study	Tx: >2y Fu: mean 5.1y (range 2- 10)	175 treated, 185 historical cohort (mean obs 3y)
Patti, 2006 ²⁴ Italy	To evaluate, compare long term safety, efficacy	126 RRMS 59% F mean age 36.7	IFN β -1a, IFN β -1b Cohort study	Tx: 6y Fu: 6y	62 IFN β 1a im, 64 IFN β 1b sc
Portaccio, 2008 ²⁵ Italy	To investigate DMT discontinuation	225 RRMS 70% F mean age 36.6	IFN β mixed (2 of 4 IFN forms) Cohort study	Tx: mean 3.1y β -1a im, 3.3y β -1b Fu: mean 4.7y β -1a im, 6.0y β -1b	By specific drug, by reasons for discon.
Rio, 2005 ²⁶⁻²⁸ Spain	To assess safety, efficacy, investigate adherence to DMT	382 RRMS 632 MS: 134 SPMS	IFN β -1a, IFN β -1b Open-label nonrandomized post- marketing observational	Tx: NR Fu: mean 4y (range 2-8)	By reasons for discon. (drugs aggregated)
Rio, 2007 ²⁹ Spain	To report post-marketing experience	146 SPMS 62% F mean age 45.1	IFN β -1b Post-marketing study	Tx: NR Fu: med. 5y (range 1-9.6)	By clinical status
Shirani, 2012 ³⁰ Canada	To investigate disability progression	2656 RRMS 76% F	IFN β mixed Retrospective cohort with historical and contemporary control groups	Tx: med. 5.1y Fu: med 5.1y tx, 4.0y untreated, 10.8y historical	868 treated, 929 untreated, 959 historical

Study Country	Study Aim	Patient Population	Drugs Study Design	Duration: Treatment, Followup	Comparison(s)
Sorensen, 2006 ³¹ Denmark	To provide data on DMT use in a population	2393 RRMS	IFN β mixed Cohort study	Tx mean: IFN β -1b 3.8y, IFN β -1a 2.7-3.7y, GA 1.8y Fu: mean 3.7y (range 0-8.8)	By specific drug, by tx duration
Trojano, 2005 ³² Italy	Surveillance, efficacy	1163: 943 RRMS, 220 SPMS (not analyzed)	IFN β mixed (n for drugs not same as analysis) Post-marketing study	Tx: results for 4y Fu: up to 6y	By specific drug (visual images only)
Trojano, 2007 ³³ Italy	To investigate disability progression	1504 RRMS 69% F mean age 33.6	IFN β -1a, IFN β -1b Cohort study	Tx: NR Fu: med. 5.7y (up to 7y)	1103 treated, 401 untreated
Trojano, 2009 ³⁴ Italy	To evaluate the effectiveness of early treatment	2570 RRMS 69% F mean age 33.5	IFN β mixed Cohort study	Tx: NR Fu: median 4.5y (up to 7y)	310 early tx, 2260 delayed tx
Tedeholm, 2013 ³⁵ Sweden	To investigate disability progression	916 RRMS	Mixed IFN β and glatiramer acetate	Tx: NR FU: 12y	186 untreated, 730 treated
Uitdehaag, 2011 ³⁶⁻³⁸ 22 centers in Europe, Canada, Australia	To evaluate safety, efficacy	382 RRMS	IFN β -1a Retrospective long-term followup of open-label extension	Tx: mean 3y min quartile, 7.5y max quartile by exposure time Fu: up to 8y	Quartiles by dose & time 96 min quartile, 95 max quartile

AEs=adverse events; ARR=Annualized relapse rate; discon=discontinuation; DMT=disease modifying treatment; EDSS=Expanded Disability Status Scale; F=female; Fu=followup; IFN β =interferon beta; GA=glatiramer acetate; im=intramuscular; LTFU=long-term followup; med=median ; mITT=modified intention-to-treat; MS=multiple sclerosis; NR=not reported; RRMS=relapse sc=subcutaneous; remitting multiple sclerosis; SD=standard deviation; SPMS=secondary-progressive multiple sclerosis; Tx=treatment; y=year

Appendix Table C2. Analytic set outcomes

Study Country	Relapse: Mean ARR (SD)	Disability: Change in Mean EDSS (SD) from Baseline	Progression to SPMS:	Mortality
Bergamaschi, 2012 ⁴ Italy			Bayesian modeling by quartile based on risk of progressing to SPMS. Highest quartile: treated 25.4%, untreated 64.4% (RR 0.23, 95% CI, 0.15 to 0.35) Lowest quartile (RR 0.27, 95% CI, 0.13 to 0.56)	
Bencsik, 2006 ¹ Hungary	Decreased from 1.29 to 0.25 (p<0.001) at 6y	Increased 0.5 (p=0.016) at 6y	NR	NR
Carmona, 2008 ⁵ Spain	Decreased from 3.2 at baseline to 1.7 at mean 4.6y, med 5.6y	NR	NR	NR
Confavreux, 2012 ⁶ North America and Europe	Decreased from baseline in all four tx dose/crossover groups	Stable in all groups with no significant differences or changes	NR	NR
Debouverie, 2007 ⁸ France	Stable, 0.4–0.6 annually for 5y	Stable: 3.1 (1.7) at baseline to 3.3 (2.1) at med. 5y	NR	NR
Ford, 2010 ¹⁰⁻¹⁴ United States	Decreased from 1.12 (0.82) at baseline to 0.25 (0.34) at mean 13.6y	Increased 0.6 (2.0) at mean 13.6y 57% stable or improved	mITT cohort 59 (25%) at mean 9.8y ongoing cohort 35 (35%) at 12.0y withdrawn cohort 24 (18.5%) at mean 6.4y	NR
Goodin, 2012 ¹⁵ Reder 2010 ^{15,16} 11 North American centers	NR	NR	NR	β-1b reduced all-cause mortality compared with placebo 21y after randomization; hazard rate of death 46% vs. placebo
Kappos, 2009 ¹⁸ North America and Europe	No significant changes or differences	No significant changes or differences	NR	NR
Miller, 2008 ²¹ United States	Decreased from 2.9 (1.4) at baseline to 0.1 (0.2) at med 12y	Increased 0.9 (1.9) at med. 12y, 57% stable or improved	NR	NR
Patti, 2006 ²⁴ Italy	NR	IFN-β1a: increased 1.03 (1.35) at 6y IFNβ-1b: increased 0.97 (1.47) at 6y (p=0.47)	β-1a: 17 (32%) β-1b: 17 (31%)	NR

Study Country	Relapse: Mean ARR (SD)	Disability: Change in Mean EDSS (SD) from Baseline	Progression to SPMS:	Mortality
Portaccio, 2008 ²⁵ Italy	β -1a im: 1.6 (1.0) at baseline to 0.4 (0.8) at 3.1y β -1b: 1.1 (0.7) at baseline to 0.7 (1.2) at 3.3y	Reported no significant changes or differences	NR	NR
Rio, 2007 ²⁹ Spain	Decreased from 0.65 at baseline (2y prior: 1.3) 0.22 at 4y	NR	Included only people with SPMS	NR
Rio, 2005 ^{27,28} Spain	IFN β -1b: 1.36 (0.7) at baseline to 0.38 (0.45) at 4y, IFN β -1a im: 1.07 (0.5) to 0.33 (0.48), IFN β -1a sc: 1.21 (0.5) to 0.41 (0.5)	NR	NR	NR
Shirani, 2012 ³⁰ Canada	NR	NR	IFN β not associated with reduced hazard of progression to EDSS 6 compared with contemporary or historical control, with multivariate analysis	NR
Tedeholm, 2013 ³⁵ Sweden	NR	NR	No difference between treated and untreated.	NR
Uitdehaag, 2011 ³⁶⁻³⁸ PRISMS Study 22 centers in Europe, Canada, Australia	No statistical analysis. β -1a sc by time exposure: 0.76 (0.55) min time quartile, 0.51 (0.49) max time quartile At 7-8 y	No statistical analysis – lower percentage confirmed EDSS progression	No statistical analysis – lower percentage convert to SPMS	NR

ARR=Annualized relapse rate; EDSS-Expanded Disability Status Scale; Fu=followup; IFN β =interferon beta; GA=glatiramer acetate; im=intramuscular; LTFU=long-term followup; med=median; mITT=modified intention-to-treat; NR=not reported; sc=subcutaneous; SD=standard deviation; Tx=treatment; y=year

Appendix Table C3. Analytic set harms

Author/Year	Harms/AEs Overall	Harms Information	Context/Comments	Results
Confavreaux, 2012 ⁶ Teriflunomide N=147	Yes AEs – full page table 2	TEAEs: treatment-emergent adverse effects (1 st dose to within 16 wks of last dose) Other AEs (spontaneously reported at visits)	Safety data (TEAEs) presented for (core + extension) and according to tx received <u>during extension phase</u> (placebo group was randomized to either dose for extension)	Detailed in Table 2: Most common TEAEs: Mild infection, fatigue, sensory disturbances, diarrhea. No serious opportunistic infections occurred (and no discontinuations due to infection). Labs: asymptomatic alanine aminotransferase increases (≤3xULN) were common (~2/3 of p both doses); ≥3xULN in 12% both doses. Mild decreases in neutrophils. Malignancies: comparable to general population in number and type – all in low dose group
Debouverie, 2007 ⁵ GA: intolerant of INFB N=205	Yes: AEs Table 6 & text p 1271	AEs and discontinue for AE Table 6. AE and discontinue reasons not mutually exclusive	Excluded patients who stopped GA (40% of patients stopped GA before LT followup → excluded)	87.3% overall had AEs: (179/205) Local injection site rxn: 166 (81%) Systemic rxns: 101 (49.3%): immediate post-injection: flushing, chest tightness, shortness of breath, palpitations, anxiety. *Only 5% of patients overall discontinued because of these AEs
Ford, 2010 ¹⁰ LT GA Ford, 2006 ¹¹ N=232	Yes but text only, pg 347, no N (%) given			1. <u>Most commonly reported AEs:</u> Accidental injury, muscle weakness, back pain, dizziness, depression, hypoesthesia, paresthesia, insomnia, URIs, UTIs, headaches, pain. 2. <u>AEs thought to be related to GA:</u> local injection-site rxns, IPIR (vasodilation, chest pain, palpitation, tachycardia, dyspnea. *No apparent time-dependent AEs emerged. No evidence of renal dysfunction, immunosuppression, malignancy, or development of other autoimmune disease was observed. One death (resp. failure during pneumonia)
Johnson, 2000 ¹² (also Johnson 03,05)	Yes: 3 statements in text	AEs brief text p 260 Safety:	Can't tell if % are for overall days of events or number of events	"Most common reported AEs were injection site rxns. Group A (2.4%), Group B (0.9%). No reports of skin necrosis. No lab deviations"
Gold, 2005 ³⁶ INFB-1a	Yes detailed: Table 2 and text p 651-654. Table 3 lab abnormal	2 tables & extensive text		Most common AEs in patients originally randomized to active tx: Injection-site inflammation (72%), headache (71%), flu-like symptoms (69%). All were generally mild and most common in first month of tx. *4yr AE profiles were comparable with those during the initial phase of study and for the most part, with each other. No association. between INFB1a and depression/suicide. Lab: most common abnormal labs were asymptomatic lymphopenia and elevated serum liver transaminase levels (mild and resolved spontaneous) ** Serious AEs detailed in text p 654. Also deaths

Author/Year	Harms/AEs Overall	Harms Information	Context/Comments	Results
PRISMS, 2001 ³⁸ (same sample as Gold, Utidehaag)	Yes p 1633 text; Table 4 p 1635.	Lists AEs by N - no %'s given - so need to find denominators in text or other tables		AEs similar to those observed in PRISMS-2; most mild Table 4: AEs by: (yrs1-4) and (yrs 3-4): Table listed by cases and without percentages. Most common: injection site, flu-like symptoms. Also lists lab abnormalities text p1633 & Table 4
Goodin, 2012 ¹⁵ Reder, 2010 ¹⁶ INFB-1b N=328	Yes: AEs Table 2 and mortality	"The great number of tx sequences renders individual analyses and commentary difficult, but some observed AEs are likely derived from tx with other agents and not from INFB" p1878. Detailed death info by dose, NAb status p1881	AEs given for patients continuously using INFB-1b in the 2 yrs prior to LTFU (n=69)	Of n=69 patients at LTF visit: Table 2 Injection site rxn 81%; Depression 42%; Flu like symptoms: 32%; Headache 28%; Malaise 23%; Fever 22%; Myalgia 22%; Liver transaminase increase 10%.
Kappos, 2009 ¹⁸ N=418	Yes –text p 991: web appendix	Comparison is early vs. delayed tx groups INFB-1b.	web appendix for table.	% of patients who had 'at least one serious AE: Early tx: 61 (21%); Delayed tx: 42 (24%). 40 (23%) of 173 delayed who had post base blood taken had at least 1 + for NAb. More on titers p 992
Miller, 2008 ²¹ 22 yrs N=46	Yes text only p 497	No. discontinuing due to serious adverse events.		"Most common AEs in ≥50% of patients:" Injection site rxns (soreness, redness, swelling, itching). 6 who took GA for up to 22 yrs reported lipoatrophy. None reported skin necrosis
Patti, 2006 ²⁴ INFB1a vs INFB1b, 6 yrs of therapy N=126	Text only p 244. Also NAb	6 yr AE: text summary only no N or % Number with NAb at yr 6: text p 244	(Also text AEs in discontinues: authors mix AE and AE/discontinue info in both subsections)	"Most frequent SEs were flu like symptoms, fever, headache, injection-site rxn, fatigue, myalgia, increased spasticity and depression. Headache was significantly more common in Group A (Avonex) and injection site rxn in Group B Betaferon. NSD between groups in other SEs. NAb yr 6: text p 244
Portaccio, 2008 ²⁵ IFN mixed N=225	Yes – minimal - text p 132-133 and Table 2	FU duration mean 4.2 yrs. No. discontinuing due to serious adverse events		Patients discontinuing due to SE (14.7%) did so significantly earlier than patients who suspended IFNB due to perceived lack of efficacy (28.9%). Med survival times 1.0y vs 2.3y (log rank test p=0.009). Suspension due to SE associated with a higher relapse rate in yr prior to IFNB. Confirmed in patients with followup of at least 4 yr.
Rio, 2005 ^{27,28} INFB in N=236 4y, 168 5y, 96 6y, 62 7r, 22 8y	Yes – little	Summary comments in text p 798 Safety. Minimal details		"No unexpected AEs. All treatments were well tolerated and AEs in accordance with those previously associated with INFB (data not shown) Most AEs were more frequent in first months of treatment and reduced after first 6 mo. Frequency of AEs was similar in all groups except for one AE: injection site reactions were more common in SQ INFB. On the other hand, 3 patients developed allergic reaction to Rebif with urticarial and angioedema. In all 3 INFB was interrupted and symptoms resolved with specific treatment"

Author/Year	Harms/AEs Overall	Harms Information	Context/Comments	Results
Rio, 2007 ²⁹ N=146 SPMS 1y,89 at least 3y	Yes minimal - not useable; See text	Text comments – no denominators p 852	Unclear what AE text is for stoppers vs. nonstoppers, nor what the denominator is	“...AEs were in accordance with those previously associated with INFB (data not shown). Most AEs were more frequent during the first months of treatment then reducing in frequency after the first 6 months. Only in 3 patients did AEs lead to therapy discontinuation. Nevertheless, some unexpected AEs were observed as follows: 4 patient died (3 sepsis, 1 pulmonary hemorrhage), 1 patient had herpes zoster, 1 intracerebral hemorrhage and one had GI bleeding” p 852

ARR=Annualized relapse rate; EDSS-Expanded Disability Status Scale; Fu=followup; IFN β =interferon beta; GA=glatiramer acetate; im=intramuscular; LTFU=long-term followup; med=median; mITT=modified intention-to-treat; NR=not reported; sc=subcutaneous; SD=standard deviation; Tx=treatment; y=year

Appendix Table C4. Discontinuation details by study (if reported) from full reporting set

Author, Year Drugs	Adverse Event	Lack of Efficacy	Progression of Disability	Intended Pregnancy	Long- term Stable MS	Death	Protocol Violation	Other Treatment	Patient Decision
<i>Glatiramer acetate</i>									
Debouverie, 2007 ⁸	Y	Y “aggravation of MS”	Y	N	N	N	N	N	Y “other”*
Ford, 2010 ¹⁰	Y	Y “perception of disease worsening”	Y	Y	Y “benign”	Y	Y “difficulty, inability, or unwillingness to adhere to protocol”	Y	Y 95/132 “patient decision” with subcategories
Miller, 2008 ²¹	Y	N	Y	Y	N	N	Y “did not complete or return forms”	Y	Y 15/28 “patient withdrew consent” 8/15 progressed at least 1.0 EDSS
Glatiramer acetate	3	2	2	2	1	1	2	2	3
<i>Teriflunomide</i>									
Confavreux, 2012 ⁶	Y	Y “perception of lack of efficacy”	N	N	N	Y	Y	N	*Y “subject did not wish to continue”, “other”
Teriflunomide	1	1	0	0	0	1	1	0	1
<i>INFβ-1a</i>									
Uitdehaag, 2011 ³⁷ Gold 2005 ³⁶	Y	N	Y	Y	N	Y	N	N	*Y “patient decision”, “other”
Interferon beta-1a	1	0	1	1	0	1	0	0	1
<i>INFβ-1b</i>									
Bencsik, 2006 ¹	Y	N	Y	Y	N	Y	Y	N	N
Carmona, 2008 ⁵	Y	Y “insufficient efficacy”	Y	Y	N	Y	N	N	Y “voluntary withdrawal”**
Kappos, 2009 ¹⁸	Y	Y	N	Y	N	N	Y	Y	Y “other”***, “withdrew consent”**
Rio, 2007 ²⁹	Y	Y “inefficacy (increase of disability or rr)”	Y	N	N	Y	N	N	Y “by own will”*
Interferon beta-1b	4	3	3	3	0	3	2	1	3
<i>INFβ mixed</i>									
Cunningham, 2010 ⁷	Y	Y “perceived lack of	N	N (excluded	Y “long- term	NA	NA	Y	Y “miscellaneous”**

Author, Year Drugs	Adverse Event	Lack of Efficacy	Progression of Disability	Intended Pregnancy	Long- term Stable MS	Death	Protocol Violation	Other Treatment	Patient Decision
		efficacy"		from study)	stable"				
Mesaros, 2012 ¹⁹	Y	Y	Y	Y	N	Y	N	Y	Y "own will"*; "other"
O'Rourke, 2007 ²³	Y	Y	Y	Y	N	N	N	N	N
O'Rourke, 2005 ²²	Y	Y	Y	Y	N	N	N	Y	Y "noncompliance"*
Patti, 2005 ²⁴	Y	N	Y	Y	N	N	N	Y	N
Portaccio, 2008 ²⁵	Y	Y	N	Y	N	N	N	Y	Y "patient decision"*
Trojano, 2005 ³²	Y	N	Y	N	N	N	N	N	Y "voluntary withdrawal"*
Interferon beta mixed	7	5	5	5	1	1	0	5	5
DMT mixed									
Milanese, 2005 ²⁰	Y	Y	Y	Y	N	N	N	Y	Y "no consent"*
Rio, 2005 ²⁷	Y	Y	Y	Y	N	Y	N	Y	Y "voluntary withdrawal"*; "own will decision"*
Sorenson, 2006 ³¹	Y	Y	Y	Y	N	N	N	Y	Y "other"* "unknown"* "NAB"
DMT mixed	3	3	3	3	0	1	0	3	3

DMT=disease-modifying therapy; *not explained; **explained further

Appendix Table C5. Studies of natalizumab discontinuation

Study, Location	Population, Mean EDSS	Design	Sample Size, Reason(s) for Interruption	DMT Prior to NTZ	Duration of NTZ	Duration of Interruption	DMT During Interruption
ARR Outcomes							
Havla, 2013 ³⁹ Germany	MS patients	Retrospective cohort	n=36 26/36 fingolimod: 25 fear of PML, 2 treatment failure, 4 desire to switch; 10/36 no DMT: 5 fear of PML, 3 family planning, 1 treatment failure, 1 side effects	All, NR details	median 27.6 mo (median 27 doses, range 6-57)	median 13 mo observation; median 13.7 wks (fingolimod) or no DMT	26/36 FD, 10/36 none
Havla, 2011 ⁴⁰ Germany	MS patients, EDSS 3.7	Prospective cohort	n=13 Mostly drug holiday ("mainly because of fear of PML")	All, NR details	mean 26.3 mo (range 3-45)	mean 8.7 mo (range 3-16)	7/13 GA, 6/13 none
Jokubaitis, 2014 ⁴¹ Australia and International	MS patients	Retrospective cohort	N=89/536 NR	89 NTZ to FD 350 IFN β or GA to FD 97 none to FD	31.8 mo	median 2.6 mo for NTZ to FD	Not applicable
Kaufman, 2011 ⁴² United States	RRMS patients, EDSS 2.4	Retrospective chart review	n=48 Drug holiday or NR (advised drug holiday after 12 mo on NTZ)	39 failing DMT, 2 none, 7 NR	mean 12.3 mo (range 4-24)	mean 11.3 mo (range 7-24)	23 GA, 13 IFN β , 7 other, 5 none; DMT initiated 3 mo after NTZ or without pause
Kerbrat, 2011 ⁴³ France	RRMS patients with very active disease, EDSS 2.7	Retrospective cohort	n=27 17/27 drug holiday, 4/27 side effects (frequent infections: 2, rash: 1, fatigue: 1), 3/27 pregnancy planning, 3/27 patient stopped	All, NR details	mean 12 mo (range 6-23)	mean 6 mo	None
O'Connor, 2011 ⁴⁴ Canada	MS patients, EDSS 2.4	Prospective, post hoc analysis of trial data	n=949 Drug holiday	NR	28.4 mo, median 34 doses (range 1-41)	8 mo observation	9.9% IFN β , 2.4% GA,
Rossi, 2013 ⁴⁵ Italy	RRMS patients, EDSS 2.8	Prospective cohort	n=40 Drug holiday	35 IFN β , 5 none	mean 15.2 mo (range 12-18)	up to 12 mo	GA 4 wks after NTZ

Study, Location	Population, Mean EDSS	Design	Sample Size, Reason(s) for Interruption	DMT Prior to NTZ	Duration of NTZ	Duration of Interruption	DMT During Interruption
Sorensen, 2014, ⁴⁶ Denmark	MS patients with very active disease, EDSS 4.1 (range 0-8)	Retrospective; national registry	n=375 186 preferred to switch (mostly due to fear of PML), 44 treatment failure, 43 neutralizing antibodies, 26 pregnancy related, 20 side effects, 48 other, 8 unknown	320 first-line DMT, 44 mitoxantrone, 9 none, 2 IVIG	mean 32.4 mo (range 5.8–75.6 mo)	mean 3.8 mo (range 0–53.3 mo)	244 FD, 36 mitoxantrone, 30 resumed NTZ, 15 GA, 14 IFN β s.c., 9 other IFN β , 17 other, 10 none
MRI Outcomes only							
Boriello, 2012 ⁴⁷ Spain	RRMS patients, median EDSS 5.0	Prospective cohort post-marketing	n=23 Drug holiday	NR	mean 19 doses (range 12–28)	mean 117 days (90-150)	Pulsed steroids
Boriello, 2011 ⁴⁸ Spain	MS patients	Prospective cohort post-marketing	n=21 Drug holiday	1 none, 2 NR, 18 DMT NR details	24 consecutive mo	mean 111.5 days (range 90-174)	None
Miravalle, 2011 ⁴⁹ United States	MS patients with active disease, 75% RRMS, 25% SPMS, EDSS 3.3	Prospective cohort	n=32 Drug holiday	All, NR details	mean 17.3 mo (range 12+)	mean 4 mo	None

DMT=disease-modifying treatment; EDSS-Expanded Disability Status Scale; Fu=followup; GA=glatiramer acetate; IFN β =interferon beta; IVIG=intravenous immunoglobulin; mo=month; MS=multiple sclerosis; NR=not reported; NTZ=natalizumab; PML-progressive multifocal leukoencephalopathy; RRMS=relapse remitting multiple sclerosis; SPMS=secondary progressive multiple sclerosis; wks=weeks

Appendix Table C6. Outcomes for studies of natalizumab discontinuation

Study, Location	ARR Before NTZ Mean (SD)	ARR After NTZ Mean (SD)	MRI Pre-NTZ Mean (SD) or Med (Range)	MRI After NTZ Mean (SD) or Med (Range)	Reported Rebound	Definition of Rebound/Severe Flare
ARR and MRI outcomes						
Havla, 2013 ³⁹ Germany	fingolimod: 2.2 no DMT: 1.5	fingolimod: 0.0 no DMT: 1.5	(visual image only)	no significant change from baseline to post (visual image only)	3/36	Sustained EDSS worsening (>1 EDSS steps) and widespread disease activity (>1 GELs) on MRI
Havla, 2011 ⁴⁰ Germany	2.2 (1.5)	1.7 (1.4)	9/13 had GELs	9/12 had GELs	4/13	Subjective: severe relapse with sustained EDSS worsening and widespread disease activity on MRI
Jokubaitis, 2014 ⁴¹ Australia and International	1.54	0.38	NR	NR	No	Compared ARR pre- and post-NTZ; also compared ARR and distribution of severe relapse among those who switched to FD from NTZ, first-line or no DMT
O'Connor, 2011 ⁴⁴ Canada	On-study placebo ARR: 0.73	at 7 mo (peak): 0.71	n=339: 1.6 (0.2) GELs	n=60 at 6 mo (peak observed): 1.2 (0.4) GELs	None	Worsening of disease activity beyond pretreatment levels
Kaufman, 2011 ⁴² United States	0.52 (range 0–3)*	0.35	NR	NR	None	Subjective: severe relapse as has been reported by others (West and Cree 2010, subjective: clinically severe flare and mean 16 GELs (range 6-40))
Kerbrat, 2011 ⁴³ France	2.3 (1.1)	at 6 mo: 1.8	21/27 had GELs, mean 2.8 (range 0-13)	13/19 had GELs, mean 9.1 (range 0-50)	4/27	Subjective: severe relapse and 20+ GELs (range 23-50)
Sorensen, 2014, ⁴⁶ Denmark	0.94	1-6 mo: 0.63 7-12 mo: 0.55	NR	NR	83/375 or 42/375	Higher individual relapse rate after cessation of NTZ than before NTZ
MRI outcomes only						
Rossi, 2013 ⁴⁵ Italy	2.3 (0.9)	0.6 (0.8)	Significantly higher (visual only)	15/29 had GELs, of the 15: mean 1.0 (1.1)	None	Subjective: MRI parameters were not consistent with rebound of disease activity
Boriello, 2012 ⁴⁷ Spain	2.1	NR	16/23 had CELs	7/23 had CELs of the 7, no med. change from baseline (2, 0-15) to post (3, 1-11)	2	Subjective: severe disabling relapse and a large number of CELs

Study, Location	ARR Before NTZ Mean (SD)	ARR After NTZ Mean (SD)	MRI Pre-NTZ Mean (SD) or Med (Range)	MRI After NTZ Mean (SD) or Med (Range)	Reported Rebound	Definition of Rebound/Severe Flare
Boriello, 2011 ⁴⁸ Spain	2.3	NR	16/19 had CELs	8/19 had CELs of the 9, no med. change from baseline (1, 0-12) to post (3, 0-20)	None	Subjective: disease activity worsens beyond pre-treatment severity
Miravalle, 2011 ⁴⁹ United States	1y prior: 1.3 (1.1), 2y prior: 2.3 (1.5)	NR	n=31: 17/31 had GELs, mean 1.9 (2.9)	n=29: 12/29 had GELs, of the 12: mean 9.5 (12.4), (baseline mean 2.0 (2.8*), p .001	NR or 1?	Subjective: NR for observational study design

ARR=Annualized relapse rate; CELs=contrast-enhancing lesions; GELs=gadolinium enhancing lesions; med.=median; MRI=magnetic resonance imaging; mo=month; NR=not reported; NTZ=natalizumab. *This study confirmed ARR through clinical visits

Appendix Table C7. Studies of women with MS who experienced pregnancy and their fetuses

Study, Location	Population	Design	Number of Exposed Pregnancies, Intervention	Definition of Exposure, Mean Exposure Duration	Number of Unexposed Pregnancies, Comparison Group(s)
Interferon beta 1a					
Sandberg-Wollheim, 2011 ⁵⁰ Sweden	Women with MS who experienced pregnancy and their fetuses	Prospective, global drug safety database	425 IFN β -1a s.c.	During pregnancy 4 wks	None; general population data used for comparison
Sandberg-Wollheim, 2005 ⁵¹ Sweden	Women with MS who experienced pregnancy and their fetuses	Prospective, individual patient data from 8 trials	41 IFN β -1a	Within 2 wks of conception or during pregnancy NR	6 Placebo 22 No DMT at least 2 wks prior to pregnancy
Interferon beta mixed					
Amato, 2010 ⁵² Italy	Women with MS who experienced pregnancy and their fetuses	Prospective cohort, 21 clinics	88 IFN β 10 β -1b 21 β -1a sc 22 mg 22 β -1a sc 44 mg 35 β -1a im	Within 4 wks from conception or during pregnancy 4.6 wks	318 no DMT at least 4 wks prior to pregnancy
Boskovic, 2005 ⁵³ Canada	Women with mostly* MS who experienced pregnancy and their fetuses	Prospective cohort, women who contacted risk counseling program	23 IFN β	During pregnancy 9 wks (range 2-38) 21 MS: <1 st tri *2 non-MS: 21, 38 wks	21 No DMT at least 4 wks prior to pregnancy 20 Healthy women who had been counseled for nausea or vomiting during pregnancy
Patti, 2008 ⁵⁴ Italy	Women with MS who experienced pregnancy and their fetuses	Retrospective cohort, one clinic	14 IFN β	During pregnancy 9 wks	17 DMT naïve 7 No DMT at least 1 mo prior to pregnancy
Interferon beta mixed, glatiramer acetate					
Fragoso, 2013 ⁵⁵ Brazil, UK, Mexico, Argentina	Women with MS who experienced pregnancy and their fetuses	Retrospective, voluntary database	41 GA 17 IFN β 3 other DMT	Continuous DMT at least 8 wks during pregnancy 18.4 wks (range 8-40)	89 No DMT at least 3 mo prior to pregnancy
Hellwig, 2012 ⁵⁶ Germany	Women with MS who experienced pregnancy and their fetuses	Retrospective, risk counseling database	78 IFN β 15 IFN β -1b 63 IFN β -1a 41 GA	Last injection after last menstrual period 8.8 wks (5 DMT full term)	216 Last injection before last menstrual period
Finkelsztejn, 2011 ⁵⁷ Brazil	Women with MS who experienced pregnancy and their fetuses	Retrospective cohort, provincial database	69 IFN β 20 GA 10 other DMT	During pregnancy 8 wks "around 2 mo"	43 During pregnancy

Study, Location	Population	Design	Number of Exposed Pregnancies, Intervention	Definition of Exposure, Mean Exposure Duration	Number of Unexposed Pregnancies, Comparison Group(s)
Lu, 2012 ⁵⁸ Canada	Women with MS who experienced pregnancy and their fetuses	Retrospective, voluntary database, selectively assembled by clinicians	15 IFN β 6 GA	Within 1 mo of conception or during pregnancy <2 mo	317 DMT naïve 80 No DMT at least 1 mo prior to pregnancy
Weber-Schoendorfer, 2009 ⁵⁹ Germany	Women with MS who experienced pregnancy and their fetuses	Prospective cohort, risk assessment program	69 IFN β 31 GA	During pregnancy 6.9 wks GA 8.8 wks IFN β	64 DMT naïve 1557 healthy women who had been counseled during pregnancy after nonteratogenic exposures
Glatiramer acetate					
Giannini, 2012 ⁶⁰ Italy	Women with MS who experienced pregnancy and their fetuses	Prospective cohort, 21 clinics	17 GA	Within 4 wks from conception or during pregnancy 4.9 wks	318 No DMT at least 4 wks prior to pregnancy
Natalizumab					
Hellwig, 2011 ⁶¹ Germany	Women with MS who experienced pregnancy and their fetuses	Prospective, risk counseling database	35 natalizumab	Within 8 wks of last menses or during pregnancy	23 DMT naïve

DMT=disease modifying treatment; IFN β =interferon; GA=glatiramer acetate; MS=multiple sclerosis; wks=weeks

*14/16 women received IFN for MS, 1/16 for thrombocytosis, 1/16 for essential thrombocythemia; in disease control group 10/12 women received IFN for MS, 1/12 for hepatitis C, 1/12 for wart on foot

Appendix Table C8. Fetal outcomes for DMT exposure and maternal outcomes for drug holiday

Author, Year, Location, Risk of Bias	Spontaneous Abortion (SA)	Fetal Death (FD)	Preterm Delivery (PD)	Fetal Outcomes: Reported Findings	Maternal Outcome: Postpartum Relapse Rate
Interferon					
Sandberg-Wollheim, 2011 ⁵⁰ Sweden Moderate/High	e: 49/425	e: 6/425	NR	No significant differences in rates of SA between exposed and general population	NR
Amato, 2010 ⁵² Italy High	e: 7/88 c: 20/318	e: 1/88 c: 3/318	e: 25/88 c: 58/295	Exposure associated with preterm delivery (propensity score-adjusted OR), not significantly associated with SA or FD.	NR
Patti, 2008 ⁵⁴ Italy High	e: 0/14 c: 1/25	NR	e: 1/14 c: NR	No significant differences in SA rates between exposed and unexposed groups.	NR
Boskovic, 2005 ⁵³ Canada High	e: 9/23 c: 4/21	e: 1/23 c: 0/21	e: 2/23 c: 3/21	Exposed had higher rates of SA; no significant differences in rates of FD, PF.	NR
Sandberg-Wollheim, 2005 ⁵¹ Sweden High	e: 8/41 c: 0/28	e: 1/41 c: 0/28	e: 1/41 c: 1/28	No significant differences in rates of SA, FD, or PD between exposed and general population	NR
Fragoso, 2013 ⁵⁵ Brazil, UK, Mexico, Argentina High	e: 0/17 c: 2/89	e: 0/17 c: 0/89	e: 0/17 c: 1/89	No significant differences in rates of SA, FD, or PD between exposed and unexposed	Women receiving any DMT at least 8 wks during pregnancy had significantly lower RR (p=0.001) following delivery compared to unexposed; no significant differences in RR 1y prior to or during pregnancy*
Finkelsztejn, 2011 ⁵⁷ Brazil High	e: 0/69 c: 0/43	e: 0/69 c: 0/43	NR	No significant differences in rates of SA or FD between exposed and unexposed	NR (descriptive only)
Lu, 2012 ⁵⁸ Canada High	NR	e: 0/15 c: 1/397	NR	No significant difference in rates of FD between exposed and unexposed	NR
Hellwig, 2012 ⁵⁶ Germany High	NR	NR	e: 38.9 ± 2.4wks c: 39.1 ± 2.3wks	No significant differences in wks of gestation between exposed and unexposed	Exposed group had lower postpartum RR (p<0.05)
Weber-Schoendorfer, 2009 ⁵⁹ Germany High	e: 7/60 c: 6/61	e: 0/53 c: 0/57	e: 6/53 c: 8/55	No significant differences in rates of SA, FD, or PD between IFN-exposed and unexposed.	NR

Author, Year, Location, Risk of Bias	Spontaneous Abortion (SA)	Fetal Death (FD)	Preterm Delivery (PD)	Fetal Outcomes: Reported Findings	Maternal Outcome: Postpartum Relapse Rate
Glatiramer Acetate					
Fragoso, 2013 ⁵⁵ Brazil, UK, Mexico, Argentina High	e: 2/41 c: 2/89	e: 1/41 c: 0/89	e: 1/41 c: 1/89	No significant differences in rates of SA, FD, or PD between exposed and unexposed	Women receiving any DMT at least 8 wks during pregnancy had significantly lower RR (p=0.001) following delivery compared to unexposed; no significant differences in RR 1y prior to or during pregnancy *
Lu, 2012 ⁵⁸ Canada High	NR	e: 0/6 c: 1/397	NR	No significant difference in rates of FD between exposed and unexposed	NR
Hellwig, 2012 ⁵⁶ Germany High	NR	NR	e: 39.2 ± 1.7wks c: 39.1 ± 2.3wks	No significant differences in wks of gestation between exposed and unexposed	Exposed group had lower postpartum RR (p<0.05)
Giannini, 2012 ⁶⁰ Italy	e: 1/17 c: 20/318	e: 0/17 c: 3/318	e: 4/17 c: 58/295	No significant differences in rates of SA, FD, or PD between exposed and unexposed	NR
Finkelsztejn, 2011 ⁵⁷ Brazil High	e:0/20 c: 0/43	e: 0/20 c: 0/43	NR	No significant differences in rates of SA or FD between exposed and unexposed	NR (descriptive only)
Weber-Schoendorfer, 2009 ⁵⁹ Germany High	e: 1/26 c: 6/61	e: 0/26 c: 0/57	e: 1/25 c: 8/55	No significant differences in rates of SA, FD, or PD between exposed and unexposed	NR
Natalizumab					
Hellwig 2011 ⁶¹ Germany High	e: 5/35 c: 1/23	e: 0/35 c: 1/23	e: 2/35 c: 1/23	No significant differences in rates of SA, FD, or PD between exposed and unexposed	No significant differences in RR between groups during pregnancy or post-partum; trend toward fewer post-partum relapses among exposed (e: 6/35, c: 9/23).

* timing for calculation of relapse rates not clearly reported

DMT = disease modifying treatment; IFNβ = interferon beta; FD = fetal death; OR = odds ratio; PD = preterm delivery; SA = spontaneous abortion, e = exposed group, c = comparison group

References for Appendix C

1. Bencsik K, Fuvesi J, Friczka-Nagy Z, et al. Short communication: treatment of relapsing-remitting multiple sclerosis 96 patients with IFN-beta 1b: results of a 6-year follow-up. *J Interferon Cytokine Res* 2006; Feb;26(2):96-100. PMID: 16487029.
2. Bermel RA, Weinstock-Guttman B, Bourdette D, et al. Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study. *Mult Scler* 2010; May;16(5):588-96. PMID: 20167591.
3. Bermel RA, You X, Foulds P, et al. Predictors of long-term outcome in multiple sclerosis patients treated with interferon. *Ann Neurol* 2013; Jan;73(1):95-103. PMID: 23378325.
4. Bergamaschi R, Quaglini S, Tavazzi E, et al. Immunomodulatory therapies delay disease progression in multiple sclerosis. *Mult Scler* 2012; published online May 31:1-9. PMID: 22653657.
5. Carmona O, Casado V, Moral E, et al. Interferon-beta1b in multiple sclerosis: effect on progression of disability and clinical markers of treatment response. *Eur Neurol* 2008; 60(6):279-84. PMID: 18824855.
6. Confavreux C, Li DK, Freedman MS, et al. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. *Mult Scler* 2012; Sep;18(9):1278-89. PMID: 22307384.
7. Cunningham A, Gottberg K, von Koch L, et al. Non-adherence to interferon-beta therapy in Swedish patients with multiple sclerosis. *Acta Neurologica Scandinavica* 2010; Mar;121(3):154-60. PMID: 20055771.
8. Debouverie M, Moreau T, Lebrun C, et al. A longitudinal observational study of a cohort of patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate. *Eur J Neurol* 2007; Nov;14(11):1266-74. PMID: 17956447.
9. Evans C, Tam J, Kingwell E, et al. Long-term persistence with the immunomodulatory drugs for multiple sclerosis: a retrospective database study. *Clin Ther* 2012; Feb;34(2):341-50. PMID: 22296946.
10. Ford C, Goodman AD, Johnson K, et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. *Mult Scler* 2010; Mar;16(3):342-50. PMID: 20106943.
11. Ford CC, Johnson KP, Lisak RP, et al. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. *Mult Scler* 2006; Jun;12(3):309-20. PMID: 16764344.
12. Johnson KP, Brooks BR, Ford CC, et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. *Copolymer 1 Multiple Sclerosis Study Group. Mult Scler* 2000; Aug;6(4):255-66. PMID: 10962546.
13. Johnson KP, Brooks BR, Ford CC, et al. Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial. *Mult Scler* 2003; Dec;9(6):585-91. PMID: 14664471.
14. Johnson KP, Ford CC, Lisak RP, et al. Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data. *Acta Neurologica Scandinavica* 2005; Jan;111(1):42-7. PMID: 15595937.
15. Goodin DS, Reder AT, Ebers GC, et al. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFN-1b trial. *Neurology* 2012; Apr 24;78(17):1315-22. PMID: 22496198.
16. Reder AT, Ebers GC, Traboulsee A, et al. Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS. *Neurology* 2010; Jun 8;74(23):1877-85. PMID: 20530324.
17. Ebers GC, Reder AT, Traboulsee A, et al. Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study. *Clin Ther* 2009; Aug;31(8):1724-36. PMID: 19808131.
18. Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. *Lancet neurol* 2009; Nov;8(11):987-97. PMID: 19748319.

19. Mesaros S, Stojavljevic N, Dujmovic-Basuroski I, et al. Long-term adherence to interferon-beta treatment in a cohort of RRMS patients in Belgrade, Serbia. *Clin Neurol Neurosurg* 2012; Oct;114(8):1145-8. PMID: 22425462.
20. Milanese C, Beghi E, Giordano L, et al. A post-marketing study on immunomodulating treatments for relapsing-remitting multiple sclerosis in Lombardia: preliminary results. *Neurol Sci* 2005; Dec;26 Suppl 4:S171-3. PMID: 16388352.
21. Miller A, Spada V, Beerkircher D, et al. Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis. *Mult Scler* 2008; May;14(4):494-9. PMID: 18208875.
22. O'Rourke KE, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. *Mult Scler* 2005; Feb;11(1):46-50. PMID: 15732266.
23. O'Rourke K, Walsh C, Antonelli G, et al. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis. *Mult Scler* 2007; Apr;13(3):336-42. PMID: 17439902.
24. Patti F, Pappalardo A, Florio C, et al. Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head study. *Acta Neurologica Scandinavica* 2006; Apr;113(4):241-7. PMID: 16542163.
25. Portaccio E, Zipoli V, Siracusa G, et al. Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. *Eur Neurol* 2008; 59(3-4):131-5. PMID: 18057899.
26. Rio J, Nos C, Tintore M, et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. *Ann Neurol* 2006; Feb;59(2):344-52. PMID: 16437558.
27. Rio J, Porcel J, Tellez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. *Mult Scler* 2005; Jun;11(3):306-9. PMID: 15957512.
28. Rio J, Tintore M, Nos C, et al. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre. *Journal of Neurology* 2005; Jul;252(7):795-800. PMID: 15772741.
29. Rio J, Tintore M, Nos C, et al. Interferon beta in secondary progressive multiple sclerosis : daily clinical practice. *Journal of Neurology* 2007; Jul;254(7):849-53. PMID: 17361342.
30. Shirani A, Zhao Y, Karim ME, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. *Jama* 2012; Jul 18;308(3):247-56. PMID: 22797642.
31. Sorensen PS, Koch-Henriksen N, Ravnborg M, et al. Immunomodulatory treatment of multiple sclerosis in denmark: a prospective nationwide survey. *Mult Scler* 2006; Jun;12(3):253-64. PMID: 16764337.
32. Trojano M, Paolicelli D, Zimatore GB, et al. The IFNbeta treatment of multiple sclerosis (MS) in clinical practice: the experience at the MS Center of Bari, Italy. *Neurol Sci* 2005; Dec;26 Suppl 4:S179-82. PMID: 16388354.
33. Trojano M, Pellegrini F, Fuiani A, et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. *Ann Neurol* 2007; Apr;61(4):300-6. PMID: 17444502.
34. Trojano M, Pellegrini F, Paolicelli D, et al. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. *Ann Neurol* 2009; Oct;66(4):513-20. PMID: 19847899.
35. Tedeholm H, Lycke J, Skoog B, et al. Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs. *Mult Scler* 2013; 19(6):765-74. PMID: 23124789.
36. Gold R, Rieckmann P, Chang P, et al. The long-term safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study. *Eur J Neurol* 2005; Aug;12(8):649-56. PMID: 16053475.
37. Uitdehaag B, Constantinescu C, Cornelisse P, et al. Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: Exploratory analyses from the PRISMS long-term follow-up study. *Therapeutic Advances in Neurological Disorders* 2011; //;4(1):3-14.
38. Prisms Study Group, the University of British Columbia MSMRIAG. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.[Erratum appears in *Neurology* 2001 Sep 25;57(6):1146]. *Neurology* 2001; Jun 26;56(12):1628-36. PMID: 11425926.

39. Havla J, Tackenberg B, Hellwig K, et al. Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis. *Journal of Neurology* 2013; May;260(5):1382-7. PMID: 23266894.
40. Havla J, Gerdes LA, Meinl I, et al. De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate. *Journal of Neurology* 2011; Sep;258(9):1665-9. PMID: 21431380.
41. Jokubaitis VG, Li V, Kalincik T, et al. Fingolimod after natalizumab and the risk of short-term relapse. *Neurology* 2014; Apr 8;82(14):1204-11. PMID: 24610329.
42. Kaufman MD, Lee R, Norton HJ. Course of relapsing-remitting multiple sclerosis before, during and after natalizumab. *Mult Scler* 2011; Apr;17(4):490-4. PMID: 21135017.
43. Kerbrat A, Le Page E, Leray E, et al. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients. *J Neurol Sci* 2011; Sep 15;308(1-2):98-102. PMID: 21665227.
44. O'Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. *Neurology* 2011; May 31;76(22):1858-65. PMID: 21543733.
45. Rossi S, Motta C, Studer V, et al. Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab. *Eur J Neurol* 2013; Jan;20(1):87-94. PMID: 2012-34812-013.
46. Sorensen PS, Koch-Henriksen N, Petersen T, et al. Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. *Journal of Neurology* 2014; 261(6):1170-7. PMID.
47. Borriello G, Prosperini L, Mancinelli C, et al. Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study. *Eur J Neurol* 2012; May;19(5):783-7. PMID: 22054236.
48. Borriello G, Prosperini L, Marinelli F, et al. Observations during an elective interruption of natalizumab treatment: a post-marketing study. *Mult Scler* 2011; Mar;17(3):372-5. PMID: 21148264.
49. Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. *Archives of Neurology* 2011; Feb;68(2):186-91. PMID: 20937940.
50. Sandberg-Wollheim M, Alteri E, Moraga MS, et al. Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy. *Mult Scler* 2011; Apr;17(4):423-30. PMID: 21220368.
51. Sandberg-Wollheim M, Frank D, Goodwin TM, et al. Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. *Neurology* 2005; Sep 27;65(6):802-6. PMID: 16093457.
52. Amato MP, Portaccio E, Ghezzi A, et al. Pregnancy and fetal outcomes after interferon-exposure in multiple sclerosis. *Neurology* 2010; Nov 16;75(20):1794-802. PMID: 21079181.
53. Boskovic R, Wide R, Wolpin J, et al. The reproductive effects of beta interferon therapy in pregnancy: A longitudinal cohort. *Neurology* 2005; 65(6):807-11.
54. Patti F, Cavallaro T, Lo Fermo S, et al. Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis? *Journal of Neurology* 2008; Aug;255(8):1250-3. PMID: 18677640.
55. Fragoso YD, Boggild M, MacIas-Islas MA, et al. The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis. *Clinical Neurology and Neurosurgery* 2013; //;115(2):154-9.
56. Hellwig K, Haghikia A, Rockhoff M, et al. Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. *Therapeutic advances in neurological disorders* 2012; 5(5):247-53.
57. Finkelsztejn A, Fragoso YD, Ferreira ML, et al. The Brazilian database on pregnancy in multiple sclerosis. *Clin Neurol Neurosurg* 2011; May;113(4):277-80. PMID: 21159421.
58. Lu E, Dahlgren L, Sadovnick A, et al. Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs. *Mult Scler* 2012; Apr;18(4):460-7. PMID: 21914689.

59. Weber-Schoendorfer C, Schaefer C. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. *Mult Scler* 2009; Sep;15(9):1037-42. PMID: 19692433.
60. Giannini M, Portaccio E, Ghezzi A, et al. Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. *BMC Neurol* 2012; 12:124. PMID: 23088447.
61. Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. *Mult Scler* 2011; Aug;17(8):958-63. PMID: 21613333.

Appendix D. Risk of Bias for Included KQ1 Studies

Appendix Table D1. KQ1 risk of bias for articles in analytic study set	D-2
Appendix Table D2. KQ1 risk of bias for articles in natalizumab set.....	D-4
Appendix Table D3. KQ1 risk of bias for articles in pregnancy set.....	D-5
References for Appendix D	D-6

Appendix Table D1. KQ1 risk of bias for articles in analytic study set

Study Country Funding	Type of Study	Overall Risk of Bias Assessment	Rationale
Glatiramer Acetate			
Debouverie, 2007 ¹ France Not reported	Prospective observational	High	Unclear inclusion criteria (25% “contraindication to interferon beta” not defined), unreliable outcome measure (relapse per MD), numerous unblinded outcomes assessors, no assessment of impact of attrition
Ford, 2010 ² (Johnson) United States Industry	Prospective open-label	High	Attrition, unblinded outcomes assessment
Miller, 2008 ³ United States Industry	Followup of compassionate use	High	Attrition, no assessment of impact of attrition, small sample size, unequal length of followup, competing exposures not described
Teriflunomide			
Confavreux, 2012 ⁴ N America, Europe Industry	Open-label extension of RCT: randomized placebo group	High	Attrition, no assessment of impact of attrition, reporting bias (Table 2, Fig. 2 by extension-phase drug only)
IFNβ1a			
Uitdehaag, 2011 ⁵ (PRISMS, Gold) 22 centers: Europe, Canada, Australia Not funded	Retrospective long-term followup of open-label extension of mixed design	High	High attrition, no assessment of impact of attrition, competing exposures not described, potential for recall bias (relapse outcome), small sample, post-hoc analyses
IFNβ1b			
Bencsik, 2006 ⁶ Hungary Not reported	Prospective cohort	High	Attrition, small/insufficient sample size, unblinded outcomes assessment, no comparator
Carmona, 2008 ⁷ Spain Not reported	Prospective cohort with historical control	High	Unclear selection of historical controls, insufficient reporting of baseline characteristics, attrition
Goodin, 2012 ⁸ Reder, 2010 ⁹ North America Industry	Long-term followup of RCT	Moderate	Competing exposures not described or included in the analysis
Kappos, 2009 ¹⁰ N America, Europe Industry	Open-label extension of RCT	High	Attrition, no assessment of impact of attrition
Rio, 2007 ¹¹ Spain Not reported	Post-marketing study	High	Attrition, baseline differences in case-mix between groups were not accounted for in the analysis.
Interferon beta mixed			
Patti, 2006 ¹² Italy, 2 sites Reported not industry	Open-label observational	High	Attrition, no assessment of impact of attrition, no attempt to balance differences in baseline MS characteristics across groups, inconsistent reporting (text vs. Table 1), unblinded outcomes assessment

Study Country Funding	Type of Study	Overall Risk of Bias Assessment	Rationale
Portaccio, 2008 ¹³ Italy Not reported	Retrospective cohort	High	Unequal length of treatment, unequal length of followup, lack of detail about variables used in Cox models and attempts to deal with baseline differences in MS characteristics, questionable control of confounding factors in analysis
Shirani, 2012 ¹⁴ Canada Government	Retrospective cohort (database) with historical and contemporary control groups	Moderate	Lack of detail in describing the intervention (all IFNβs considered as one therapy, breaks in treatment ignored), competing exposures not described, unblinded assessors, sample selection (limits of database capture).
Mixed Drugs			
Tedeholm, 2013 ¹⁵ Sweden Government	Retrospective cohort (databased) with historical control group	High	Selection bias, lack of generalizability of contemporary treated group to population-based historical control, probable treatment by indication
Rio, 2005 ¹⁶ Spain Not reported	Open-label nonrandomized post-marketing observational	High	Baseline differences in case-mix between groups were not accounted for in the analysis, unequal length of treatment across groups, unequal length of followup, incomplete and unclear tracking of patients over time (table values conflict with text), competing exposures not described, attrition
Bergamaschi, 2012 ¹⁷ Italy Unfunded	Retrospective cohort (database) categorized by Bayesian modeling for risk factors	Unclear	Unclear if modeling accounted for treatment by indication. Nearly 30% of the remaining registry cohort was excluded because they had not been treated, or had not been treated with a first-line therapy, or had also been treated with a second-line therapy.

Appendix Table D2. KQ1 risk of bias for articles in natalizumab set

Study Country Funding	Type of Study	Overall Risk of Bias Assessment	Rationale
ARR Outcomes			
Jokubaitis, 2014 ¹⁸ Australia and international Government, non-profit, industry	Retrospective cohort	Moderate	Retrospective, large sample with lack of individual-level outcome assessment, relapse severity measured by proxy (relapse treatment: ambulatory, hospitalization or none)
Havla, 2013 ¹⁹ Germany Not reported	Retrospective cohort	High	Retrospective, inadequate sample size, outcome (rebound definition) not clearly specified, confounding variables not addressed (reason for interruption, prior treatment)
Havla, 2011 ²⁰ Germany Not reported	Prospective cohort	High	Inadequate sample size, outcome (rebound definition) not clearly specified, confounding variables not addressed (reason for interruption), prior treatment
Kaufman 2011 ²¹ United States Not funded	Retrospective chart review	High	Retrospective, outcome (rebound definition) not clearly specified, confounding variables not addressed (reason for interruption, prior treatment)
Kerbrat 2011 ²² France Not reported	Retrospective chart review	High	Retrospective, outcome (rebound definition) not clearly specified, attrition in MRI outcomes, confounding variables not addressed (prior treatment)
O'Connor 2011 ²³ Canada Industry	Prospective post hoc analysis of trial data	High	Attrition in MRI outcomes, large sample with lack of individual-level outcome assessment, confounding variables not addressed (prior treatment)
Rossi, 2013 ²⁴ Italy Industry	Prospective cohort	High	Outcome (rebound definition) not clearly specified, attrition in MRI outcomes, confounding variables not addressed (prior treatment)
Sorensen, 2014 ²⁵ Denmark Not reported	Retrospective; national registry	High	Retrospective, confounding variables not addressed (reason for interruption, prior treatment)
MRI Outcomes			
Boriello, 2012 ²⁶ Spain Not reported	Prospective cohort post-marketing	High	Inadequate sample size, outcome (rebound definition) not clearly specified, confounding variables not addressed (baseline EDSS 5.0, prior treatment) inadequate reporting of relapses
Boriello, 2011 ²⁷ Spain Not funded	Prospective cohort post-marketing	High	Inadequate sample size, outcome (rebound definition) not clearly specified, unequal length of MRI followup, confounding variables not addressed (prior treatment)
Miravalle, 2011 ²⁸ United States Industry	Prospective cohort	High	Inadequate sample size, outcome (rebound definition) not clearly specified, inadequate reporting of relapses, confounding variables not addressed (prior treatment)
Rossi, 2013 ²⁴ Italy Industry	Prospective cohort	High	Outcome (rebound definition) not clearly specified, attrition in MRI outcomes, confounding variables not addressed (prior treatment)

ARR=annualized relapse rate; EDSS=Expanded Disability Status Scale; MRI=magnetic resonance imaging

Table Appendix D3. KQ1 risk of bias for articles in pregnancy set

Study Country Funding	Type of Study	Overall Risk of Bias Assessment	Rationale
<i>Interferon beta 1a</i>			
Sandberg- Wollheim, 2011 ²⁹ Sweden Industry	Prospective global drug safety database	High	Unintended exposures not described
Sandberg- Wollheim, 2005 ³⁰ Sweden Industry	Prospective individual patient data from 8 trials	High	Insufficient sample size, unintended exposures not described
<i>Interferon beta mixed</i>			
Amato, 2010 ³¹ Italy Not reported	Prospective cohort, 21 clinics	High	Insufficient sample size, lack of detail in describing the intervention (e.g., specific drug) in results, lack of detail in describing statistical methods
Boskovic, 2005 ³² Canada Not reported	Prospective cohort, women who contacted risk counseling program	High	Insufficient sample size, lack of detail in describing the intervention (e.g., specific drug), inappropriate comparison, statistical methods to assess the outcome used inappropriately, lack of interpretability
Patti, 2008 ³³ Italy Not reported	Retrospective cohort, one clinic	High	Retrospective design, insufficient sample size, lack of detail in describing the intervention (e.g., specific drug), lack of interpretability
<i>Interferon beta mixed, glatiramer acetate</i>			
Finkelsztejn, 2011 ³⁴ Brazil Not reported	Retrospective, voluntary database	High	Insufficient sample size, lack of detail in describing the intervention (e.g., specific drug), unintended exposures (e.g., smoking) not described, lack of interpretability
Fragoso, 2013 ³⁵ International	Retrospective, voluntary database	High	Selectively recruited participants, insufficient sample size, lack of detail in describing the intervention (e.g., specific drug), unintended exposures (e.g., smoking) not described, unclear length of followup for maternal outcomes
Hellwig, 2012 ³⁶ Germany Not funded	Retrospective, risk counseling database	High	Insufficient sample size, lack of detail in describing the intervention (e.g., specific drug), unintended exposures (e.g., smoking) not described
Lu, 2012 ³⁷ Canada Government	Retrospective cohort, provincial database	High	Insufficient sample size, lack of detail in describing the intervention (e.g., specific drug)
Weber- Schoendorfer, 2009 ³⁸ Germany	Prospective cohort, risk assessment program	High	insufficient sample size, lack of detail in describing the intervention (e.g., specific drug), inappropriate comparison
<i>Glatiramer acetate</i>			
Giannini, 2012 ³⁹ Italy Not reported	Prospective cohort, 21 clinics	High	Insufficient sample size
<i>Natalizumab</i>			
Hellwig, 2011 ⁴⁰ Germany Not funded	Prospective counseling database	High	insufficient sample size, unintended exposures (e.g., smoking) not described

References for Appendix D

1. Debouverie M, Moreau T, Lebrun C, et al. A longitudinal observational study of a cohort of patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate. *Eur J Neurol* 2007; Nov;14(11):1266-74. PMID: 17956447.
2. Ford C, Goodman AD, Johnson K, et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. *Mult Scler* 2010; Mar;16(3):342-50. PMID: 20106943.
3. Miller A, Spada V, Beerkircher D, et al. Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis. *Mult Scler* 2008; May;14(4):494-9. PMID: 18208875.
4. Confavreux C, Li DK, Freedman MS, et al. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. *Mult Scler* 2012; Sep;18(9):1278-89. PMID: 22307384.
5. Uitdehaag B, Constantinescu C, Cornelisse P, et al. Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: Exploratory analyses from the PRISMS long-term follow-up study. *Therapeutic Advances in Neurological Disorders* 2011; //;4(1):3-14.
6. Bencsik K, Fuvesi J, Fricska-Nagy Z, et al. Short communication: treatment of relapsing-remitting multiple sclerosis 96 patients with IFN-beta 1b: results of a 6-year follow-up. *J Interferon Cytokine Res* 2006; Feb;26(2):96-100. PMID: 16487029.
7. Carmona O, Casado V, Moral E, et al. Interferon-beta1b in multiple sclerosis: effect on progression of disability and clinical markers of treatment response. *Eur Neurol* 2008; 60(6):279-84. PMID: 18824855.
8. Goodin DS, Reder AT, Ebers GC, et al. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFN-1b trial. *Neurology* 2012; Apr 24;78(17):1315-22. PMID: 22496198.
9. Reder AT, Ebers GC, Traboulsee A, et al. Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS. *Neurology* 2010; Jun 8;74(23):1877-85. PMID: 20530324.
10. Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. *Lancet neurol* 2009; Nov;8(11):987-97. PMID: 19748319.
11. Rio J, Tintore M, Nos C, et al. Interferon beta in secondary progressive multiple sclerosis : daily clinical practice. *Journal of Neurology* 2007; Jul;254(7):849-53. PMID: 17361342.
12. Patti F, Pappalardo A, Florio C, et al. Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head study. *Acta Neurologica Scandinavica* 2006; Apr;113(4):241-7. PMID: 16542163.
13. Portaccio E, Zipoli V, Siracusa G, et al. Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. *Eur Neurol* 2008; 59(3-4):131-5. PMID: 18057899.
14. Shirani A, Zhao Y, Karim ME, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. *Jama* 2012; Jul 18;308(3):247-56. PMID: 22797642.
15. Tedeholm H, Lycke J, Skoog B, et al. Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs. *Mult Scler* 2013; 19(6):765-74. PMID: 23124789.
16. Rio J, Tintore M, Nos C, et al. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre. *Journal of Neurology* 2005; Jul;252(7):795-800. PMID: 15772741.
17. Bergamaschi R, Quaglini S, Tavazzi E, et al. Immunomodulatory therapies delay disease progression in multiple sclerosis. *Mult Scler* 2012; published online May 31:1-9. PMID: 22653657.
18. Jokubaitis VG, Li V, Kalincik T, et al. Fingolimod after natalizumab and the risk of short-term relapse. *Neurology* 2014; Apr 8;82(14):1204-11. PMID: 24610329.

19. Havla J, Tackenberg B, Hellwig K, et al. Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis. *Journal of Neurology* 2013; May;260(5):1382-7. PMID: 23266894.
20. Havla J, Gerdes LA, Meinl I, et al. De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate. *Journal of Neurology* 2011; Sep;258(9):1665-9. PMID: 21431380.
21. Kaufman MD, Lee R, Norton HJ. Course of relapsing-remitting multiple sclerosis before, during and after natalizumab. *Mult Scler* 2011; Apr;17(4):490-4. PMID: 21135017.
22. Kerbrat A, Le Page E, Leray E, et al. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients. *J Neurol Sci* 2011; Sep 15;308(1-2):98-102. PMID: 21665227.
23. O'Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. *Neurology* 2011; May 31;76(22):1858-65. PMID: 21543733.
24. Rossi S, Motta C, Studer V, et al. Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab. *Eur J Neurol* 2013; Jan;20(1):87-94. PMID: 2012-34812-013.
25. Sorensen PS, Koch-Henriksen N, Petersen T, et al. Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. *Journal of Neurology* 2014; 261(6):1170-7.
26. Borriello G, Prosperini L, Mancinelli C, et al. Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study. *Eur J Neurol* 2012; May;19(5):783-7. PMID: 22054236.
27. Borriello G, Prosperini L, Marinelli F, et al. Observations during an elective interruption of natalizumab treatment: a post-marketing study. *Mult Scler* 2011; Mar;17(3):372-5. PMID: 21148264.
28. Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. *Archives of Neurology* 2011; Feb;68(2):186-91. PMID: 20937940.
29. Sandberg-Wollheim M, Alteri E, Moraga MS, et al. Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy. *Mult Scler* 2011; Apr;17(4):423-30. PMID: 21220368.
30. Sandberg-Wollheim M, Frank D, Goodwin TM, et al. Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. *Neurology* 2005; Sep 27;65(6):802-6. PMID: 16093457.
31. Amato MP, Portaccio E, Ghezzi A, et al. Pregnancy and fetal outcomes after interferon-exposure in multiple sclerosis. *Neurology* 2010; Nov 16;75(20):1794-802. PMID: 21079181.
32. Boskovic R, Wide R, Wolpin J, et al. The reproductive effects of beta interferon therapy in pregnancy: A longitudinal cohort. *Neurology* 2005; 65(6):807-11.
33. Patti F, Cavallaro T, Lo Fermo S, et al. Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis? *Journal of Neurology* 2008; Aug;255(8):1250-3. PMID: 18677640.
34. Finkelsztejn A, Fragoso YD, Ferreira ML, et al. The Brazilian database on pregnancy in multiple sclerosis. *Clin Neurol Neurosurg* 2011; May;113(4):277-80. PMID: 21159421.
35. Fragoso YD, Boggild M, MacIas-Islas MA, et al. The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis. *Clinical Neurology and Neurosurgery* 2013; //;115(2):154-9.
36. Hellwig K, Haghikia A, Rockhoff M, et al. Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. *Therapeutic advances in neurological disorders* 2012; 5(5):247-53.
37. Lu E, Dahlgren L, Sadovnick A, et al. Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs. *Mult Scler* 2012; Apr;18(4):460-7. PMID: 21914689.
38. Weber-Schoendorfer C, Schaefer C. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. *Mult Scler* 2009; Sep;15(9):1037-42. PMID: 19692433.

39. Giannini M, Portaccio E, Ghezzi A, et al. Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. *BMC Neurol* 2012; 12:124. PMID: 23088447.
40. Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. *Mult Scler* 2011; Aug;17(8):958-63. PMID: 21613333.